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Abstract 
Introduction:  Type 2 diabetes is an age-related condition and is characterised 
by a progressive decline in insulin secretion.  Mitochondria play a key role in 
energy generation for insulin secretion.  We previously reported an age-related 
decline in mitochondrial DNA (mtDNA) copy number in isolated human islets.  
TFAM, mtDNA Transcription Factor A, regulates mtDNA transcription and 
mtDNA copy number.   
Aims:  We aimed to replicate the percentage decrease in mtDNA copy number 
that we observed with ageing in human islets, and to explore whether this 
affected mitochondrial function and insulin secretion.   
Methods:  Two independent models of mtDNA depletion were created.  The 
first model knocked down TFAM gene expression using siRNA technology.  The 
second model subjected cells to didanosine, a nucleoside analogue of 
adenosine with a high affinity to POLG, a mtDNA polymerase. 
Results:  Both models produced comparable levels of mtDNA depletion.  Upon 
investigating the effects of partial mtDNA depletion on mitochondrial function, 
we found that both mtDNA depletion models displayed reduced mtDNA gene 
transcription and translation.  However, neither model of mtDNA depletion 
affected ATP content or mitochondrial membrane potential.  Glucose-stimulated 
insulin secretion was decreased following mtDNA depletion in the TFAM knock 
down cells which was rescued following treatment with the insulin secretagogue 
glibenclamide.  Conversely, didanosine-induced mtDNA depleted cells showed 
increased insulin secretion. 
Conclusions:  Both models generated a similar degree of mtDNA depletion, 
which was comparable to the percentage decrease seen in human islets with 
ageing.  Both models were seen to impair mitochondrial function, but with 
opposing effects on insulin secretion.  The TFAM model findings are in line with 
previous studies of severe mtDNA depletion, suggesting that the increase in 
insulin secretion seen with didanosine is due to drug off target effects.  
Strategies to slow islet mtDNA depletion in man could help to preserve insulin 
secretion and delay the development of Type 2 diabetes. 
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2 
1 Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus is one of the most common non-communicable diseases.  The 
condition is characterised by abnormally high blood plasma glucose levels over 
a sustained period of time (chronic hyperglycaemia).  The clinical diagnosis of 
diabetes is prompted by the presence of other classical symptoms including the 
passage of increased volumes of water (polyuria) as the renal glucose threshold 
is breached, which ultimately causes an increase in thirst (polydipsia).  The 
increased blood glucose levels are also the ideal environment for yeast and 
bacteria, and so other symptoms of diabetes include slow wound healing and 
thrush.  The reduced ability of the body to metabolise glucose can culminate in 
weight loss and in extreme cases, drowsiness and coma (WHO, 1999).  These 
diabetic symptoms can often culminate in more serious complications such as 
retinopathy, neuropathy and nephropathy; resulting in blindness, nerve damage 
and kidney problems respectively. 
Diabetes is diagnosed when fasting plasma glucose is too high, typically ≥7.0 
mM (≥126 mg/dl).  Chronic exposure to such high glucose could culminate in 
microvascular damage (WHO, 2006).  Normogylcaemia, the normal blood 
glucose level, is defined between the range of 4 mM (72 mg/dl) and 7 mM (126 
mg/dl) prior to a meal (NICE, 2008).  Deviations from this normoglycaemic 
range are termed hypoglycaemia (low blood glucose, <4 mM or <72 mg/dl) and 
hyperglycaemia (high blood glucose, >10 mM or >180 mg/dl) (Diabetes UK, 
2006). 
In 1670 Thomas Willis was the first to differentiate between diabetes mellitus 
and diabetes insipidus simply by the taste of the patients’ urine:  whether it 
tasted sweet (indicating diabetes mellitus) or had no taste (indicating diabetes 
insipidus) (Willis, 1674-1675).  The two main types of diabetes mellitus were 
first fully characterised in 1951 by Lister and Nash based on their different 
aetiologies (Lister & Nash, 1951): 
Type 1 Diabetes Mellitus (T1DM) is characterised by the loss of pancreatic beta 
cells (β-cells), thought to be due to the body’s auto-immune attack on 
pancreatic islets (Atkinson & Maclaren, 1994).  Consequently, patients produce 
3 
little or no insulin and so, need to take exogenous insulin by injection; hence the 
reason why T1DM is often referred to as insulin-dependent diabetes.  The age 
of onset is relatively early, usually before 40 years. 
Type 2 Diabetes Mellitus (T2DM), also known as non-insulin-dependent 
diabetes, tends to have a more delayed age of onset of 40-60 years compared 
to T1DM.  T2DM is characterised by a decreased sensitivity to insulin, also 
referred to as insulin resistance, together with decreased insulin secretion from 
pancreatic β-cells.  However, we are now seeing an increase in childhood 
T2DM, due to the increase in childhood obesity.   
1.1.1 Glucose Homeostasis 
Blood glucose levels are kept in equilibrium by homeostasis and the hormones 
insulin and glucagon (Figure 1).  When blood glucose levels increase, this 
causes pancreatic β-cells to secrete the hormone insulin.  Insulin lowers blood 
glucose levels by promoting the uptake of glucose, via glucose transporters, by 
the liver.  Once in the liver, the glucose is converted to glycogen in a process 
called glycogenesis.  Insulin also promotes the uptake of glucose by other 
tissue cells such as muscle and fat.  The uptake of glucose by liver, fat or 
muscle cells causes a decrease in blood glucose concentration. 
If, however, the blood glucose level falls below the normoglycaemic range, this 
prompts pancreatic α-cells to secrete the hormone glucagon.  Glucagon 
promotes the breakdown of stored glycogen in the liver to glucose, in a process 
called glycogenolysis.  Glucose is then released into the bloodstream 
subsequently increasing the blood glucose concentration. 
Pancreatic α- and β-cells are found in the islet of Langerhans and constitute the 
endocrine section of the pancreas, a glandular organ located in the abdominal 
cavity, beneath the stomach and attached to the duodenum of the small 
intestine.   
Chronic inability to maintain blood glucose homeostasis culminates in the onset 
of diabetes mellitus. 
  
  
 
 
Figure 1 Glucose homeostasis
Blood glucose levels are maintained between 4 mM and 7 mM by homeostasis.  When 
glucose levels are too hi
insulin, which promotes the uptake of glucose by liver, muscle and fat cells.  In the 
liver, glucose is converted to glycogen by glycogenesis.  Uptake of glucose from the 
blood causes a decrease in
are too high, the hormone glucagon is secreted from pancreatic 
targets the liver where it promotes the hydrolysis of stored glycogen to glucose, via 
glycogenolysis.  It also promot
carbohydrate carbon substrates via gluconeogenesis.  Glucose is released from the 
liver cell causing a rise in blood glucose concentration.
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1.1.2 Type 2 Diabetes Mellitus (T2DM) 
The development of T2DM has been linked to a decrease in insulin action, 
referred to as insulin resistance, as target cells are no longer sensitive to the 
effects of insulin.  This insulin resistance is coupled with a decrease in insulin 
secretion from the pancreatic β-cells.  Impaired glucose tolerance (IGT) is 
thought to be an intermediary step in the pathogenesis of T2DM, and is 
associated with impaired insulin secretion (IDF, 2011).  IGT is determined 
following an oral glucose tolerance test (OGTT) whereby the patient is 
administered a maximum of 75 g oral glucose after an 8-12 hour fast and the 
whole blood glucose level measured after 2 hours.  IGT is diagnosed if the 
whole blood glucose level is ≥ 6.7 mmol/l (venous) or ≥ 7.8 mmol/l (capillary) 
following the 2 hour post glucose load (WHO, 2006).  IGT is not a clinical entity 
on its own, but predisposes the patient to developing diabetes if the IGT is not 
addressed (WHO, 2006).  It has been suggested that insulin resistance in 
muscle as well as defective insulin secretion contribute to IGT (WHO, 2006). 
T2DM is thought to account for 90% of all diabetes cases worldwide (WHO, 
2008a).  The prevalence of diabetes was predicted to be around 366 million 
people in 2011; this is expected to rise to 552 million by 2030 (IDF, 2011).  In 
the UK alone, the prevalence of diabetes was estimated to be 1,765,000 in 
2000, predicted to rise to 2,668,000 by 2030 (WHO, 2008b).  It is believed that 
around half of the people with diabetes are undiagnosed, with diabetes causing 
4.6 million deaths in 2011 (IDF, 2011).  There has also been an alarming 
increase in the number of children developing T2DM, the main underlying cause 
of this is thought to be linked to sedentary lifestyle and obesity.    
These facts and figures simply highlight the scale of the problem and prompt 
the need for further research into the disease. 
1.1.3 T2DM Risk Factors 
Over recent years, especially in developed countries, there has been a general 
increase in the average human life expectancy.  This has contributed, along 
with other factors such as improved hygiene, healthcare, and the development 
of treatments for many infectious diseases, to an overall increase in the 
prevalence of age-related, non-communicable diseases such as T2DM, 
cardiovascular disease (CVD) and some cancers (Hitman, 1999).   
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1.1.3.1 Environmental Risk Factors 
Several environmental factors have been linked to the onset of T2DM, the main 
one being obesity.  This can be attributed to people leading a more sedentary 
lifestyle and so, exercising less.  In children especially, since the advancements 
in technology and the development of computers, games consoles and mobile 
phones for example, children are more likely to stay indoors rather than go 
outside and exercise.  Poor diet and our current fast-food and junk food culture 
can also be held accountable for increases in obesity and ultimately, T2DM.  
Exercise intervention (Trenell et al., 2008; Praet & Van Loon, 2009) and severe 
calorie restriction (R. Taylor, 2011) have both proven effective means of 
preventing T2DM disease progression, or even reversing T2DM. 
1.1.3.2 Genetic Risk Factors 
The majority of T2DM risk is environmental, but there is a growing body of 
evidence detailing genetic predisposition.  Previous family history of T2DM, 
especially first degree relatives, has been seen to increase risk of developing 
T2DM (Annis et al., 2005).  The presence of any genetic markers or ‘thrifty 
gene(s)’ has also been implicated as a genetic risk factor for T2DM (Hitman, 
1999).  The Thrifty Gene Hypothesis was first proposed in 1962 by James Neel 
and proposes that so-called ‘thrifty’ genes, genes that are now thought to 
predispose to T2DM, were once beneficial and hence, favoured in the process 
of natural selection.  In time however, these genes have been rendered 
detrimental (Neel, 1962).   
Candidate gene studies (listed in Table 1) have identified many T2DM 
susceptibility genes including: PPARG (encodes the peroxisome proliferator-
activator receptor-γ protein) (Altshuler et al., 2000; Florez et al., 2007) and 
KCNJ11 (encodes the Kir6.2 subunit of the β-cell ATP sensitive K+ channel) 
(Hani et al., 1998).  Both protein products of these genes are targets of the anti-
diabetes treatment drugs thiazolidinediones and sulphonylureas respectively.  
Risk alleles in the TCF7L2 gene, encoding a key transcription factor component 
of the Wnt signalling pathway, have also been associated with increased risk of 
developing T2DM (Grant et al., 2006; Cauchi et al., 2007).   
The increasing use of genome wide association (GWA) studies to identify single 
nucleotide polymorphisms (SNPs) has identified new T2DM susceptibility genes 
(listed in Table 1).  Genes identified as containing T2DM susceptibility SNPs by 
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GWA studies include HHEX (encodes a protein thought to be essential for β-cell 
development) (Pascoe et al., 2007; Sladek et al., 2007), IRS1 (encodes insulin 
receptor substrate 1, which is involved in insulin signalling) (Rung et al., 2009) 
and FTO (fat mass and obesity associated gene) (Frayling et al., 2007).  
Important regulators of the cell cycle have also been identified as T2DM 
susceptibility genes, including CDKN2A/2B, CDC123 and CDKAL1, thus 
opening up the possibility of additional therapeutic approaches for the treatment 
of T2DM (Pascoe et al., 2007; Sladek et al., 2007; Steinthorsdottir et al., 2007; 
Zeggini et al., 2008). 
There are now approximately 40 DNA variants of T2DM susceptibility genes 
that have been identified (Imamura & Maeda, 2011), but these are thought to 
only account for 10% of the known T2DM heritability (Bonnefond et al., 2010).   
1.1.3.3 Demographic Risk Factors 
Demographic risk factors including age, ethnicity and sex have also been 
implicated in the development of T2DM.  The increased prevalence of T2DM 
has been linked with ageing, due to a decrease in insulin secretion and 
decreased β-cell function (discussed in Section 1.1.4).  T2DM is seen more 
commonly in South-Asian or African-Caribbean ethnic groups in the UK 
(Diabetes UK, 2009).  Females who are overweight and have polycystic ovary 
syndrome, or have previously had gestational diabetes are also more prone to 
developing T2DM (Diabetes UK, 2009). 
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Gene 
(suggested) Locus Protein Assumed effect of risk allele 
Biological candidate gene studies 
PPARG 3p25 Peroxisome proliferator-activated 
receptor-γ Decreased insulin sensitivity, decreased insulin clearance 
KCNJ11 11p15.1 K inwardly-rectifying channel, 
subfamily J, member 11 
Decreased β-cell function, decreased glucose-stimulated 
insulin secretion (GSIS), decreased insulin sensitivity 
HNF1B 17cenq-21.3 Hepatocyte nuclear factor 1-beta Decreased β-cell function 
WFS1 4p16 Wolfram syndrome 1 (wolfamin) Decreased β-cell function, decreased insulin secretion 
GCK 7p15.3-p15.1 Glucokinase (Hexokinase 4) Decreased β-cell function, decreased GSIS, increased fasting glucose, increased glycated haemoglobin 
Exploration of linkage peaks 
TCF7L2 10q25.3 Transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
Decreased β-cell function, decreased incretin-stimulated 
insulin secretion, decreased GSIS, decreased proinsulin 
conversion, decreased insulin sensitivity, decreased 
disposition index, increased fasting glucose, increased 2h-
glucose 
GWAS for T2D 
CDKN2A/2B 9p21 Cyclin-dependent kinase inhibitor 2A/2B 
Decreased β-cell function, decreased GSIS, decreased 
disposition index 
CDKAL1 6p22.3 CDK5 regulatory subunit associated protein 1-like 1 
Decreased β-cell function, decreased GSIS, decreased 
proinsulin conversion, decreased disposition index 
SLC30AB 8q24.11 Solute carrier family 30 (zinc transporter) member 8 
Decreased β-cell function, decreased GSIS, decreased 
proinsulin conversion, decreased disposition index, increased 
fasting glucose, increased 2h-glucose, increased glycated 
haemoglobin 
IGF2BP2 3q27.2 Insulin-like growth factor 2 mRNA binding protein 2 
Decreased β-cell function, decreased GSIS, decreased 
disposition index 
THADA 2p21 Thyroid adenoma associated 
Decreased β-cell function, decreased insulin sensitivity, 
decreased second-phase insulin secretion, decreased 
disposition index, decreased GLP-1 and arginine-stimulated 
insulin response 
NOTCH2 1p13-p11 Neurogenic locus notch homolog protein 2 (Drosophila) NA 
CDC123 10p13 Cell division cycle 123 homolog (Saccharomyces cerevisiae) Decreased β-cell function, decreased insulin secretion 
CAMK1D  Calcium/calmodulin-dependent protein kinase type 1D  
HHEX 10q23 Haematopoietically expressed homeobox 
Decreased β-cell function, decreased GSIS, decreased insulin 
sensitivity, decreased proinsulin conversion, decreased 
disposition index 
IDE  Insulin-degrading enzyme  
TSPAN8 12q14.1-q21.1 Tetraspanin 8 
Decreased β-cell function, decreased insulin secretion, 
decreased insulin sensitivity 
LGR5 12q22-q23 Leucine-rich repeat-containing G protein-coupled receptor 5  
ADAMTS9 3p14.3-p14.2 ADAM metallopeptidase with thrombospondin type 1 motif. 9 Decreased insulin sensitivity 
JAZF1 7p15.2-p15.1 Juxtaposed with another zinc finger protein 1 
Decreased β-cell function, increased insulin secretion, 
increased fasting insulin 
IRS1 2q36 Insulin receptor substrate 1 Increased insulin resistance, decreased insulin sensitivity, increased fasting insulin, increased 2h-insulin 
KCNQ1 11p15.5 K voltage-gated channel, KQT-like 
subfamily, member 1 
Decreased β-cell function, decreased insulin secretion, 
decreased incretin secretion 
FTO 16q12.2 Fat mass and obesity-associated protein 
Increased risk of obesity, increased body mass index, 
increased fat mass, increased triglycerides and cholesterol 
GWAS for T2D-related traits 
GCKR 2p23 Glucokinase (Hexokinase 4) 
regulator 
Increased insulin resistance, increased fasting insulin, 
increased fasting glucose, increased 2h-glucose 
MTNR1B 11q21-q22 Melatonin receptor 1B 
Decreased β-cell function, decreased GSIS, decreased 
disposition index, increased fasting glucose, increased 
glycated haemoglobin 
ADCY5 3q13.2-q21 Adenylated cyclase 5 Decreased β-cell function, increased fasting glucose, increased 2h-glucose 
PROX1 1q32.2-q32.3 Prospero homeobox 1 Decreased β-cell function, increased fasting glucose 
DGKB 7p21.2 Diacylglycerol kinase, beta 90 kDa Decreased β-cell function, increased fasting glucose 
TMEM195  Transmembrane protein 195  
 
Table 1 The most reported T2DM susceptibility genes and associated small 
nucleotide polymorphism (SNP) loci 
This table is taken from (Bonnefond et al., 2010) and records the most popularly 
reported susceptibility genes associated with increased T2DM risk along with 
associated SNP loci and suspected disease phenotype.  
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1.1.4 T2DM and Ageing 
The increased prevalence of T2DM can be attributed to many underlying 
factors, the predominantly documented risk factor being obesity.  But there is 
clear evidence that the increase in T2DM prevalence is also linked to the effects 
of ageing.  In an American population of 20-74 year olds, the prevalence of total 
diabetes was found to increase from 2.0% in individuals under 44 years old, to 
17.7% at age 65-74 years (Harris et al., 1987).  The National Health and 
Nutrition Examination Survey (NHANES) found that the prevalence of diabetes 
increased with advancing age with approximately one third of the American 
elderly population being diagnosed with T2DM (Cowie et al., 2009).   
T2DM prevalence in the over 65 population has increased from 17.7% in the 
1976-1980 NHANES survey (Harris et al., 1987), to 21.6% in the 1999-2002 
NHANES survey (Cowie et al., 2006) and 31.6% in the 2005-2006 NHANES 
survey (Cowie et al., 2009).  This increase in T2DM prevalence in the over 65s 
may be due to the elderly living longer, but it does not explain why the 
prevalence of T2DM consistently increases with advancing age (Harris et al., 
1987; Cowie et al., 2006; Cowie et al., 2009; Centre for Disease Control and 
Prevention, 2011).  It has also been shown that the prevalence of undiagnosed 
diabetes and isolated post-challenge hyperglycaemia increased with advancing 
age (Resnick et al., 2000). 
So why does the prevalence of T2DM increase with advancing age?  There is 
evidence to suggest an age-related deterioration in glucose tolerance linked to 
a progressive decrease in pancreatic β-cell function may be to blame.  Basu 
and colleagues demonstrated that tolerance to glucose deteriorates with age.  
They investigated 67 elderly and 21 young healthy participants after ingestion of 
a mixed meal followed by an intravenous injection of glucose 14 hours later.  
The group were able to show that the elderly participants had increased fasting 
glucose and exhibited decreased insulin secretion, suggesting impairment of β-
cell function (Basu et al., 2003). 
Animal models of T2DM have been presented including the Goto-Kakizaki (GK) 
rat.  The GK rat is a non-obese substrain of the Wistar rat produced by selective 
breeding, with glucose intolerance as selection criterion, which develops T2DM 
early in life.  The GK rat was originally developed by Goto and Kakizaki back in 
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1975 (Goto et al., 1976) and since then, has been used as a putative model of 
T2DM in the study of many pathways and processes including prediabetes 
(Movassat et al., 2008), glucagon-like peptide-1 (GLP-1) (Tourrel 2002 
Diabetes), superoxide generation in vascular tissue (Gupte et al., 2010) as well 
as ageing (Gao et al., 2011; Nie et al., 2011).  Investigations using GK rats have 
shown that impaired glucose-stimulated insulin secretion, increased insulin 
resistance, decreased β-cell mass and increased hyperglycaemia all correlate 
with advancing age (Goodman et al., 1983; Berthelier et al., 1997; O'Rourke et 
al., 1997; Suzuki et al., 1997; Movassat et al., 2008; Gao et al., 2011).   
It is now widely recognised that progressive impairment of pancreatic β-cell 
function seems to be a key perpetrator in the pathogenesis of T2DM (Porte, 
2001; Poitout & Robertson, 2002; Prentki et al., 2002; Leahy, 2005).  Rudenski 
et al. developed a mathematical linear regression model to predict islet β-cell 
function and insulin sensitivity, and concluded that in 131 T2DM patients, β-cell 
function declines at a rate of 1.5% per year, but with no significant change in 
insulin sensitivity (Rudenski et al., 1988).  This study shows that there is a 
reduced β-cell function in patients with T2DM, which is age-dependent.  
Furthermore, there is evidence that insulin secretion (Chang & Halter, 2003) 
and β-cell function (Basu et al., 2003) decline with age in the general, non-
diabetic population. 
As well as the growing body of evidence suggesting the progressive decline in 
β-cell function, coupled with deterioration in glucose tolerance being implicated 
in the increased prevalence of T2DM in the ageing population, other factors 
associated with ageing have also been suggested.  These include increased 
adiposity, medication, less physical activity and other coexisting illnesses 
(Chang & Halter, 2003).  As we are continually making advancements in 
medical science, people are living a lot longer and so, the age-related onset of 
T2DM will only increase further. 
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1.1.5 Glucose Metabolism in the Pancreatic β-cell 
The release of insulin from pancreatic β-cells begins with cellular stimulation by 
glucose.  Glucose enters the β-cell by a glucose transporter (GLUT) protein on 
the cell surface.  There are many glucose transporters, each specific for 
individual cell types, GLUT2 transporters are predominantly found in pancreatic 
β-cells as well as liver hepatocytes.  GLUT4 proteins however, are restricted to 
cells where glucose transport is insulin sensitive, such as muscle cells and 
adipose tissue.  Other glucose transporters include GLUT1 (ubiquitously found 
in most tissues, but abundant in red blood cells), GLUT 3 (preferentially 
expressed in brain neurones), GLUT5 (fructose transporter found in human 
enterocyte luminal membrane, adipocytes and skeletal muscle), GLUT6 
(pseudogene with no protein product) and GLUT7 (intracellular glucose 
transporter found in liver) (Klip et al., 1994). 
Once inside the cell, glucose is then metabolised by glycolysis in the cytosol, 
followed by the tricarboxylic acid cycle and the electron transport chain in the 
mitochondria. 
1.1.5.1 Glycolysis 
Glycolysis, derived from the Greek words ‘glyk’ meaning sweet and ‘lysis’ 
meaning dissolution, is the first step in glucose metabolism.  It occurs in the cell 
cytosol and is a sequence of reactions resulting in the breakdown of glucose 
into pyruvate.  Carbohydrates such as glucose are the principal fuel source for 
β-cells, but other substrates include amino acids and fatty acids.  Once glucose 
enters the β-cell, it is rapidly phosphorylated to form glucose-6-phosphate by 
glucokinase, also known as hexokinase IV or D (Matschinsky et al., 2006).  
Glucokinase is thought to play a dual role by initiating the storage of glucose to 
glycogen in the liver, as well as being a glucose sensor in pancreatic β-cells and 
subsequently the rate limiting step in glycolysis (Matschinsky & Ellerman, 1968).  
This second role of glucokinase was first proposed by Matchinsky and Ellerman 
in 1968, but it was initially received with a mixed reception.  It was only 
accepted many years later when evidence was published in the 1990’s on the 
role glucokinase mutations played in hypo- and hyperglycaemia, coupled with 
the discovery and development of glucokinase activator drugs (Matschinsky et 
al., 2006). 
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Following formation of glucose-6-phosphate via glucose phosphorylation by 
glucokinase, glucose-6-phosphate is metabolised further by a series of 
reactions to eventually form pyruvate.  Pyruvate is then converted to acetyl-CoA 
in the mitochondrial matrix, which is the main substrate for the tricarboxylic acid 
cycle.  Glycolysis is a low energy yielding process compared to the electron 
transport chain, but following the breakdown of one molecule of glucose to form 
two molecules of pyruvate, there is a net yield of two molecules of ATP (Stryer, 
1995). 
1.1.5.2 Tricarboxylic Acid Cycle 
After pyruvate, the end product of glycolysis, has been converted to acetyl-CoA 
in the mitochondrial matrix, acetyl-CoA enters the tricarboxylic acid cycle for 
further metabolism.  The tricarboxylic acid (TCA) cycle is so called because 
citric acid, a form of tricarboxylic acid, is both an entry product and end product 
in this series of reactions thus, completing the cycle.  Also commonly referred to 
as the Krebs cycle, after Sir Hans Adolf Krebs’s discovery in the 1930’s, the 
TCA cycle consumes acetate and water to generate CO2 and the electron 
carriers NADH and FADH2.  Acetyl-CoA (two carbon) condenses with 
oxaloacetate (four carbon) to generate cycle intermediate citrate (six carbon).  
After a series of oxidation reactions, two carbon atoms leave the cycle in the 
form of two CO2 molecules, and the four carbon oxaloacetate is regenerated.  
The TCA cycle is often described as an anaplerotic pathway in that pyruvate 
can be converted to acetyl-CoA (via pyruvate dehydrogenase) or to 
oxaloacetate (via pyruvate carboxylase) and so, ensures restoration of the TCA 
cycle intermediates (see Figure 3).  The cycle can then continue and the overall 
products of the reaction, NADH and FADH2, used to shuttle electrons across 
the electron transport chain. 
1.1.5.3 Electron Transport Chain 
The electron transport chain (ETC), also known as oxidative phosphorylation, 
utilises the electron carriers generated from the TCA cycle to shuttle electrons 
across the respiratory chain complexes, to maintain a H+ concentration gradient 
across the inner mitochondrial membrane.  Protons then flow back down the 
concentration gradient via ATP Synthase, thus generating ATP by oxidative 
phosphorylation in the process.  The respiratory chain, situated on the inner 
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mitochondrial membrane, consists of five complexes, Complex I – V.  
Complexes I, III and IV are H+ pumps, Complexes II and V however are not. 
Electrons are first transported to Complex I (NADH Dehydrogenase) by NADH, 
where they are transferred onto coenzyme-Q (CoQ, also known as ubiquinone).  
CoQ then shuttles the electrons to Complex III (Ubiquinol-Cytochrome c 
Reductase).  Both Complexes I and III are H+ pumps and so, as the electrons 
are transferred onto the electron carriers, they are used to pump H+ ions across 
the mitochondrial inner membrane, into the intermembrane space.  This 
maintains a H+ concentration gradient across the inner mitochondrial 
membrane.  Complex II (Succinate Dehydrogenase) does not act as a H+ pump, 
but functions as part of the TCA cycle, catalysing the conversion of succinate to 
fumarate, generating FADH2 in the process.  Electrons are then transferred 
from Complex II to Complex III by CoQ, the same electron carrier used to 
shuttle electrons from Complex I.  Once at Complex III, electrons are 
transferred onto a different electron carrier, cytochrome c, and are subsequently 
shuttled across to Complex IV.  Complex IV (Cytochrome c Oxidase) is the final 
H+ pump in the ETC and catalyses the transfer of electrons from cytochrome c 
to molecular oxygen, the terminal acceptor.  The electrochemical H+ gradient 
generated by Complexes I, III and IV is used to generate ATP.  As H+ ions flow 
back down the protein gradient into the mitochondrial matrix, ADP is converted 
to ATP by oxidative phosphorylation, catalysed by Complex V (ATP Synthase).  
It is estimated that for every molecule of glucose metabolised, 38 molecules of 
ATP are generated in total: 32 molecules of ATP are produced by the electron 
transport chain, 2 molecules are produced by the Krebs cycle, and 4 molecules 
are produced by glycolysis.  However, 2 molecules of ATP are used in 
glycolysis and so, the net gain of ATP molecules per molecule of glucose 
metabolised is 36 (Stryer, 1995). 
All complexes of the respiratory chain, except Complex II, consist of many 
subunits that are both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) 
encoded.  Complex II is the only complex that is entirely nDNA encoded.  ATP 
generated by the ETC cannot diffuse from the mitochondrial matrix into the cell 
cytosol, but is instead exported by adenosine nucleotide translocator, ANT 
(Maechler & Wollheim, 2001) (refer to Figure 3). 
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Figure 2 The tricarboxylic acid (TCA) cycle and the electron transport chain 
(ETC) 
Pyruvate, generated from glycolysis in the cell cytosol, enters the mitochondrial matrix 
where it becomes converted to acetyl-CoA.  Acetyl-CoA enters the TCA cycle, where a 
series of oxidation reactions generate the electron carriers NADH and FADH2, which 
shuttle electrons across the ETC.  The ETC is situated along the inner mitochondrial 
membrane and consists of five complexes, Complex I – V.  Protons are pumped into 
the mitochondrial intermembrane space by Complexes I, III and IV.  The H+ ions then 
flow back down the proton gradient via Complex V, generating ATP by oxidative 
phosphorylation in the process.  Complex II converts succinate to fumarate, both 
intermediate metabolites in the TCA cycle.   
Figure taken from (Maechler & Wollheim, 2001).  
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1.1.6 Glucose-Stimulated Insulin Secretion 
In pancreatic β-cells, glucose metabolism is closely associated with insulin 
secretion (Wollheim, 2000).  There are two phases of insulin secretion.  The first 
phase (acute or early insulin secretion) is instantaneous using intracellular 
vesicle stores of insulin, reaching a maximum level of secretion within 3 – 5 
minutes and lasting for approximately 10 minutes (Porte, 2001).  The second 
phase (late secretion) happens after first phase insulin secretion and relies on 
de novo insulin synthesis as well as intracellular insulin stores.  It is gradual, in 
contrast to the short sharp first phase insulin release, and continues for as long 
as there is a glucose stimulus (Porte, 2001). 
Metabolism of glucose by glycolysis, the TCA cycle and the ETC subsequently 
causes an increase in the ATP/ADP ratio in the cell cytosol, as ATP is released 
from the mitochondria.  This rise in ATP promotes the closure of ATP-sensitive 
K+ channels (KATP) on the β-cell plasma membrane.  These KATP channels pump 
K+ ions out of the cells giving the inside of the plasma membrane a more 
negative charge compare to the outside of the plasma membrane.  Therefore, 
closure of the KATP channels causes plasma membrane depolarisation and 
subsequent opening of voltage-gated Ca2+ channels (Ashcroft et al., 1994).  
This is a key step in glucose-stimulated insulin secretion.  The increase in 
cytosolic Ca2+ as a result of Ca2+ channels opening induces the migration of 
intracellular insulin granules to the cell surface (Ashcroft et al., 1994).  Fusion of 
intracellular insulin vesicles with the plasma membrane promotes exocytosis 
and secretion of insulin from the β-cell.  Several other additive signals are 
proposed to assist in this metabolism-secretion coupling, as indicated in Figure 
3 (Maechler & Wollheim, 2001). 
 
  
  
 
 
 
Figure 3  Model for glucose
cells   
Glucose is taken up by the cell where it is then converted to pyruvate (Pyr) by 
glycolysis.  Pyr then enters the mitochondri
is then able to enter the TCA cycle.  The electron carriers gen
(NADH and FADH2) are then used to shuttle electrons along the respiratory chain 
located on the inner mitochondrial membrane, where ATP is generated by oxidative 
phosphorylation.  ATP enters the cell cytosol, resulting in an increase
ratio and ultimately, depolarisation of the cell membrane via the closure of the ATP
sensitive K+ channels.  This causes an influx of Ca
promotes insulin exocytosis following vesicular fusion with the plasma membr
Figure adapted from 
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1.2 Mitochondria 
1.2.1 Mitochondrial Structure and Function 
The term mitochondria was derived from the Greek ‘mitos’, meaning thread, and 
‘chondros’, meaning granule.  The expression was originally coined by Carlos 
Benda back in 1898 whilst investigating spermatogenesis (Benda, 1898).  
Mitochondria are double membrane bound organelles often described as the 
‘power packs’ of the cell, as they are the major source of cellular energy in the 
form of adenosine triphosphate (ATP).  Mitochondria are divided into four main 
structural units: two membranes (inner and outer mitochondrial membrane) that 
enclose two aqueous spaces (intermembrane space and mitochondrial matrix 
respectively).  The inner mitochondrial membrane is highly convoluted 
producing structures called cristae.  The cristae give a large surface area in 
which oxidative phosphorylation can occur, as the components of the 
respiratory chain are embedded in the inner mitochondrial membrane.  The 
outer mitochondrial membrane encloses the inner mitochondrial membrane, 
and produces the intermembrane space, the region between the two 
membranes.  The second aqueous compartment, the mitochondrial matrix, is 
encompassed by the inner mitochondrial membrane and contains enzymes and 
metabolite intermediates required for the TCA cycle, as well as mtDNA (Stryer, 
1995). 
1.2.2 Mitochondrial DNA 
Mitochondrial DNA (mtDNA) is a circular, double stranded DNA molecule of 
16.6 kb in length in humans (Attardi & Schatz, 1988).  It encodes only 37 genes, 
including 13 polypeptides essential for the respiratory chain, as well as RNA 
molecules required for the translation of these polypeptides within the 
mitochondria, including 22 transfer RNAs (tRNAs) and 2 ribosomal RNAs 
(rRNAs) (Maechler & Wollheim, 2001; Taylor & Turnbull, 2005) (Figure 4).  The 
remaining protein components required to complete the respiratory chain 
complexes are nuclear encoded, as are the cellular machinery involved in 
mtDNA replication and maintenance.  Human mtDNA is not inherited by 
traditional Mendelian genetics, but is instead maternally inherited.  Also, unlike 
chromosomal nuclear DNA, there is more than one copy of the mitochondrial 
genome present within each cell (Taylor & Turnbull, 2005). 
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Like nuclear DNA, mtDNA is packaged into structures called nucleoids in order 
to maintain genetic stability.  These nucleoid structures are thought to consist of 
several copies of mtDNA as well as a group of proteins believed to be involved 
in mtDNA replication including: mitochondrial transcription factor A (TFAM), 
mitochondrial single stranded binding protein (mtSSB) and the helicase Twinkle 
(Wang & Bogenhagen, 2006).  The nucleoid structure of mtDNA has striking 
similarities to that of the nucleoid structure bacterial DNA.  These similarities 
include both nucleoid structures being of approximately 70 nm in diameter, 
containing 5-7 genome copies per nucleoid as well as both nucleoid structures 
being anchored to the membrane (Clay Montier et al., 2009).  These similarities 
can be seen to support the endosymbiont hypothesis that strives to explain the 
origin of mtDNA. 
1.2.3 The Endosymbiont Hypothesis 
Mitochondria are believed to have evolved from an endosymbiotic relationship 
between a prokaryotic bacterium and a eukaryotic cell containing nDNA 
(Margulis, 1981; Gray, 1989).  The endosymbiont hypothesis proposes that 
mitochondria and chloroplasts were originally descendants of the archaic 
eubacteria, more specifically from the cyanobacteria and α-purple bacteria 
phyla respectively (Gray, 1988).  These bacteria then formed a close 
endosymbiotic relationship with an as yet unidentified nDNA-containing 
eukaryotic cell, and through a series of evolutionary process(es), have 
ultimately formed internal cellular organelles with their own distinct genome.  
This distinct genome is thus believed to be a remnant of the original archaic 
relationship.  Mitochondria are semi-independent in that they are capable of 
mtDNA replication independent of the cell cycle but conversely, they are 
incapable of functioning autonomously (Gray, 1989). 
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Figure 4 Human mitochondrial DNA (mtDNA)
Human mtDNA is a 16.6
mitochondrial matrix.  It encodes 13 polypeptides t
phosphorylation.  The other components of the respiratory chain are nuclear encoded, 
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1.2.4 mtDNA Replication and Transcription 
Although it is widely accepted that the replication of mtDNA occurs 
independently of the cell cycle and hence, nuclear DNA replication 
(Bogenhagen & Clayton, 1977), the precise mechanism of mammalian mtDNA 
replication is still hotly debated.  Two possible mechanisms elucidating the 
process of mtDNA replication have been proposed.  The strand-displacement 
model was initially presented in 1982 (Clayton, 1982) and suggests that mtDNA 
replication is asynchronous and unidirectional.  The model implies that 
replication of the leading, heavy (H) strand occurs first at an origin referred to as 
OH, situated in the displacement (D)-loop region of mtDNA (Figure 4).  This is 
then followed by replication of the lagging, light (L) strand, which begins when 
H-strand synthesis is about two-thirds complete, thus exposing the origin OL 
and allowing L-strand synthesis to begin.  The synthesis of H- and L-strands 
occur in opposing directions.  
In 2000, however, Holt et al. suggested a mechanism of mtDNA replication that 
involves a coupling of both leading- and lagging-strand synthesis.  This 
suggestion is supported by the groups’ results, which were based on two-
dimensional agarose gel electrophoresis (Holt et al., 2000).  These findings 
have been substantiated by additional investigations (Yang et al., 2002; 
Bowmaker et al., 2003). 
The replication of mtDNA is tightly coupled to the mtDNA transcription and so, 
many of the key components involved in mtDNA transcription are utilised in 
mtDNA replication also.  mtDNA transcription factor A (TFAM) is a mtDNA 
transcription factor thought to be involved in regulating mtDNA copy number as 
well as a key player in mtDNA transcription (Alam et al., 2003; Ekstrand et al., 
2004).  TFAM, together with RNA polymerase, binds mtDNA in order to 
synthesise an RNA primer.  This primer is then processed by a mitochondrial 
RNA processing (MRP) complex and the processed primer is then used to help 
initiate mtDNA replication.  The daughter mtDNA molecule is synthesised via 
DNA polymerase γ (POLG), a heterodimeric polymerase with proof-reading 
ability due to the catalytic subunit PolγA, and processivity capabilities due to the 
subunit PolγB (Carrodeguas et al., 2001).  mtDNA single-stranded binding 
(mtSSB) proteins bind single stranded mtDNA to prevent the mtDNA reverting 
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back to its natural double stranded form and promote mtDNA stabilisation.  The 
helicase Twinkle has also been implicated in mtDNA replication, destabilising 
the mtDNA double helical structure prior to replication by utilising its 5’-3’ 
helicase activity (Spelbrink et al., 2001).  These are the key components of 
mtDNA replication and transcription, and are also part of mtDNA nucleoids.  All 
of these accessory proteins required for mtDNA transcription and replication are 
nuclearly encoded, perhaps suggesting an overall nuclear control of mtDNA. 
1.2.5 Homoplasmy and Heteroplasmy 
Mitochondrial DNA differs greatly from nuclear DNA in that it exhibits polyploidy: 
there is more than one complete copy of the mtDNA genome per cell.  The 
mtDNA copy number can vary, but it is thought that there can be up to several 
thousand copies of the mtDNA genome per cell (Taylor & Turnbull, 2005).  
These mtDNA copies can be exact replicas of one another, homoplasmic, or 
they can exhibit slight variations between copies culminating in more than one 
mtDNA genotype, heteroplasmic.   
The terms homoplasmy and heteroplasmy are generally used to describe 
various mutations of mtDNA and whether these mutations affect all copies of 
mtDNA within the cell (homoplasmic mutation) or only some copies 
(heteroplasmic mutation).  Cells are still capable of functioning correctly up to a 
certain level of mtDNA mutation, or mutational threshold.  Once the 
heteroplasmic mutational level exceeds this threshold, then the result is 
normally manifestation of disease symptoms due to possible disruption in 
biochemical and/or cellular processes (Taylor & Turnbull, 2005). 
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1.3 mtDNA Copy Number 
1.3.1 mtDNA Threshold Effect 
As mentioned previously, mtDNA is polyploid, and the multiple copies of mtDNA 
present per cell can be heteroplasmic or homoplasmic (Section 1.2.5).  
Heteroplasmic cells harbouring both mutant and wild type mtDNA can function 
normally, as long as the ratio of mutant to wild type mtDNA does not exceed a 
certain threshold. Once this threshold is surpassed, then the mutant mtDNA 
load may be visible as a phenotypic or biochemical defect (Rossignol et al., 
2003).  This so called ‘phenotypic threshold effect’ has been shown in multiple 
patients and cell models (Moraes et al., 1992; Sciacco et al., 1994; Bai et al., 
2000). 
Sciacco and colleagues took muscle biopsies from four patients with 
mitochondrial myopathy and using PCR, found the levels of deleted (∆) mtDNA, 
exhibiting a common deletion of around 755 bp, varied amongst microdissected 
muscle fibres.  In normal muscle fibres the levels of ∆-mtDNA were predicted to 
be around 31% ± 26.  This was found to increase in diseased muscle fibres, 
with the levels of ∆-mtDNA reaching 95% ± 2.  The group concluded that a 
mutant mtDNA load of >85% was needed to impair respiratory function (Sciacco 
et al., 1994).  Similarly, whilst investigating the A3243G point mutation in 
MELAS patients, Moraes et al. found that a mutant load greater than 90% 
caused mitochondrial proliferation in muscle fibres, culminating in the ragged 
red fibre phenotype associated with MELAS patients (Moraes et al., 1992).  
Finally, Bai and colleagues showed that a nonsense mutation in ND5, a mtDNA 
encoded subunit of Complex I of the respiratory chain, resulted in decreased 
glutamate/malate dependent mitochondrial respiration when mutant mtDNA 
exceeded 40% of the overall mtDNA population (Bai et al., 2000).  Taken 
together, these studies indicate that mitochondrial dysfunction ensues only 
when the heteroplasmic ratio of mutant to wild type mtDNA exceeds a certain 
threshold. 
1.3.2 Regulation of mtDNA Copy Number 
In recent years, much insight has been gained with regards to mitochondrial 
function, genetics and biology; however, there are still gaps in our knowledge as 
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to the precise mechanism by which mtDNA copy number is regulated.  There 
are several key proteins that have been implicated with the maintenance of 
mtDNA copy number, the main ones including mitochondrial transcription factor 
A, B1 and B2 (TFAM, TFB1M and TFB2M), nuclear respiratory factor 1 and 2 
(NRF-1/-2), peroxisome proliferator-activator receptor-γ coactivator-1α (PGC-
1α), and polymerase-γ (POLG). 
1.3.3 Peroxisome Proliferator-Activator Receptor-γ Coactivator-1α (PGC-1α) 
PGC-1α is a coactivator of peroxisome proliferator-activator receptor-γ 
(PPARγ), a ligand-activated transcription factor involved in adipogenesis 
(Tontonoz et al., 1994), and is thought to mediate mitochondrial biogenesis.  
PCG-1α transcription is activated through many signalling pathways including 
cAMP, MAPK and nitric oxide (Figure 5) (Puigserver & Spiegelman, 2003).  
PGC-1α is known to confer transcriptional specificity by only interacting with, 
and activating, specific genes and transcription factors in certain cell types 
(Handschin & Spiegelman, 2006). 
The regulation of PGC-1α transcription involves many external stimuli and 
differs from cell type to cell type.  In brown adipose tissue (BAT), thermogenesis 
induces PGC-1α expression whereas in muscle, low ATP levels and exercise 
cause PGC-1α transcription.  PGC-1α, once expressed, is capable of auto-
regulating its own transcription and additionally, factors that bind PGC-1α 
further downstream, for example PPARγ, Foxo1 and MEF2, are also involved in 
the regulation of PGC-1α (Handschin & Spiegelman, 2006).  Cyclic AMP 
response element (CRE) binding protein, CREB, is the main transcription factor 
involved in PGC-1α expression.  It has been suggested that the proteasomal 
degradation pathways, as well as PGC-1α proteolysis by calpain proteins in 
response to increased Ca2+ levels, are responsible for the regulation of PGC-1α 
turn over (Rasbach et al., 2008). 
1.3.4 Nuclear Respiratory Factor 1 and 2 (NRF-1 & NRF-2) 
NRF-1 and NRF-2 are nuclear encoded transcription factors thought to be 
activated by PGC-1α.  Initially, NRF-1 was found to activate cytochrome c gene 
expression (Evans & Scarpulla, 1989) but in 1994, Virbasius and Scarpulla 
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reported that both NRF-1 and NRF-2 are responsible for activation of TFAM 
(Virbasius & Scarpulla, 1994).  Virbasius and Scarpulla demonstrated that the 
TFAM proximal promoter requires interaction with the NRF-1 and NRF-2 
recognition sites at guanine nucleotide contacts prior to activation.  When these 
guanine nucleotide contacts were mutated, NRF-1 and NRF-2 binding was 
inhibited and promoter activity in the COS-1 transfected cells was dramatically 
reduced (Virbasius & Scarpulla, 1994).  Both NRFs have also been implicated 
in the regulation of the mitochondrial transcription specificity factors, TFB1M 
and TFB2M (Gleyzer et al., 2005).   
1.3.5 Mitochondrial Transcription Factor B1 and B2 (TFB1M & TFB2M) 
The essential mitochondrial transcription machinery required in order to initiate 
mtDNA transcription include: mitochondrial RNA polymerase (POLRMT), 
mitochondrial transcription factor B2 (TFB2M) and mitochondrial transcription 
factor A (TFAM) (Falkenberg et al., 2002; Metodiev et al., 2009).  TFB2M and 
POLRMT first interact to form a heterodimer, before co-localising with TFAM on 
the mtDNA promoter (Falkenberg et al., 2002).  Mitochondrial transcription 
factor B1 is a paralogue of TFB2M, but is technically not a transcription factor 
per se (Metodiev et al., 2009; Litonin et al., 2010).  Instead, TFB1M functions as 
a 12S rRNA methyltransferase, required for the integrity of the small mtDNA 
encoded ribosomal subunit (Metodiev et al., 2009). 
1.3.6 Mitochondrial Transcription Factor A (TFAM) 
Mitochondrial transcription factor A, more commonly known as TFAM but 
previously known as mtTFA, is a transcription factor involved in the transcription 
and replication of mtDNA, as well as the regulation of mtDNA copy number.  But 
the precise role of TFAM is still unknown.  TFAM is nuclear encoded and upon 
activation, translocates from the nucleus to the mitochondria where it initiates 
mtDNA transcription and replication (Shadel & Clayton, 1993).  There are three 
promoter regions in mtDNA: light strand promoter (LSP), heavy strand promoter 
1 (HSP1) and heavy strand promoter 2 (HSP2); TFAM is thought to bind to the 
LSP and HSP1 promoters to initiate mtDNA gene transcription (Campbell et al., 
2012). 
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The mature human TFAM protein shares 78% homology with the murine TFAM 
protein (Kaufman et al., 2007).  TFAM is a 25 kDa high mobility group (HMG) 
protein, and contains two conserved HMG box domains of ~80 amino acids, 
which are found in many eukaryotic transcription factors and chromosomal 
proteins (Parisi & Clayton, 1991).  The HMG domains, HMG box 1 and HMG 
box 2, facilitate TFAM binding to the minor grooves of mtDNA, enabling the 
transcription factor to bend mtDNA, thus allowing easier access for other 
proteins.  Situated between the two HMG domains is the linker domain, 
responsible for strengthening TFAM/DNA binding by making additional contacts 
to the phosphodiester backbone of DNA (Campbell et al., 2012).  Downstream 
of the second HMG domain is the carboxyl (C)-terminal tail, believed to be 
important during initiation of mtDNA transcription (Ohgaki et al., 2007).  
Overlapping the HMG box 2 domain and the C-terminal tail is the coiled-coil 
domain, implicated in TFAM homodimerisation (Kaufman et al., 2007; Campbell 
et al., 2012). 
As well as having roles in mtDNA transcription, TFAM also has an important 
role in packaging mtDNA into nucleoids (Larsson, 2010).  The TFAM protein is 
often described as exhibiting positive cooperativity, that is, when one TFAM 
protein binds to DNA, it encourages the binding of other TFAM proteins, 
possibly due to the DNA already having a kinked structure (Kaufman et al., 
2007).  It has been suggested that TFAM binds to DNA as a homodimer at a 
stoichiometry of one TFAM homodimer per 37.2 bp and so, approximately 900 
TFAM molecules per mtDNA genome (Campbell et al., 2012).  This high TFAM 
abundance is supported by other independent studies (Ghivizzani et al., 1994; 
Dairaghi et al., 1995; Kaufman et al., 2007).  Other groups have suggested that 
TFAM coats the entire length of mtDNA, much like a single stranded binding 
protein (Takamatsu et al., 2002; Alam et al., 2003; Ohgaki et al., 2007).  
Conversely, low TFAM abundance has also been documented.  In HeLa cells, it 
was predicted that there were only 50 TFAM proteins per mtDNA genome 
(Cotney et al., 2007), and in HEK293 cells, a mere 35 TFAM proteins per 
mtDNA genome (Maniura-Weber et al., 2004).  Whether the abundance of 
TFAM molecules per mtDNA genome is specific to cell type remains to be 
elucidated. 
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In vivo studies looking at TFAM knockdown models have highlighted the 
importance of this protein.  Larson et al. produced heterozygous and 
homozygous knockdowns of the TFAM gene in mice.  They documented that 
the heterozygous mice had ~35-40% depletion in mtDNA, in comparison to the 
wild-type, as well as respiratory chain deficiency in the heart.  The homozygous 
mice, however, failed to reach the end of gestation due to a severe depletion in 
mtDNA and serious respiratory chain deficiencies such as abolished oxidative 
phosphorylation (Larsson et al., 1998).  This was the first time TFAM was found 
to have a direct role in mitochondrial biogenesis in vivo.  Since then, the same 
group have successfully knocked down TFAM expression in mice in various cell 
types including pancreatic β-cells (Silva et al., 2000), cardiomyocytes (J. Wang 
et al., 1999; Li et al., 2000), skeletal muscle cells (Wredenberg et al., 2002) and 
pyramidal neurones (Sorensen et al., 2001). 
In 2004, Erkstrand et al. linked TFAM function with direct regulation of mtDNA 
copy number in mammals.  The group developed transgenic mice containing 
large genomic fragments harbouring the human TFAM gene.  The resultant 
mice were found to ubiquitously overexpress the human TFAM protein, which 
resulted in a general increase in mtDNA copy number.  Southern blotting was 
conducted to quantify the level of mtDNA relative to 18S nuclear DNA, and the 
result was an increase in mtDNA in heart, kidney and muscle cells of the 
transgenic mice overexpressing human TFAM when compared to wild-type 
mice (Ekstrand et al., 2004). 
The mechanism by which TFAM is able to regulate mtDNA copy number in vivo 
is still hotly debated.  Two possible mechanisms have been proposed.  The first 
involves transcription-mediated copy number control in which an increase in 
TFAM gene expression causes an increase in mtDNA transcription as the 
imported TFAM proteins target the LSP and promote priming for DNA synthesis 
(Campbell et al., 2012).  The second implies that the non-specific genome wide 
binding of TFAM to mtDNA is involved in regulating copy number as it stabilises 
mtDNA steady-state levels, possibly reducing mtDNA turnover (Campbell et al., 
2012). 
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1.3.7 Polymerase γ (POLG) 
Polymerase γ (POLG) is the main DNA polymerase involved in mtDNA 
replication.  The enzyme contains a polymerase domain and an exonuclease 
domain, thus enabling high-fidelity replication of mtDNA, with an estimated 1 
error per 500,000 bp (Longley et al., 2001; Lee & Johnson, 2006).  There are 
over 80 pathogenic mutations in POLG in humans, which are often linked to the 
onset of progressive external ophthalmoplegia (PEO), Alpers syndrome and 
ataxia (Kujoth et al., 2007).  Most POLG mutations are recessive, but a few 
display dominant inheritance (Kujoth et al., 2007).  Mutations in POLG result in 
reduced polymerase fidelity as incorrect nucleotides are incorporated, or in 
large scale mtDNA deletions due to the polymerase stalling (Kujoth et al., 
2007). 
Mouse models have been developed in which the exonuclease domain of 
POLG was rendered inactive following a point mutation, producing PolgD257A 
knock-in mice with limited mtDNA proofreading ability (Trifunovic et al., 2004; 
Kujoth et al., 2005).  Both groups were able to demonstrate that mtDNA 
replication error rates increased at least 3- to 5-fold (Trifunovic et al., 2004), 
culminating in the accumulation of age-related mtDNA mutations.  Not only that, 
but the mice also showed signs of premature ageing such as greying hair and 
hair loss, early loss of fertility, weight loss, as well as reduced bone density and 
muscle mass (Trifunovic et al., 2004; Kujoth et al., 2005).  Kujoth et al. 
concluded that the accumulation of mtDNA mutations that promote apoptosis 
was to blame for the accelerated ageing seen in these mice (Kujoth et al., 
2005).   
In summary, it is clear that PGC-1α, NRF-1/-2, TFB1M, TFB2M, TFAM and 
POLG all play important roles during the process of mitochondrial biogenesis, 
and these roles are all integrated.  Figure 5 graphically summarises the process 
of mitochondrial biogenesis under the control of PGC-1α. 
  
  
 
 
Figure 5 Potential model for mitochondrial biogenesis and gene expression
(1) Adrenergic or cytokine receptor activation trigger
signalling cascades (2) Activated PKA phosphorylates the transcription factor, CREB, 
and the PCG-1α gene is transcribed (3) Activated p38 MAPK directly phosphorylates 
the PGC-1α protein, thus activating it (4) PGC
transcription and activation (5) TFAM translocates to the nucleus culminating in 
transcription and replication of mtDNA.  cAMP, cyclic adenosine monophosphate; PKA, 
protein kinase A; MAPK, mitogen
element (CRE) binding protein; PGC
coactivator-1α; NRF-
transcription factor A.
Figure adapted from 
 
28 
s the PKA and p38 MAPK cell 
-1α activates the NRFs resulting in TFAM 
-activated protein kinase; CREB, cA
-1α, peroxisome proliferator
1 and -2, nuclear response factors -1 and -2; TFAM, mitochondrial 
 
(Puigserver & Spiegelman, 2003). 
 
 
   
MP response 
-activator receptor-γ 
29 
1.4 mtDNA Abnormalities and Diabetes 
1.4.1 mtDNA Depletion and Pancreatic β-cell Function 
There is an age-dependent progressive decline in β-cell function seen in the 
normal non-diabetic population (Basu et al., 2003; Chang & Halter, 2003).  The 
cause of this reduced β-cell function has been attributed in part to the effects of 
mtDNA depletion (Soejima et al., 1996; E. D. Kennedy et al., 1998; Silva et al., 
2000; Cree et al., 2008).  Severe mtDNA depletion has been produced in rodent 
pancreatic β-cells with the use of ethidium bromide (EtBr), an inhibitor of mtDNA 
replication (Soejima et al., 1996; E. D. Kennedy et al., 1998; Tsuruzoe et al., 
1998).  EtBr-induced mtDNA depleted cells exhibited decreased glucose-
stimulated insulin secretion, which was accredited to severe mitochondrial 
dysfunction, shown by reduced cytochrome c oxidase enzyme activity (Soejima 
et al., 1996; E. D. Kennedy et al., 1998; Tsuruzoe et al., 1998).  Similarly, Silva 
et al. (Silva et al., 2000) produced tissue specific disruption of the TFAM gene in 
mouse pancreatic β-cells, which resulted in substantial mtDNA depletion 
compared to littermate control mice.  Akin to the EtBr-induced mtDNA depletion 
studies, Silva et al. also showed that insulin secretion was reduced in mutant 
islets, which was accompanied by deficient cytochrome c oxidase activity; in 
addition to reduced mitochondrial membrane hyperpolarisation and impaired 
Ca2+ signalling.   
A paper published during my studentship described how transcriptional 
silencing of the pancreatic duodenal homeobox 1 (Pdx1) gene in vivo in rat 
models resulted in partial mtDNA depletion (Gauthier et al., 2009).  PDX1 is a β-
cell specific transcription factor believed to play a regulatory role in embryonic 
development and differentiated function (Servitja & Ferrer, 2004; Oliver-
Krasinski & Stoffers, 2008).  It was shown that PDX1 deficiency causes 
mitochondrial dysfunction as well as defective insulin secretion, which was 
postulated to occur through TFAM suppression.  These findings were further 
confirmed following adenoviral overexpression of TFAM, which was found to 
increase mtDNA copy number, mitochondrial function and insulin secretion 
(Gauthier et al., 2009).  However, in view of the critical role of PDX1 in global β-
cell function, it remains to be determined whether targeted TFAM knockdown 
and partial mtDNA depletion affects insulin secretion. 
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The impaired stimulus-secretion coupling reported in these studies is due to a 
defective electron transport chain and loss of mitochondrial ATP production, as 
a result of the loss of mtDNA encoded subunits following mtDNA depletion 
(Soejima et al., 1996; E. D. Kennedy et al., 1998; Tsuruzoe et al., 1998).  
Glucose-stimulated insulin secretion was restored following treatment with 
agents that increased intracellular Ca2+ concentration such as the depolarising 
agent KCl (E. D. Kennedy et al., 1998) or the insulin secretagogue 
glibenclamide (T. Hayakawa et al., 1998; Tsuruzoe et al., 1998), thus 
demonstrating that the cause of impaired stimulus-secretion coupling was 
mitochondrial in origin. 
Taken together, these studies indicate that mtDNA depletion, whether partial or 
severe, drastically affects pancreatic β-cell function by causing reduced insulin 
secretion as well as mitochondrial dysfunction. 
1.4.2 mtDNA Mutations and Diabetes 
Mitochondrial DNA mutations are thought to account for approximately 1% of all 
diabetes cases (Maassen et al., 2001) and there is evidence to show an 
increased prevalence of diabetes in patients with inherited mtDNA abnormalities 
(Maassen et al., 2004).  The most common mtDNA mutation associated with 
diabetes is the A3243G mutation in the tRNALys(UUR) gene.  This AG transition 
at nucleotide 3243 is thought to prevent transcription termination, as this is the 
recognition site for a protein involved in terminating transcription of rRNA genes 
(Christianson & Clayton, 1986; Kruse et al., 1989).  The A3243G mutation was 
first discovered in patients with mitochondrial myopathy, encephalopathy lactic 
acidosis, stroke-like episode (MELAS), a progressive neurodegenerative 
disorder with diabetes often seen as an accompanying symptom (Goto et al., 
1990).  But the mutation has also been implicated in the onset of maternally 
inherited diabetes and deafness (MIDD) (van den Ouweland et al., 1992).  The 
exact biochemical consequences of the A3243G mutation are unknown, but the 
diabetogenic nature of the A3243G mutation has been hypothesised by a 
reduction in the cytosolic  ATP/ADP ratio, culminating in impaired insulin 
secretion (Maassen et al., 2004).  Indeed, impaired insulin secretion is a key 
characteristic of diabetic patients with mtDNA abnormalities (Lynn et al., 2003).  
Maassen et al. showed carriers of the A3243G mutation to exhibit an impaired 
first and second phase insulin response to a 10 mmol/l hyperglycaemic clamp, 
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when compared to non-carriers of the mutation (Maassen et al., 2004).  A key 
finding from the study by Lynn et al. was that there was a low percentage ratio 
of A3243G mutated to wild type mtDNA in β-cells (<25%) compared to other 
tissues examined such as muscle (60%) and brain (66-78%).  These findings 
suggest that there is an increased susceptibility in β-cells to mitochondrial 
dysfunction (Lynn et al., 2003).   
1.4.3 Mitochondrial Dysfunction and T2DM 
T2DM has been associated with β-cell specific knockdown of the mitochondrial 
transcription factor TFAM, in which diabetes presented in the TFAM knockout 
mice from 5 weeks of age (Silva et al., 2000).  Interestingly, Silva et al. also 
demonstrated that the phenotype of the TFAM knockout mice changed with 
time.  The group observed that young mutant mice (7 weeks of age) were 
diabetic with normal β-cell mass, whereas older mutant mice (>14 weeks of 
age) remained diabetic, but were seen to have reduced β-cell mass, suggesting 
that impaired insulin secretion occurs at younger ages.  The group were able to 
conclude that during the progression of mitochondrial diabetes, there is first an 
impaired stimulus-secretion coupling in mutant cells, which is followed by β-cell 
loss (Silva et al., 2000). 
T2DM has also been associated with a common gene variant in mitochondrial 
transcription factor B1 (TFB1M), a mtDNA methyltransferase (Koeck et al., 
2011).  The rs950994 risk allele correlated with reduced insulin secretion, 
elevated postprandial glucose levels and increased risk of developing T2DM 
(Koeck et al., 2011).  In addition, it has been postulated that an age-dependent 
deterioration of β-cell function is to blame for the onset of diabetes in carriers of 
the A3243G mutation, rather than a cellular resistance to insulin (Maassen et 
al., 2004). 
1.5 Mitochondrial Dysfunction and Ageing 
1.5.1 Free Radical Theory of Ageing and Reactive Oxygen Species (ROS) 
In 1956, Denham Harman proposed the free radical theory of ageing from his 
observations on radiation and reactive oxygen species (ROS).  Harman was the 
first to advocate that ageing, and age-related degenerative diseases, may be 
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the result of cellular oxidative damage from endogenously generated ROS 
(Harman, 1956).  It was not until McCord and Fridovich’s discovery of the 
superoxide scavenger enzyme superoxide dismutase in 1969, that Harman’s 
free radical theory of ageing was considered seriously (J. M. McCord & 
Fridovich, 1969; Balaban et al., 2005).  Further investigations have corroborated 
Harman’s original theory, and current understanding is that metabolic rate and 
resultant generation of ROS are the cause of ageing in man, due to the 
accumulation of cell oxidative damage with age (Balaban et al., 2005). 
Reactive oxygen species (ROS) are very small, highly reactive molecules.  
They are predominantly generated by the mitochondria (estimated around 90%) 
however, other sources of ROS generation include peroxisomal lipid 
metabolism, cyclooxygenase enzymatic activity as well as plasma membrane 
bound NADPH oxidase activity (Balaban et al., 2005).  In the mitochondria, the 
main sites of ROS generation are thought to be at Complex I and Complex III 
on the respiratory chain, when electrons react with free molecular oxygen, 
producing free radicals (Balaban et al., 2005).   
Natural defences against ROS include the enzyme superoxide dismutase 
(SOD) as well as antioxidants such as vitamin E, uric acid and vitamin C.  The 
scavenging enzyme SOD functions by converting superoxide molecules into 
oxygen and hydrogen peroxide, H2O2 (J. M. McCord & Fridovich, 1969; J.M. 
McCord & Fridovich, 1988).  H2O2 is then broken down further by the catalase 
enzyme to form oxygen and hydrogen, which have a much less damaging effect 
on cells.   
1.5.2 Role of mtDNA mutations and oxidative damage in ageing 
mtDNA mutations can culminate in a variety of clinical disorders, mainly 
because mitochondria are ubiquitously expressed in most cell types.  Some of 
the main disorders associated with mtDNA mutations are categorised in Table 
2.  Holt et al. were the pioneering group to link deletions in mtDNA with the 
onset of human disease in 1988 (Holt et al., 1988).  Patients with mutations in 
nuclear encoded genes involved in oxidative phosphorylation or mtDNA 
maintenance are thought to develop symptoms similar to patients with 
mitochondrial disorders (Shoubridge, 2001; Zhu et al., 2009), indicating the 
importance of mtDNA maintenance in disease progression also.  The majority of 
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mtDNA deletions occur in the major arc of the mtDNA genome, which is 
between OH, nucleotides 110-441, and OL, nucleotides 5721-5798 (He et al., 
2002) (see Figure 4). 
The formation of 8-oxo-2’-deoxyguanosine (oxo8dG), a known product of 
radiation damage, has commonly been used as a biomarker of DNA oxidative 
damage, where increased levels of DNA damage and hence oxo8dG formation, 
are found to correlate with increasing age (Balaban et al., 2005).  An age-
dependent accumulation of oxo8dG has been reported in human skeletal 
muscle (Zhang et al., 1998) and human diaphragm muscle (M. Hayakawa et al., 
1991).  The levels of oxo8dG were found to be significantly higher in mtDNA 
compared to nDNA of rat liver tissue (Richter et al., 1988).  The general 
consensus is that this is because mtDNA are more prone to oxidative damage, 
which could result in mutations, because of their close proximity to the major 
source of ROS generation, the electron transport chain.  This is not helped by 
the fact that there is a distinct lack of mtDNA repair mechanisms and so, when 
mutations do occur, they are not always corrected (Clayton et al., 1974; Richter, 
1988).   
It is widely accepted that mtDNA base-substitution mutations also accumulate 
with advancing age in multiple tissues and species, including rodents, rhesus 
monkeys and humans (Kujoth et al., 2007; Larsson, 2010).  The age-dependent 
accumulation of these point mutations has been attributed to ROS-induced 
oxidative damage or replication errors caused by POLG (Michikawa et al., 
1999).  
However, there is emerging evidence that argues that mutations in mtDNA are 
not solely the result of oxidative damage, but could be the consequence of 
errors in replication, thus implicating POLG (Madsen et al., 1993; Zheng et al., 
2006; Larsson, 2010).   
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mtDNA 
Disorder 
Clinical Phenotype Mutation Gene Hetero- or 
Homoplasmic 
Mode of Inheritance 
Kearns-Sayre 
syndrome 
Progressive myopathy, 
opthalmoplegia, 
cardiomyopathy 
Single large-scale 
deletion 
Several deleted genes Heteroplasmic Usually sporadic 
Pearson 
syndrome 
Pancytopoenia, lactic 
acidosis 
Single large-scale 
deletion 
Several deleted genes Heteroplasmic Usually sporadic 
MELAS Myopathy, 
encephalopathy lactic 
acidosis, stroke-like 
episode 
3243A>G 
3271T>C 
TRNL1 Heteroplasmic Maternal 
Individual mutations ND1 & ND5 Heteroplasmic Maternal 
MIDD Diabetes, deafness 3243A>G TRNL1 Heteroplasmic Maternal 
LHON Optic neuropathy 3460G>A 
11778G>A 
14484T>C 
ND1 
ND4 
ND6 
Hetero/Homoplasmic 
Hetero/Homoplasmic 
Hetero/Homoplasmic 
Maternal 
Maternal 
Maternal 
Myopathy and 
diabetes 
Myopathy, weakness, 
diabetes 
14709T>C TRNE Hetero/Homoplasmic Maternal 
MILS Progressive brain stem 
disorder 
8993T>C ATP6 Heteroplasmic Maternal 
MERRF Myoclonic epilepsy, 
myopathy 
8344A>G  
8356T>C 
TRNK Heteroplasmic Maternal 
 
Table 2 Conditions that have been linked to mutations in mtDNA   
This table has been adapted from (Taylor & Turnbull, 2005) and details some of the diseases that can manifest as a result of mtDNA mutation.  
MELAS: Mitochondrial myopathy, encephalopathy lactic acidosis, stroke-like episode; MIDD: maternally-inherited diabetes and deafness; LHON: 
Leber hereditary optic neuropathy; MILS: maternally-inherited Leigh syndrome; MERRF: myoclonic epilepsy and ragged-red fibres. 
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1.5.3 Mitochondrial Dysfunction Increases with Age 
It is widely documented that mitochondrial dysfunction increases with advancing 
age (Shigenaga et al., 1994; Balaban et al., 2005).  This may be owing to the 
age-dependent accumulation of mutations caused by oxidative damage to 
mtDNA.  For example, in COX1 deficient cells, cells devoid of the mtDNA 
encoded cytochrome c oxidase subunit 1 (COX1) of Complex IV, there are high 
levels of mutant mtDNA (Sciacco et al., 1994; Moslemi et al., 1996).  The high 
level of mutant mtDNA in COX1 deficient cells is possibly due to clonal 
expansion of individual deletions/point mutations (He et al., 2002).  These 
COX1 deficient cells have been shown to have severe respiratory chain 
dysfunction (Sciacco et al., 1994; Moslemi et al., 1996).  It has also been shown 
that accumulation of COX1 deficient cells correlates with advancing age (Muller-
Hocker, 1990; Cottrell, Blakely, Johnson, Ince, Borthwick, et al., 2001).  
There is thought to be a mosaic respiratory chain deficiency in ageing (Larsson, 
2010).  Mitochondrial DNA replication occurs independently of the cell cycle 
(Bogenhagen & Clayton, 1977) and so, one molecule of mtDNA can be 
replicated multiple times, or not at all.  This clonal expansion of mtDNA explains 
how some daughter cells exhibit respiratory function and some do not: because 
they contain different levels of mutated mtDNA.  As discussed in Section 1.3.1, 
the levels of mtDNA mutation need to exceed the mtDNA threshold before we 
see their phenotypic effects on the respiratory chain.  This theory is supported 
by studies that show mosaicism of respiratory chain deficiency in various ageing 
human tissues including heart (Muller-Hocker, 1989), skeletal muscle (Fayet et 
al., 2002), neurones (Cottrell, Blakely, Johnson, Ince, & Turnbull, 2001; Bender 
et al., 2006), and colon (Taylor et al., 2003). 
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1.5.4 mtDNA Copy Number Depletion and Ageing 
In addition to mutations or deletions in mtDNA being associated with advancing 
age, there is also a body of evidence linking decreased mtDNA abundance with 
ageing (Laderman et al., 1996; Barazzoni et al., 2000; Short et al., 2005; 
Kaaman et al., 2007; Cree et al., 2008; Hartmann et al., 2011).  An age-related 
decline in mtDNA copy number has been reported in various human tissues 
including skeletal muscle (Welle et al., 2003; Short et al., 2005; Menshikova et 
al., 2006; Lanza et al., 2008), pancreatic islets (Cree et al., 2008), fibroblasts 
(Laderman et al., 1996) and adipocytes (Kaaman et al., 2007).  In human 
pancreatic islets for example, mtDNA copy number was significantly reduced in 
non-diabetic islet donors aged ≥50 years compared to donors aged ≤50 years.  
The mean mtDNA copy number was found to decrease by 50% in individuals 
aged between 17 and 75 years of age (see Figure 6). 
These findings have been replicated in rodent (Barazzoni et al., 2000) and fish 
(Hartmann et al., 2011) animal models, investigating the mtDNA abundance in 
various extracted tissues.  But it seems the mtDNA loss seen with age may be 
tissue specific, as Barazzoni et al. reported a significant age-dependent 
reduction in mtDNA copy number in rat skeletal muscle and liver, but mtDNA 
levels remained the same in aged heart (Barazzoni et al., 2000).  Similarly, 
Hartman et al. reported that mtDNA copy number was significantly reduced in 
fish muscle, liver, brain, skin and dorsal fin tissues, but remained unchanged 
with advancing age in kidney, gill, eye or spleen (Hartmann et al., 2011).   
It is known that various conditions can affect mtDNA copy number, which may 
explain the tissue specific effect of age-dependent changes in mtDNA copy 
number.  For example, cardiac hypertrophy, a condition in which there is an 
increase in cardiac muscle mass, is commonly associated with ageing in 
humans and rodents (Lakatta, 1993).  Artificially-induced cardiac hypertrophy 
was found to increase the mtDNA content in chickens (J. M. Kennedy et al., 
1991) and rats (Meerson & Pomoinitsky, 1972; Rajamanickam et al., 1979).  It 
has also been shown that endurance exercise can increase both mitochondrial 
density (Holloszy & Coyle, 1984) and mtDNA content (Menshikova et al., 2006; 
Lanza et al., 2008) in human skeletal muscle.  Therefore, these are 
considerations that need to be taken into account when analysing the mtDNA 
abundance of specific tissues. 
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Conversely, there are also reports that mtDNA copy number does not change in 
ageing human heart or skeletal muscle (Miller et al., 2003), or increases with 
age in fibroblast cell culture (Shmookler Reis & Goldstein, 1983) and human 
neurones (Barrientos et al., 1997).  Although Schmookler Reis and Goldstein 
reported an increase in mtDNA abundance in late passage fibroblast cells 
compared to early passage fibroblasts, it was also reported that late passage 
cells were generally of a greater mass than younger passage cells and so, 
when mtDNA was normalised to volume of cytoplasm or protein mass, 
passage-dependent increases in mtDNA abundance were eradicated 
(Shmookler Reis & Goldstein, 1983).  Similarly, Barrientos et al. also showed 
that mtDNA copy number increases with age, but the group also demonstrated 
that mtDNA transcript levels decreased with advancing age, so could the 
increase in mtDNA copy number compensate for the loss of mtDNA 
transcription?  And is this a cell specific trait? (Barrientos et al., 1997). 
In summary, a reduction in mtDNA abundance has been reported to correlate 
with advancing age (Laderman et al., 1996; Barazzoni et al., 2000; Short et al., 
2005; Kaaman et al., 2007; Cree et al., 2008; Hartmann et al., 2011).  However, 
there are also contradictory reports whereby mtDNA copy number does not 
change (Barazzoni et al., 2000; Miller et al., 2003; Hartmann et al., 2011), or 
increases with advancing age (Shmookler Reis & Goldstein, 1983; Barrientos et 
al., 1997).  These conflicting reports may be due to tissue specific responses to 
ageing.  But it has been reported that there is an age-dependent reduction in 
mtDNA copy number in human islets (Cree et al., 2008). 
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Figure 6 Relationship between mtDNA copy number and islet donor age   
These data are taken from (Cree et al., 2008).  The group investigated the relationship 
between mtDNA copy number and age in isolated clinical grade human islet 
preparations from 15 non-diabetic donors.  The group were able to demonstrate that 
the mean mtDNA copy number declined by around 50% in non diabetic islet donors 
aged between 17 and 75 years of age (r2 = -0.53, p=0.04). 
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1.5.5 Artificial mtDNA Depletion 
Loss of mtDNA copy number in cell lines has previously been achieved 
following chemical intervention using inhibitors of mtDNA replication, most 
commonly ethidium bromide (Chandel & Schumacker, 1999; Singh, 2006; 
Magda et al., 2008).  Cells were chemically treated for prolonged periods of 
time to produce p0 cells that are completely devoid of mtDNA, also known as 
rho0 cells.  As mtDNA encodes key components of the respiratory chain, these 
p0 cells are typically incapable of aerobic respiration, becoming dependent on 
pyruvate and uridine for growth (King & Attardi, 1989).  Previous studies in 
pancreatic β-cells found that mitochondrial transcription, translation and insulin 
secretion were greatly impaired in p0 cells compared to untreated control cells 
(Soejima et al., 1996).   
1.5.6 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Ethidium bromide is capable of intercalating with any double stranded DNA, 
including nDNA.  Therefore, more specific chemical treatments are being 
deployed to reduce mtDNA copy number, including nucleoside reverse 
transcriptase inhibitors (NRTIs).  NRTIs are nucleoside analogues of the 
naturally occurring nucleotides used in the replication of viral DNA: adenosine, 
thymidine, guanosine, cytidine and uridine.  They are a family of chemicals used 
to treat patients suffering from the human immunodeficiency virus (HIV).  NRTI 
triphosphates were originally synthesised in the 1960s (Mitsuya et al., 1990), 
but it was in 1987 that the Food and Drug Administration (FDA) first approved 
clinical use of the first NRTI, zidovudine (AZT), to treat HIV patients (FDA, 
2009).  There are now seven NRTIs approved by the FDA for the treatment of 
HIV: zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), 
lamivudine (3TC), abacavir (ABC) and emtricitabine (FTC) (Hӧschele, 2006).   
By targeting the HIV reverse transcriptase (HIV-RT) enzyme, NRTIs prevent 
viral DNA replication and halt disease progression.  NRTIs preferentially target 
HIV-RT, but they are also known to have high affinity for POLG (Kakunda, 
2000; Lewis et al., 2003).  There seems to be a hierarchy of NRTI affinity for 
certain polymerases: HIV-RT >> POLG > DNA pol-β > DNA pol-α = DNA pol-ε 
(Kakunda, 2000; Lewis et al., 2003).  There also seems to be a hierarchy of 
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NRTI influence on POLG inhibition: zalcitabine (ddC) ≥ didanosine (ddI) ≥ 
stavudine (d4T) > lamivudine (3TC) > zidovudine (AZT) > abacavir (ABC) 
(Kakunda, 2000).   
Several mechanisms of POLG inhibition have been proposed.  These include 
NRTI competition with naturally occurring dNTPs; mtDNA daughter strand 
termination following NRTI incorporation; the incorporated NRTI molecule being 
resistant to exonucleolytic removal by POLG; and the cellular accumulation of 
monophosphorylated forms of the NRTI drug, thus inhibiting the exonucleolytic 
activity of POLG (Lewis, 2003).  Inhibition of this polymerase ultimately 
culminates in mtDNA synthesis impairment, which is believed to be the 
perpetrator in NRTI-induced mitochondrial toxicity, a symptom seen in HIV 
patients undergoing highly active antiretroviral therapy (HAART) (Hoschele, 
2006; Lee, 2003).   
Indeed, one of the major issues with long term NRTI treatment is mitochondrial 
toxicity.  In a mouse study, it was shown that long term treatment with AZT 
resulted in oxidative damage in liver mtDNA (de la Asuncion et al., 1999).  
NRTI-induced mitochondrial oxidative damage has also been shown in rats 
(Szabados et al., 1999) and cell lines (Yamaguchi et al., 2002).  It has even 
been reported that some HIV strains have started to develop a resistance to 
AZT treatment (Mitsuya et al., 1990).  Long term NRTI use has also been 
implicated with insulin resistance in HIV-infected women (Tien et al., 2008).  
Tien et al. investigated insulin resistance in a cohort of 2870 women from a 
variety of ethnic backgrounds, between 2000 and 2007.  Insulin resistance was 
calculated using the homeostatic model assessment (HOMA) model, in which 
fasting glucose and insulin levels were inputted into a mathematical equation.  
The group concluded that there was a positive correlation between the number 
of years of stavudine use and insulin resistance in HIV-infected women, with 
insulin resistance increasing at a rate of 6% per additional year of stavudine 
treatment.  It is interesting to note that 284 patients were actually excluded from 
this study after developing T2DM (Tien et al., 2008).  This study is supported by 
other reports demonstrating a relationship between insulin resistance and 
duration of NRTI use, and like the Tien et al. study, a proportion of the HIV-
infected patients studied were already diagnosed with T2DM (Hadigan et al., 
2001; Brown et al., 2005; Lo et al., 2005).  Hadigan et al. demonstrated that 
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hyperinsulinaemia was greater in HIV-infected patients receiving HAART 
compared to non-HIV-infected control individuals (Hadigan et al., 2001).  Lo et 
al. illustrated that HIV patients receiving NRTI therapy had high lactate levels 
(hyperlactataemia), possibly due to the increase in lactate production as 
glucose is metabolised via glycolysis as a result of NRTI-induced mitochondrial 
toxicity (Lo et al., 2005). 
These studies show that long term usage of NRTI triphospahtes prevents the 
pathogenesis of HIV, but at the cost of mitochondrial toxicity with long term 
NRTI exposure. 
1.5.6.1 Didanosine (ddI) 
Didanosine (ddI), one of the seven FDA approved NRTIs for the treatment of 
HIV, is a nucleoside analogue of adenosine.  When ddI enters the cell, it is 
converted to its active form dideoxyadenosine triphosphate (ddATP) through a 
series of phosphorylations.  This active form of ddI then competes with the 
active form of adenosine, deoxyadenosine triphosphate (dATP) for 
incorporation into the newly synthesised DNA strand (Mitsuya et al., 1990; 
Lewis et al., 2003).  Newly incorporated nucleosides are attached to the 
growing DNA daughter strand by phosphodiester linkages, which occur 
between the 5’ phosphate group of one nucleoside and the 3’-OH group of the 
adjacent nucleoside.  As ddI lacks the 3’-OH group required for phosphodiester 
linkage, strand termination ensues following ddI incorporation (Mitsuya et al., 
1990) (Figure 7). 
Didanosine is one of the more potent inhibitors of POLG (Kakunda, 2000), but it 
is also one of the less cytotoxic (Lake-Bakaar et al., 2001).  Whilst investigating 
the effect of various NRTIs on human pancreatic Capan-1 cells, Lake-Bakaar et 
al. concluded that ddI, and its intracellular metabolite ddA (dideoxyadenosine), 
caused least cytoxicity compared to the other three NRTIs investigated.  All 
NRTIs studied had an effect on mtDNA elongation as expected, but of all the 
parameters measured, including cell proliferation, ATP content, lactate release 
into culture medium, and oxygen consumption, ddI seemed to exhibit less 
cytotoxic effects in the Capan-1 cells (Lake-Bakaar et al., 2001). 
  
  
Figure 7 Didanosine structure and mechanis
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1.6 Aims 
The principal aim of this work was to investigate the hypothesis that an age-
related decline in mtDNA copy number in pancreatic β-cells contributes to the 
decrease in insulin secretion seen with advancing age. 
To explore this hypothesis, we aimed to satisfy the following objectives: 
• To develop models of mtDNA depletion using the mouse pancreatic β-cell 
line, MIN6.  
• To use these models to explore the effect(s) of mtDNA depletion upon 
indices of β-cell function, including insulin synthesis and secretion, 
mitochondrial function and cell proliferation. 
• To investigate whether insulin secretagogues such as Glibenclamide 
could rescue the loss of insulin secretion seen with partial mtDNA 
depletion. 
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2 Methods 
2.1 MIN6 cell culture 
Mouse insulinoma, or MIN6 cells, are a mouse pancreatic β-cell line derived 
from transgenic mice expressing the simian virus 40 large T antigen under the 
control of the rat proinsulin promoter (Miyazaki et al., 1990).  They are 
particularly useful in that they respond well to external changes in glucose 
concentration and secrete insulin accordingly.  MIN6 cells were kindly donated 
by Dr Susan Campbell and Dr Catherine Arden and all experiments conducted 
when the cells were between passages 23 and 31.  Unless otherwise stated, all 
cell culture reagents used were manufactured by Gibco, and supplied by Life 
Technologies (Paisley, UK). 
2.1.1 Media preparation 
MIN6 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 4500 mg/L D-glucose, L-glutamine, sodium pyruvate and 
sodium bicarbonate.  The DMEM was then further supplemented in house with 
15% (v/v) filter sterilised foetal bovine serum (FBS), 100 U/ml penicillin, 100 
mg/ml streptomycin, and 0.0005% (v/v) β-mercaptoethanol (Sigma, Dorset, 
UK). 
2.1.2 Thawing cells 
Cells were rapidly thawed in a water bath before adding to 9 ml pre-warmed 
complete growth medium.  The cell suspension was then centrifuged at 1750 
rpm for 3 mins to pellet the cells.  The supernatant was removed and cells were 
resuspended in 10 ml complete growth medium before transferring to a 75 cm2 
flask.  Cells were then incubated at 37 °C 5% CO2 in a humidified incubator. 
2.1.3 Passaging cells 
Cells were passaged when approximately 80-90% confluent, which tended to 
be between 5-7 days after initially seeding them.  Complete growth medium was 
aspirated from the flask and residual traces of serum were removed by washing 
the cells with Dulbecco’s Phosphate Buffered Saline (PBS).  Cells were 
detached from the flask by adding 2 ml 1X trypsin-EDTA solution and incubating 
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for 3-5 mins at 37 °C until the majority of cells had detached.  To aid 
detachment of remaining cells, the flask was gently tapped on the palm of the 
hand.  Eight ml complete medium was then added to the flask to deactivate the 
trypsin, before centrifuging the cell suspension at 1750 rpm for 3 mins.  The 
supernatant was removed and pelleted cells resuspended in an appropriate 
volume of complete growth medium.  Typically, a confluent flask was split 1:5.  
Growth medium was changed every 2-3 days. 
2.1.4 Freezing cells 
Cells were washed and trypsinised as previously described in Section 2.1.3.  
The cell pellet was resuspended in 1 ml MIN6 freeze juice, which consisted of 
FBS with 10% (v/v) DMSO, and was immediately transferred into a cryo 
preservation tube.  Cells were then frozen down in a Nalgene 5100 1°C ‘Mr 
Frosty’ containing isopropanol alcohol and stored overnight at -80°C.  The ‘Mr 
Frosty’ freezes down the cells at 1°C per minute, thus preventing the formation 
of ice crystals inside the cells.  This prevents the cells becoming full of water 
and bursting when they are later thawed. 
2.2 Culturing cells with didanosine (ddI) to deplete mtDNA 
2.2.1 Preparation of ddI stocks 
Didanosine (Sigma, Dorset, UK) was reconstituted with Dulbecco’s PBS to 
make a stock concentration of 10 mM.  The 10 mM stocks were further diluted 
in PBS to produce 1 mM working stocks.  One mM working stocks were then 
used to treat the MIN6 cells, and diluted in complete MIN6 growth medium to 
the desired concentration. 
2.2.2 Haemocytometer cell count 
A confluent 75 cm2 flask was trypsinised and put into suspension as previously 
described in Section 2.1.3.  Once the cell pellet was resuspended in 10 ml 
growth medium, a haemocytometer was used to estimate the number of cells 
per ml.  Ten µl of the cell suspension was mixed with 10 µl trypan blue 0.4% 
(Sigma, Dorset, UK).  Trypan blue is a diazo dye that permeates cells with a 
compromised plasma cell membrane, and can be used to exclude dead cells 
during a cell count.  Ten µl of the 1:2 dilution of cells/trypan blue was then 
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added to the haemocytometer counting chamber and counted under a light 
microscope.    
2.2.3 Treatment of MIN6 cells with ddI to deplete mtDNA 
Cells were seeded at 200,000 cells per well and left overnight to settle.  Cells 
were then treated for 5 days with 50 µM ddI or PBS.  One hundred µl 1 mM ddI 
was diluted in 1900 µl complete growth medium and the 2 ml volume added to 
each well of a 6 well plate.  PBS was used as the drug vehicle control.  Cells 
were then incubated at 37 °C 5% CO2 in a humidified incubator, with treatment 
medium replaced every 2-3 days.  Because the cells were seeded at such a 
sparse density, they were able to grow in the same culture vessel for the 
duration of the 5 day treatment. 
2.3 Neon transfections of MIN6 cells to knock down TFAM mRNA 
expression 
Optimal transfection conditions for the MIN6 cells were found to be by 
electroporation, using the Neon transfection system (Life Technologies, Paisley, 
UK).   
2.3.1 MIN6 transfection medium 
MIN6 transfection medium differs from normal MIN6 growth medium in that it 
does not contain penicillin or streptomycin (see Section 2.1.1).  The antibiotics 
could enter the transfected cell through the compromised cell plasma 
membrane and cause cell death, which is why they are excluded. 
2.3.2 Preparing adherent cells 
When cells reached ~80% confluency, they were trypsinised, pelleted and 
washed with PBS prior to cell counting using trypan blue exclusion, as 
previously described in Section 2.2.2.  The required number of cells were 
pelleted and resuspended in Resuspension Buffer R, from the 10 µl Neon 
transfection kit (Life Technologies, Paisley, UK).  It was important that the cells 
were resuspended in a suitable volume, so that each 10 µl volume contained 
200,000 cells, this was the number of cells transfected and added per well.  The 
TFAM-429 or the TFAM-193 siRNA probe was then added to the 200,000 cells 
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at a final concentration of 100 nM per well.  A Scrambled medium GC content 
siRNA probe (Life Technologies, Paisley, UK) was used as a transfection 
control.  The Scrambled siRNA is not complementary to any mammalian mRNA 
sequence and so would not produce gene knock down, but the cells would still 
be exposed to foreign siRNA. 
2.3.3 Electroporation 
The Neon transfection system is unique in that it uses the electroporation 
chamber created in the 10 µl tip in order to deliver a high voltage electric field to 
the biological sample.  Once the Neon tip was attached to the Neon pipette, 10 
µl of the cell suspension / siRNA probe mixture was taken up, and the pipette 
locked into the Neon pipette docking station.  Two pulses, each of 1200 V and 
20 ms apart, were delivered to the cells.  The Neon pipette was detached from 
the docking station and cells pipette into a 24 well plate, each well containing 
0.5 ml of pre-warmed transfection medium.  It was imperative that no air 
bubbles were in the pipette tip prior to electroporation as this would result in 
arcing of the electrical pulse, visible as a spark at the tip electrode, and a 
possible reduction in transfection efficiency.  After transfection was complete, 
cells were mixed by gently rotating the plate and incubated for 72 hours in a 
humidified incubator (37 ˚C, 5% CO2). 
2.4 Real-time PCR 
Real-time PCR uses fluorescent dyes / probes and the heat-stable Thermus 
aquaticus (Taq) polymerase in the amplification of a target gene.  The amount 
of fluorescence is proportional to the amount of amplified PCR product and can 
be measured in ‘real-time’, with fluorescence emitted from the well being 
measured per PCR cycle using a thermal cycler detector.  There are different 
probes, dyes and fluorophores that can be utilised during real-time PCR.  The 
two that were used in this thesis were the TaqMan hydrolysis probes and the 
SYBR-Green fluorescent dye. 
2.4.1 SYBR Green 
Real-time PCR using the SYBR Green dye was utilised when quantifying 
mtDNA levels relative to a nuclear encoded reference gene.  DNA was 
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extracted from the MIN6 cells and quantified prior to real-time PCR.  SYBR-
Green is a cyanine fluorescent dye capable of binding to the minor groove of 
double stranded DNA (dsDNA).  When bound to DNA, SYBR-Green fluoresces 
and the degree of fluorescence is directly proportional to the amount of dsDNA 
present. 
2.4.1.1 DNA extraction 
DNA was extracted from the MIN6 cells using the DNeasy Blood & Tissue DNA 
extraction kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions.  Briefly, cells were washed with PBS, trypsinised and pelleted.  The 
cell pellets were then snap frozen in liquid nitrogen and stored at -80 ˚C until 
DNA extraction.  To extract the DNA, cell pellets were first rapidly thawed and 
resuspended in PBS.  Cells were lysed and proteins, especially nucleases, 
were degraded following addition of Buffer AL and proteinase K respectively.  
Cell lysis was aided by a 10 minute incubation at 56 ˚C after which, 100% 
ethanol was added to precipitate the DNA.  Samples were thoroughly 
homogenised by vortexing before transferring into a DNeasy Mini spin column.  
DNA was bound to the column membrane following centrifugation at 6000 g.  
The bound DNA was then washed with Buffer AW1 and Buffer AW2.  The 
column was centrifuged for 3 min at 16,000 g to dry the membrane and ensure 
all ethanol was removed.  Finally, after transferring the column into a new 
collection tube, DNA was eluted from the column using Buffer AE, incubating at 
room temperature for 1 min and then centrifuging at 6000 g for 1 min. 
2.4.1.2 DNA quantification 
The NanoDrop ND-1000 Spectrophotometer was used to determine the 
concentration of DNA.  One µl of DNA was placed onto the lower loading pad.  
The top pad was then closed thus creating a column of fluid through which a 
light beam could be passed through.  An absorbance curve was generated, 
ideally peaking at 260 nm for nucleic acids.  The amount of DNA, given in ng/µl, 
was then used to standardise all DNA samples to the same concentration prior 
to real-time PCR.  DNA was diluted in 100 ng/ml tRNA as the tRNA prevents 
the DNA adhering to the plastic tubes/plates, this is particularly important at 
lower DNA concentrations. 
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2.4.1.3 SYBR Green real-time PCR 
Following DNA extraction and standardisation, real-time PCR was used to 
assess the relative expression of mtDNA encoded target gene ND5 to the 
nDNA encoded reference gene GAPDH, using the SYBR Green fluorescent 
dye.  All reactions were performed in triplicate in a LightCycler 480 Multiwell 
Plate 96 (Roche, Welwyn Garden City, UK) and sealed with LightCycler 480 
Sealing Foil (Roche, Welwyn Garden City, UK). 
Primer sequences for ND5, 87 bp amplicon: 
Forward Primer: 5’ – CTGGCAGACGAACAAGAC – 3’ 
Reverse Primer: 5’ – GAGGCTTCCGATTACTAGG – 3’ 
Reaction components for ND5 reaction: 
Reaction components Supplier 
Volume per 20 µl 
reaction 
Final 
concentration 
LightCycler 480 SYBR Green 
I Master, 2x conc. 
Roche 10 µl 1x 
Forward primer, 5 µM Sigma 1.2 µl 300 nM 
Reverse primer, 5 µM Sigma 1.2 µl 300 nM 
PCR Water Roche 5.6 µl N/A 
DNA, 25 ng/µl N/A 2 µl 50 ng 
 
Primer sequences for GAPDH, 208 bp amplicon: 
Forward Primer: 5’ – CAATGTGTCCGTCGTGGATCT – 3’ 
Reverse Primer: 5’ – GTCCTCAGTGTAGCCCAAGAT – 3’ 
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Reaction components for GAPDH reaction: 
Reaction components Supplier 
Volume per 20 µl 
reaction 
Final 
concentration 
LightCycler 480 SYBR Green 
I Master, 2x conc. 
Roche 10 µl 1x 
Forward primer, 5 µM Sigma 2 µl 500 nM 
Reverse primer, 5 µM Sigma 2 µl 500 nM 
PCR Water Roche 4 µl N/A 
DNA, 25 ng/µl N/A 2 µl 50 ng 
 
Primer oligonucleotide sequences for both genes were synthesised by Sigma 
and supplied lyophilised.  Primers were reconstituted in TE buffer (Sigma, 
Dorset, UK) to a stock concentration of 100 µM as per manufacturer’s 
instructions.  Primers were then further diluted in TE buffer to working stocks of 
5 µM. 
PCR was conducted using the Roche LightCycler 480 thermo cycler and the 
following parameters: 
Pre-incubation: Enzyme activation  95 ˚C  5 min 
Amplification: Denaturation   95 ˚C  10 sec 
   Annealing/Extension 60 ˚C  20 sec 
Melt Curve:  Denaturation   95 ˚C  5 min 
   Annealing   65 ˚C  1 min 
   Increase temp to 97 ˚C at rate of 0.11 ˚C / sec 
   5 acquisitions per ˚C 
Hold:       40 ˚C  ∞ 
50 cycles 
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2.4.2 TaqMan 
Real-time PCR using the TaqMan hydrolysis probes was employed when 
investigating mRNA gene expression.  In this instance, RNA was extracted from 
the MIN6 cells and quantified prior to real-time PCR.  Unlike SYBR-Green which 
is capable of binding to any dsDNA, TaqMan hydrolysis probes are specific to 
the region of interest.  The probe has a 5’ reporter and a 3’ quencher.  Upon 
incorporation into the amplified region of interest, the Taq polymerase cleaves 
the quencher, which has an inhibitory effect of the reporter dye.  This means the 
reporter is no longer inhibited by the quencher, and so it fluoresces.  As with 
SYBR-Green, fluorescence is proportional to the amount of amplified DNA. 
2.4.2.1 RNA extraction 
RNA was extracted from cells using the GenElute Mammalian Total RNA 
Miniprep kit (Sigma, Dorset, UK).  Cell lysis solution (10 µl β-mercaptoethanol in 
1 ml lysis buffer) was added directly to the wells after adherent cells had been 
washed with PBS.  Lysates could be snap frozen with liquid nitrogen and stored 
at -80 ˚C for later RNA isolation if required.  RNA lysates were then spun 
through a filtration column to aid DNA shearing and remove cellular debris.  
Filtrate was retained and 70% ethanol added to precipitate the RNA.  RNA 
filtrates were then spun through a second RNA binding column.  Bound RNA 
was washed and an on-column DNase digest (Qiagen, Crawley, UK) 
performed, ensuring any contaminating genomic DNA was degraded.  Bound 
RNA was washed again to remove the DNase enzyme and eluted in elution 
buffer. 
2.4.2.2 RNA quantification and integrity 
RNA was quantified using the Agilent 2100 BioAnalyzer, a unique machine 
capable of the accurate analysis and quantification of RNA.  Samples are 
loaded onto an RNA chip containing interconnecting microchannels used for the 
electrophoretic separation of RNA fragments based on size.  The Agilent RNA 
6000 Nano Kit (Agilent Technologies, Stockport, UK) was used to analyse RNA.  
Briefly, the RNA chip was pressurised using the chip priming station and filtered 
matrix gel.  Five µl marker was pipetted into all 12 sample wells as well as the 
marker well on the chip, followed by 1 µl RNA or 1 µl molecular weight ladder.  
The chip was then run on the Agilent BioAnalyzer machine.  RNA samples were 
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only reverse transcribed if the RNA integrity number (RIN) was ≥8 and there 
were only two bands present on the electropherogram, indicating the 18S and 
28S ribosomal subunits. 
2.4.2.3 cDNA synthesis 
RNA concentrations obtained from the Agilent BioAnalyzer were used to 
standardise all RNA samples to 150 ng RNA.  RNA was reverse transcribed 
following manufacturer’s instructions in the First Strand cDNA Synthesis Kit 
(Invitrogen, Life Sciences Ltd, Paisley, UK).  Reactions were set up as follows: 
 
Reaction components 
Stock 
concentration 
Volume per 20 µl 
reaction 
Final 
concentration 
Random Hexamer Primer 50 ng/µl 1 µl 2.5 ng/µl 
RNA X ng/µl X µl 150 ng 
DEPC-Treated Water N/A X µl N/A 
dNTP Mix 10 mM 2 µl 1 mM 
cDNA Synthesis Buffer 5x 4 µl 1x 
DTT 0.1 M 1 µl 5 mM 
RNase OUT 40 U/µl 1 µl 2 U/µl 
Cloned AMV RT 15 U/µl 1 µl 0.75 U/µl 
 
RNA was denatured by heating at 70 ˚C for 2 mins to remove secondary 
structures before preparing cDNA synthesis reactions.  Complementary DNA 
was reverse transcribed following 10 min incubation at room temperature, 
allowing the primers to anneal, and then incubating at 50 ˚C for 45 mins to allow 
cDNA synthesis to occur.  The reaction was terminated by incubating 85 ˚C for 
5 mins, consequently inactivating the AMV RT enzyme. 
2.4.2.4 TaqMan real-time PCR 
TaqMan hydrolysis probes were obtained from Applied Biosystems (Life 
Sciences Ltd, Paisley, UK) and are detailed below. 
 
54 
 
TaqMan 
probe 
Species 
Gene 
accession 
number 
Assay ID 
Amplicon 
length 
Exon 
boundary 
TFAM Mouse NM_009360.4 Mm00447485_m1 81 2-3 
COX1 Mouse NC_005089.1 Mm04225243_g1 78 1-1 
Ins1 Mouse NM_008386 Mm_01259683_g1 77 1-2 
B2M Mouse NM_009735.3 Mm_00437762.m1 77 1-2 
 
Reaction components for TaqMan real-time PCR reaction: 
Reaction components Supplier 
Volume per 20 µl 
reaction 
Final 
concentration 
LightCycler 480 Master I, 2x 
conc. 
Roche 10 µl 1x 
TaqMan primer/probe, 20X ABI 1 µl 1x 
PCR Water Roche 7 µl N/A 
cDNA, 150 ng/µl N/A 2 µl 300 ng 
 
PCR was conducted using the Roche LightCycler 480, adhering to the 
parameters below. 
Pre-incubation: Enzyme activation  95 ˚C  10 min 
Amplification: Denaturation   95 ˚C  15 sec 
   Annealing/Extension 60 ˚C  1 min 
Hold:       40 ˚C  ∞ 
2.4.3 Qiagen AllPrep Kit for simultaneous DNA/RNA extraction 
For samples where DNA and RNA were required from the same sample, DNA 
and RNA was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Crawley, 
UK).  Briefly, cells were washed with ice cold PBS before adding 350 µl Buffer 
RLT/β-mercaptoethanol (10 µl β-mercaptoethanol per 1 ml Buffer RLT) directly 
50 cycles 
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to each well to lyse the cells.  Cell lysates were scraped into a screw cap 
Eppendorf using a cell scraper/pipette, and could be snap frozen and stored at  
-80 ˚C for later extraction if required.  Homogenised lysates were then 
transferred to an AllPrep DNA spin column and centrifuged for 30 sec at >8000 
g.  This allowed the DNA to bind to the column, and RNA to pass through into 
the flow-through.  The DNA-bound columns were transferred into a new 
collection tube and kept at 4 ˚C until RNA extraction was complete.  Two 
hundred and fifty µl of 100% ethanol was added to the RNA flow-through and 
mixed thoroughly to precipitate RNA.  RNA precipitate was transferred to an 
RNeasy spin column and spun for 15 sec at >8000 g to allow RNA to bind to the 
column.  Flow-through was discarded and bound RNA was washed following 
addition of 350 µl Buffer RW1 and spinning >8000 g for 30 sec.  At this stage, 
we carried out the optional on-column DNase digest to ensure limited DNA 
contamination using the Qiagen DNase kit (Qiagen, Crawley, UK).  After the 15 
min incubation with DNase, bound RNA was washed again with 350 µl Buffer 
RW1.  This was followed by washing twice with 500 µl Buffer RPE, discarding 
eluate between each wash and centrifuging >8000 g for 30 sec.  After the final 
wash, the columns were spun for 2 mins at >8000 g to remove excess ethanol.  
Finally, RNA was eluted following addition of 35 µl RNase-free water and 
centrifuging >8000 g.  Eluted RNA was stored at -80 ˚C, quantified (Section 
2.4.2.2), and reverse transcribed (Section 2.4.2.3) prior to real-time PCR 
(Section 2.4.2.4). 
DNA columns were retrieved from 4 ˚C temporary storage.  Columns were 
washed by adding 500 µl Buffer AW1 and centrifuging >8000 g for 30 sec.  
Flow-through was discarded and columns were washed again with 500 µl Buffer 
AW2.  Columns were centrifuged for 2 mins at full speed to ensure complete 
removal of ethanol, and flow-through was discarded.  Finally, DNA was eluted 
from the column by adding 50 µl Buffer EB (preheated to 70 ˚C).  Columns were 
incubated for 2 min at room temperature before centrifuging for 1 min at >8000 
g.  Purified DNA was stored at -20 ˚C and quantified (Section 2.4.1.2) prior to 
real-time PCR using SYBR-Green (Section 2.4.1.3).  
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2.4.4 Gel electrophoresis 
To ensure that only the gene of interest was amplified, real-time PCR products 
were separate on a 1% agarose gel, which was prepared using 1X TBE buffer 
(89 mM Tris-base, 89 mM Boric acid, 2 mM EDTA pH 8.0).  Two µl of 10 mg/ml 
ethidium bromide (Sigma, Dorset, UK) was added per 100 ml molten gel to 
allow visualisation of the separated DNA fragments.  PCR products were 
prepared for gel electrophoresis by adding an appropriate volume of 6X DNA 
loading dye (10 ml dH2O, 15% (w/v) Ficoll 900, 0.25% (w/v) Bromophenol Blue) 
to the 20 µl PCR reaction.  The gel was run with a potential difference of 70-90V 
across the gel using 1X TBE buffer.  Bands were visualised using AlphaImager 
2200 UV transilluminator system and captured images were printed using a 
Mitsubishi P91D printer doc. 
2.4.5 Delta Ct quantification 
Quantification of gene expression following the TaqMan assays was performed 
using the Delta-Delta Ct (∆∆Ct) method (Schmittgen & Livak, 2008).  Briefly, the 
∆Ct for the treated samples (∆Cttreated) was calculated by finding the Ct 
difference between the target and reference genes for the treated sample 
(Cttarget – Ctreference)treated.  The ∆Ct for the control/calibrator/untreated samples 
(∆Ctuntreated) was then calculated by finding the Ct difference between the target 
and reference genes for the untreated sample (Cttarget – Ctreference)untreated.  The 
∆∆Ct was then calculated by ∆Cttreated – ∆Ctuntreated.  Fold change was finally 
calculated by raising 2 to the power of –∆∆Ct, to take into account the reaction 
efficiency. 
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For the mtDNA copy number assay, the same calculation was performed 
however; we multiplied the ∆∆Ct ratio by 2 to compensate for GAPDH being 
diploid. 
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Standard deviations were calculated using the sum of squares formula below, 
where s1 is the target gene standard deviation and s2 is the reference gene 
standard deviation. 
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Graphs were then plotted using the target/reference gene ratio and sum of 
squares calculated standard deviation.  When data was compiled from multiple 
experiments, the standard error of the mean (SEM) was used to represent 
variability, which was calculated as follows.  Where n represents the number of 
repeated experiments. 
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2.5 Glucose-stimulated insulin secretion (GSIS) 
Method detailed below has been adapted from (Ishihara et al., 1994). 
2.5.1 Krebs-Hepes buffer 
Krebs-Hepes buffer (119 mM NaCl, 4.74 mM KCl, 2.54 mM CaCl2, 1.19 mM 
MgCl2, 1.19 mM KH2PO4, 25 mM NaHCO3, 10 mM Hepes, 0.5% BSA) was 
made fresh upon each use.  Buffer was made up in dH2O and the pH was 
brought down to 7.4 using 1M HCl before addition of the BSA.  The buffer was 
then filter sterilised using 0.22 micron filters, and preheated to 37 ˚C before use. 
2.5.2 GSIS 
Cells were washed twice with Krebs-Hepes buffer to remove traces of growth 
medium, before pre-incubating cells with Krebs-Hepes buffer at 37 ˚C for 30 
mins.  After the 30 min pre-incubation, cells were washed again with Krebs-
Hepes buffer before stimulating them with either 3 mM or 25 mM glucose.  An 
appropriate volume of 10% glucose solution (Sigma, Dorset, UK) was added to 
Krebs-Hepes buffer and cells were incubated at 37 ˚C for 1 hour.  During the 
glibenclamide experiments (Chapter 6), cells were also incubated with 0.1 µM 
glibenclamide (Sigma, Dorset, UK) in addition to 3 mM or 25 mM glucose during 
the 1 hour incubation period.  The medium containing the secreted insulin was 
collected in ice cold tubes and centrifuged at 1000 g at 4 ˚C for 5 min to remove 
cell debris.  Supernatant was retained and stored at -20 ˚C for later 
determination of insulin secretion.  Cells were washed with PBS and harvested 
in protein extraction buffer as described in Section 2.9.1. 
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2.5.3 Insulin ELISA 
Insulin secretion was determined using the high range rat insulin ELISA kit 
(Mercodia AB, Upsala, Sweden) following the manufacturer’s protocol.  The kit 
utilises the sandwich ELISA (enzyme-linked immunosorbant assay) technique, 
which uses two different monoclonal antibodies, the capture and detector 
antibody, to detect and quantify the antigen of interest, insulin.  In brief, the 
samples were diluted in Krebs-Hepes buffer at a dilution that allowed them to 
fall in the middle of the linear range of the standard curve.  This would have 
been determined in an initial ELISA that ran a few samples in a variety of 
dilutions.  The diluted samples were added to the ELISA well, already pre-
coated with the capture antibody, along with the enzyme conjugate solution, 
which contained the detector antibody.  The plate was incubated for 2 hours at 
room temperature on a plate shaker.  This incubation allowed any insulin 
present in the samples to be captured by the capture antibody coating the 
bottom of the well.  The detector antibody present in the enzyme conjugate 
solution would then be able to bind to the bound insulin.  After the 2 hour 
incubation period, unbound insulin and detector antibody was removed by a 
series of 6 washes.  Substrate TMB was then added to the wells and plates 
were incubated for 15 min at room temperature.  The detector antibody is an 
enzyme-linked antibody and so following addition of the substrate, the enzyme 
is cleaved and a chromogenic signal generated.  The intensity of the 
chromogenic signal therefore, is proportional to the amount of insulin present.  
The substrate reaction was stopped following addition of the acid stop solution 
and absorbance was recorded at 450 nm.  Insulin concentration of unknown 
samples was calculated using a standard curve of known insulin concentrations.  
2.5.4 Protein normalisation 
Insulin concentrations generated from the ELISA were normalised to protein 
concentration, thus ensuring that differences in insulin secretion were due to 
glucose stimulus and not differences in cell number.  Proteins were extracted 
from cells as detailed in Section 2.9.1 and quantified using the Bradford assay, 
as detailed in Section 2.9.2. 
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2.6 Insulin content 
To determine the insulin content of cells following GSIS, cells were first washed 
with ice cold PBS.  PBS was again added to the wells and cells were scraped 
from the bottom of the well using a rubber policeman or a pipette tip.  Cell 
lysates were transferred to a screw cap tube and snap frozen using liquid 
nitrogen.  To ensure insulin was liberated from intracellular insulin-containing 
vesicles, cell lysates were repeatedly freeze-thawed.  This entailed rapidly 
thawing cell lysates in a water bath before freezing them again in liquid 
nitrogen, and was repeated a total of three times.  Insulin-containing lysates 
were kept on ice at all times and insulin content was determined using the 
Mercodia Insulin ELISA kit (as described in Section 2.4.3).  Protein 
quantification was performed as described in Section 2.4.4 in order to normalise 
insulin content data to whole cell protein content.  It was ensured that the insulin 
ELISA and protein quantification were performed on the same day as insulin 
was liberated from the cells via liquid nitrogen freeze-thaw, in order to try and 
prevent degradation of the samples. 
2.7 ATP assay 
2.7.1 ATP extraction 
ATP was extracted from cells using 10% perchloric acid (PCA; Sigma, Dorset, 
UK).  Ten % PCA was prepared by diluting 70% PCA stock solution and adding 
2% (v/v) universal indicator solution (Sigma, Dorset, UK).  After addition of 10% 
PCA to the well, cell lysates were scraped into screw cap tubes and samples 
briefly sonicated to aid ATP liberation.  Samples were centrifuged 13,000 g for 
12 min at 4 ˚C to pellet cell debris, which was retained for later protein 
extraction and quantification (see Sections 2.6.2 and 2.6.4).  The supernatant 
was transferred to a separate tube and could be snap frozen for later ATP 
quantification if required. 
2.7.2 Protein extraction 
Protein was extracted from the cell pellet obtained after centrifuging the 10% 
PCA cell lysates.  This was to allow normalisation of ATP content to whole cell 
protein content.  After removing as much of the PCA supernatant as possible, 
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the cell pellet was resuspended in a suitable volume of 0.15 M NaOH in order to 
extract protein.  A control well was always used in each experiment in which 
cells were extracted in 0.15 M NaOH only, to compare against the protein 
extraction of the PCA cell pellets.  It was always found that protein content was 
reduced by approximately 50% following PCA extraction.  This loss in protein 
was then corrected using the protein obtained from the control well.  Samples 
could be snap frozen and stored at -80 ˚C for later protein quantification if 
required. 
2.7.3 ATP quantification 
2.7.3.1 Sample neutralisation 
Samples were extracted in acidic PCA which needed to be neutralised before 
ATP could be quantified.  As the universal indicator solution had already been 
added to the 10% PCA prior to addition to the cells, pH changes could be 
witnessed via a colour change, where acidic solution would be red, neutral pH 
was green, and alkaline solutions would be dark blue / purple.  Samples were 
neutralised by slowly adding 3 M K2CO3 until samples changed colour from red 
to green.  Following addition of K2CO3, PCA came out of solution and formed a 
white precipitate at the bottom of the tube.  Samples were incubated on ice for 
10 min before centrifuging at 13,000 g for 6 min at 4 ˚C to pellet the white PCA 
precipitate.  Neutralised samples were then kept on ice ready for quantification 
using the ATP assay. 
2.7.3.2 ATP standard preparation 
ATP stocks were diluted to 10 mM and stored at -80 ˚C.  Working stocks of 1 
mM were prepared fresh for each assay, and ATP standards were prepared in 
neutralised 10% PCA.  ATP is not stable at low concentrations so 1 mM ATP 
stocks were discarded after use. 
2.7.3.3 ATP assay 
ATP was quantified using the ATP Bioluminescent Assay Kit (Sigma, Dorset, 
UK) as per manufacturer’s instructions.  The kit consists of an ATP Assay Mix 
which contains the luciferin and luciferase needed for the conversion of ATP to 
adenyl-luciferin, and an ATP Assay Mix Dilution Buffer used to dilute the ATP 
Assay Mix.  The assay exploits the following two reactions: 
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ATP + Luciferin      Adenyl-luciferin + PPi 
 
Adenyl-luciferin + O2    Oxyluciferin + AMP + CO2 + Light 
When ATP is the limiting factor in the reaction, the amount of light emitted is 
proportional to the ATP present and so, can be used to quantify the amount of 
ATP present. 
After loading 10 µl sample/standard to a white 96-well microtitre plate, 100 µl 
main reagent was added per well and luminescence read immediately using the 
Spectramax M5E luminometer.  The main reagent was prepared immediately 
prior to use by adding 70 µl ATP Assay Mix to 7 ml ATP Assay Mix Dilution 
Buffer.  ATP concentrations of unknown samples were calculated using the ATP 
standard curve of known ATP concentrations. 
2.7.4 Protein quantification 
Protein extracted in 0.15 M NaOH from the PCA cell pellet was quantified using 
the Lowry assay (Lowry et al., 1951) as opposed to the Bradford assay 
(Bradford, 1976), the reason for this being that the Coomassie Blue reagent 
was not compatible with 0.15 M NaOH.  The Lowry assay was first described by 
Lowry et al. (1951) and relies on the reduction of the Folin-phenol reagent by 
proteins, resulting in a yellow to blue colour change.  The reaction occurs in two 
stages: firstly, proteins react with the copper in an alkaline copper tartrate 
solution; secondly, the copper-treated proteins then react with the Folin-phenol 
reagent.  A colour change is visible as the oxidised amino acids in the protein 
reduce the Folin-phenol reagent. 
The alkaline copper tartrate solution was made up to begin with, and consisted 
of 10% (w/v) NA2CO3 in 0.5 M NaOH, dH2O, 2% (w/v) Na+ / K+ tartrate, 1% 
(w/v) CuSO4.5H2O, always made up in the ratio 10:40:1:1 respectively.  One 
hundred µl of the alkaline copper tartrate solution was then added to 10 µl 
protein sample per well of a clear 96-well microtitre plate.  The samples were 
then incubated at room temperature for 15 min to allow the proteins to react 
with the copper.  After which, 150 µl Folin-Ciocalteu’s reagent (Sigma, Dorset, 
Firefly Luciferase 
Mg++ 
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UK; diluted 1:20 in dH2O) was added per well.  Plates were then incubated at 
room temperature for 30 min to allow the copper-treated proteins to reduce the 
Folin-phenol reagent.  Absorbance was measured at 750 nm using a plate 
reader and protein concentration estimated using a BSA standard curve of 
known concentrations. 
Estimated protein concentrations were then used to normalise data generated 
from the ATP assay. 
2.8 Lactate Dehydrogenase (LDH) assay 
The LDH assay was performed using the PromoKine LDH Cytotoxicity II Kit 
(PromoKine, Heidelberg, Germany) in order to ascertain percentage cell 
cytotoxicity.  The assay quantifies LDH release from cells in the cell culture 
medium.  LDH converts the end product of glycolysis, pyruvate, into lactate 
during anaerobic respiration in a reversible reaction.  It would only be released 
from cells if the cell plasma membrane was compromised, indicating cell 
damage or cell death due to possible toxicity.  LDH release is detected with the 
help of the WST-1 reagent in the kit.  LDH oxidises lactate producing NADH in 
the process, which reacts with WST-1 forming a water soluble yellow-orange 
formazan dye.  The intensity of this colour change reaction is directly 
proportional to the amount of LDH present.  LDH cytotoxicity of the samples is 
then expressed as a percentage of the LDH positive control used in the assay. 
The cell medium supernatant was retained from cells to be assessed for the 
effects of cellular cytotoxicity.  An aliquot of normal MIN6 cell culture medium 
was taken at the same time for use as a negative control.  All samples were 
kept at -20 ˚C. 
All kit reagents were reconstituted as per manufacturer’s instructions.  An LDH 
assay reaction mix was made up by diluting WST 1: 50 in the LDH assay buffer.  
Ten µl of sample to be analysed was added to a clear flat bottomed 96-well 
plate, with each sample assayed in triplicate.  One µl of the LDH positive control 
was added to the positive control wells.  Normal cell culture medium was used 
as a negative control and 10 µl was added to the negative control wells.  Finally, 
100 µl of the LDH reaction mix was added to all wells and the plate was 
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incubated at 37 ˚C for 30 mins.  After the 30 min incubation, absorbance was 
read at 450 nm using a plate reader. 
The average OD readings for the negative control wells was subtracted from the 
OD readings of all other wells, including sample wells and LDH positive wells.  
This is because LDH can be detected from the serum and phenol red present in 
most cell culture mediums.  Therefore, to prevent false positive results, we 
deduct this background LDH from all OD readings.   
The cytotoxicity for the samples was then calculated as a percentage relative to 
the average OD reading for the LDH positive wells, which exhibited 100% 
cytoxicity. 
2.9 Western blotting 
2.9.1 Protein extraction 
Cells were washed with ice cold PBS and extracted in ice cold protein extraction 
buffer (100 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM EDTA, 25 mM KF, 0.1% 
Triton X-100, 0.5 mM sodium orthovanadate, 1X protease inhibitor cocktail).  
Protein lysates were scraped from the bottom of the cell culture plate using a 
rubber policeman / pipette tip before being transferred into a screw cap 
eppendorf tube.  Samples were sonicated at 5-10 µm amps for 10 sec to aid cell 
lysis and liberate proteins.  Protein samples were then snap frozen using liquid 
nitrogen, and stored at -80 ˚C until protein quantification. 
2.9.2 Protein quantification 
Extracted proteins were quantified using the colorimetric Bradford assay 
(Bradford, 1976) and the Coomassie Blue reagent (Pierce, Thermo Fisher 
Scientific, Cramlington, UK).  Under acidic conditions, the Coomassie-dye 
reagent binds to certain protein residues, and in doing so, causes a shift in 
absorbance which is measured at 595 nm using a plate reader.  This shift in 
absorbance can be seen as a colour change from brown to blue and the degree 
of blue colour change is proportional to the amount of protein present. 
Two hundred and fifty µl Coomassie Blue reagent was added to 5 µl of the 
protein sample in a clear microtitre 96-well plate.  After 10 min incubation at 
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room temperature, absorbance was measured using a plate reader at 595 nm.  
Protein concentrations were estimated against a BSA standard curve of known 
concentrations. 
2.9.3 Protein sample preparation 
Using the protein concentrations estimated from the Bradford assay, samples 
were prepared in 4X SDS loading buffer (0.25 M Tris-HCl, pH 6.8, 8% SDS, 
40% Glycerol, 0.008% Bromophenol blue, 20% β-mercaptoethanol, dH2O) and 
protein extraction buffer so that all samples contained 25 µg protein.  Samples 
were then denatured by incubating for 10 min at 37 ˚C and cell debris removed 
by centrifuging 13,000 rpm for 3 min.  By denaturing the samples, secondary / 
tertiary protein structures were removed, thus ensuring that proteins were 
separated according to polypeptide chain length and not protein structure.  The 
supernatant was retained and used when loading samples during SDS-PAGE. 
2.9.4 SDS-PAGE 
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) was 
implemented to separate proteins on the basis of polypeptide length only.  The 
detergent SDS (sodium dodecyl sulphate) binds to the polypeptide backbone 
and aids protein denaturation.  In the process, the negatively charged SDS 
molecule results in the proteins having an overall negative charge.  This allows 
the proteins to migrate through the polyacrylamide gel when an electrical 
current is applied. 
SDS-PAGE gels are formed when the acrylamide is polymerised by TEMED 
and APS (ammonium persulphate).  The pores formed during acrylamide 
polymerisation enable the migration of the polypeptides.  The higher the 
percentage of acrylamide used, the smaller the gel pores formed and so, allows 
easier separation of smaller polypeptides. Vice versa, the lower the percentage 
acrylamide used, the larger the pores formed, and so, allows easier separation 
of larger polypeptides. 
Twelve % SDS-PAGE gels were prepared using the Mighty Small SE200 Series 
multiple gel casters (Hoefer Scientific Instruments, San Francisco, USA). A 12% 
resolving gel (dH2O, 12% acrylamide, 375 mM Tris pH 8.8, 0.1% SDS, 0.1% 
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APS, 0.05% TEMED) was prepared and poured into the gel caster.  When the 
resolving gel had set, a 4% stacking gel (dH2O, 4% acrylamide, 125 mM Tris pH 
6.8, 0.1% SDS, 0.1% APS, 0.05% TEMED) was prepared and poured into the 
gel caster on top of the resolving gel.  When the stacking gel had set, SDS-
PAGE gels were released from the gel caster and the Mighty Small II SE250 
(Hoefer Scientific Instruments, San Francisco, USA) gel electrophoresis 
apparatus set up.  The tank was filled with 1X electrode running buffer (2.5 mM 
Tris, 19.2 mM Glycine, 0.1% SDS) and 25 µg protein was loaded per lane.  A 
full range rainbow molecular weight marker (Amersham Biosciences, GE 
Healthcare, Chalfont St. Giles, UK) was also loaded to estimate protein size.  A 
current of 30-50 mA was applied per gel.  The gels were allowed to run until the 
bromophenol blue indicator dye had reached the bottom of the gel, which 
typically took 1.5 – 2 hrs. 
2.9.5 Western blot 
After SDS-PAGE, the separated proteins were transferred onto a Hybond-ECL 
nitrocellulose membrane (Amersham Biosciences, GE Healthcare, Chalfont St. 
Giles, UK) using the Hoefer TE Series Transfer Electrophoresis Unit (Hoefer 
Scientific Instruments, San Francisco, USA).  The transfer tank was filled with 
transfer buffer (dH2O, 10% CAPS buffer (0.1 M CAPS, pH 11.1), 10% 
methanol).  All sponges, blotting paper and nitrocellulose membranes were pre-
soaked in transfer buffer before setting up the transfer cassette.  The transfer 
cassette was then loaded into the transfer tank, and a 250 mA current passed 
through the system for a period of 2 hrs, allowing the transfer of proteins from 
the SDS-PAGE gel, to the nitrocellulose membrane.  Correct transfer of proteins 
to the nitrocellulose membrane was checked using Ponceau S (Sigma, Dorset, 
UK).  Membranes were stained with Ponceau S for a few minutes and if transfer 
was successful, the proteins would show up as distinct red bands.  Ponceau S 
staining is reversible and so, proteins were de-stained following a series of 
washes with TBS-T wash buffer (65 mM Tris pH 7.4, 150 mM NaCl, 0.1% 
Tween-20). 
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Antibody Supplier Catalogue 
number 
Raised in Expected 
protein size 
Reacts with Dilution Polyclonal/ 
Monoclonal 
Anti-COX1 MitoSciences 
(AbCam) 
MS404-SP Mouse 40 kDa Anti-mouse, human, rat, 
bovine 
1:10,000 Monoclonal 
Anti-SDH70 MitoSciences 
(AbCam) 
MS204-SP Mouse 70 kDa Anti-mouse, human, rat, 
bovine 
1:10,000 Monoclonal 
Anti-β-Actin Sigma A5441-2ML Mouse 42 kDa Anti-mouse, canine, guinea 
pig, feline, pig, chicken, sheep, 
rabbit, rat, human, bovine 
1:10,000 Monoclonal 
Anti-TFAM Sigma SAB1401383-
100UG 
Rabbit 27 kDa Anti-mouse, human 1:1000 Polyclonal 
Anti-Mouse IgG (γ-chain 
specific)-Peroxidase 
antibody 
Sigma A3673-1ML Goat N/A Anti-mouse 1:2000 Polyclonal 
Anti-Rabbit IgG (whole 
molecule) Peroxidase 
Antibody 
Sigma A0545-1ML Goat N/A Anti-rabbit 1:1000 Polyclonal 
 
 
Table 3 Western blotting antibody details 
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2.9.6 Immunodetection 
Immunodetection began by first blocking non-specific binding sites using a 5% 
Marvel solution (5% Marvel milk powder in TBS-T).  Membranes were blocked 
by incubating at room temperature for 1 hr with agitation, after which, 
membranes were washed for 5 mins, three times with TBS-T.  Membranes were 
probed with the primary antibody for 16 hrs overnight at 4 ˚C with agitation.  
Primary antibodies used are listed in Table 3, and were made up in TBS-T with 
1% Marvel.   
The following day, blots were washed thoroughly with 3 x 5 min washes, before 
addition of the secondary detection antibody, which was conjugated to the 
horseradish peroxidase (HRP) enzyme.  As with the primary antibody, the 
secondary antibody solutions were made up in wash buffer TBS-T with 1% 
Marvel (detailed in Table 3).  Blots were incubated for 1 hr at room temperature 
with agitation after which, blots were thoroughly washed with 3 x 5 min washes.  
Bound antibodies were detected by addition of an enhanced chemiluminescent 
(ECL) solution, which contains a peroxide substrate for the secondary antibody 
conjugated HRP enzyme.  Blots were incubated for 5 min at room temperature 
with agitation, with 2.5 ml SuperSignal West Pico Luminol Enhancer solution 
(Thermo Fisher Scientific, Cramlington, UK) and 2.5 ml SuperSignal West Pico 
Stable Peroxide solution (Thermo Fisher Scientific, Cramlington, UK).  After the 
ECL incubation, blots were placed in a Saran wrap envelope and secured in a 
developing cassette with tape, ready for autoradiography. 
2.9.7 Chemiluminescent Detection 
Following addition of the ECL solution, the peroxide substrate in the ECL 
solution reacts with the secondary antibody conjugated HRP enzyme, resulting 
in light being emitted as a product of the reaction.  When a photographic film is 
placed on top of the membrane, the light emitted from the HRP-peroxide 
reaction exposes the film and when developed, can be seen as dark bands 
depicting the protein of interest.  Blue X-ray film (Thermo Fisher Scientific, 
Cramlington, UK) was placed on the nitrocellulose membrane in the Saran wrap 
envelope, inside the developing cassette.  The cassette was closed and the film 
exposed for a certain amount of time.  It was important that the film was not 
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over exposed, which would affect densitometric quantification of the protein 
bands.  The film was then developed by first incubating in Kodak GBX 
Developer (Sigma, Dorset, UK) for 1 min, washing in dH2O for 20 sec, 
incubating in Kodak GBX Fixer (Sigma, Dorest, UK) for 1 min followed by 
washing again in dH2O for 20 sec.  The developer and fixer were diluted 1:10 in 
dH2O prior to use and all developing was carried out in a dark room. 
2.9.8 Densitometry 
Protein bands were quantified using the GS-800 Calibrated Densitometer 
(BioRad Laboratories, Bath, UK) and the Quantity One 4.2.3 BioRad software.  
Beta Actin was used as a loading control and so all proteins were normalised to 
β-Actin. 
2.10 Fluorescent Microscopy 
2.10.1 MitoTracker 
MIN6 cell mitochondria were stained using MitoTracker Orange CMTMRos 
(Sigma, Dorset, UK), which passively diffuses across the cell plasma 
membrane, and accumulates in active mitochondria.  There are many 
MitoTracker stains available but the Orange CMTMRos was chosen as it is 
retained after cells have been fixed and permeabilised. 
2.10.1.1 MitoTracker Stock Preparation 
Lyophilised MitoTracker was resuspended in DMSO to a stock concentration of 
1 mM as per manufacturer’s instructions.  MitoTracker working stocks were then 
prepared in non-supplemented DMEM high glucose medium. 
2.10.1.2 MitoTracker Staining 
Cells were cultured in 75 cm2 flasks until ~80% confluent.  24hrs prior to 
MitoTracker staining, cells were split into 6 well plates, with each well containing 
a glass coverslip.  Cells were incubated with MitoTracker staining solution for 30 
min at 37 ºC.  Following incubation, the MitoTracker staining solution was 
removed and cells washed with pre-warmed PBS.  Cells were then fixed by 
incubating in complete MIN6 growth medium containing 3% formaldehyde for 
15 min at 37 ºC, and washed thrice with pre-warmed PBS.  Finally, cells were 
permeabilised with PBS containing 0.1% Triton X-100 for 40 min at 37 ˚C.  After 
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washing three times with pre-warmed PBS, coverslips were removed from the 
bottom of each well, and mounted onto glass slides using Vectashield mounting 
medium with DAPI (Vector Laboratories, Peterborough, UK).  The coverslip was 
kept in place by applying a layer of clear nail polish to the edges of the 
coverslip.  The MitoTracker (mitochondrial) and DAPI (nuclear) stains were 
excited at 554 nm and 360 nm respectively, emitting at 576 nmn and 460 nmn 
respectively.  The fluorescence was viewed using the TRITC filter (MitoTracker) 
and the UV filter (DAPI) on a Leica SP2 UV upright confocal system.  Gain and 
offset were kept the same during analysis of the series. 
2.10.2 JC-1 
Cells were stained with JC-1 to measure mitochondrial membrane potential.  
The JC-1 dye is unique in that when in the cell cytosol, it exists in its monomeric 
form and emits a green fluorescence.  When the dye enters the mitochondrial 
matrix however, it forms J-aggregates and there is a spectral shift, resulting in 
the dye emitting a red fluorescence.  Therefore mitochondrial membrane 
potential can be measured as a ratio of red / green fluorescence. 
2.10.2.1 JC-1 Stock Preparation 
Lyophilised JC-1 dye (Invitrogen, Life Sciences Ltd, Paisley, UK) was 
reconstituted by resuspending in DMSO to a stock concentration of 5 mg/ml.  
JC-1 was then further diluted in DMSO to working stocks of 400 µg/ml.  All 
stocks were stored protected from light at -20 ºC. 
2.10.2.2 JC-1 Staining 
MIN6 cells were cultured in 6-well plates prior to staining.  Cells were washed 
with pre-warmed PBS before addition of JC-1 staining medium, which consisted 
of normal MIN6 growth medium supplemented with JC-1 and the nuclear stain 
Hoechst 33342  (Sigma, Dorset, UK) to final concentrations of 2 µg/ml and 5 
mM per well, respectively.  Cells were incubated in JC-1 staining medium for 10 
min at 37 ºC to allow both dyes to permeate the cells.  Excess dye not taken up 
by the cells was removed by washing the cells twice in pre-warmed PBS.  
Normal MIN6 growth medium was then added to cells before imaging the cells 
immediately.  Cells were placed in the live cell imaging chamber which was pre-
warmed to 37 ºC, and images were taken on the Nikon Eclipse TE2000-S 
inverted microscope at x40 magnification using the Photometrics CoolSNAP 
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HQ2 Turbo 1394 camera.    JC-1 cytoplasmic monomers were imaged using a 
470 nm ± 40 nm excitation filter, 520 nm ± 40 nm emission filter whereas JC-1 
mitochondrial J-aggregates were imaged using a 575 nm ± 25 nm excitation 
filter, 632 nm ± 40 nm emission filter.  Nuclei were imaged using a 402 nm ± 15 
nm excitation filter, 455 nm ± 50 nm emission filter.  All images were taken with 
1.5 sec exposure (JC-1 monomer), 1 sec exposure (JC-1 aggregate) and 0.5 
sec exposure (nuclear stain). 
2.10.2.3 JC-1 Image Quantification 
All images were quantified using ImageJ.  Fluorescence was quantified 
between the threshold of 45-255 for green fluorescence and 30-255 for red 
fluorescence.  A 100 µm size bar (102.67 pixels) was used to calculate area.  
The ratio of red / green fluorescence, and hence mitochondrial membrane 
potential, was calculated for each field.  The mean and standard deviation were 
then calculated from the six fields taken for each well. 
2.11 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism version 5.01 
(GraphPad Software, San Diego, California, USA) and presented as mean ± 
SEM (for multiple experiments) or SD (for singular experiments).  Significance 
was tested with one-way ANOVA followed by a paired t test.  If data were not 
normally distributed, then data were transformed using y=√y prior to statistical 
analysis.  A probability (p) value of <0.05 was considered significant. 
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3 Mitochondrial DNA depletion in MIN6 cells: Didanosine 
treatment 
3.1  Introduction 
The aim of the research reported in this chapter was to develop a model of 
mtDNA depletion specifically in the murine pancreatic β-cell line MIN6.  A 
reduction in mtDNA copy number has been linked to ageing in many cell types, 
including fibroblasts (Laderman et al., 1996), muscle cells (Short et al., 2005) 
and pancreatic β-cells (Cree et al., 2008).  It is thought that mitochondrial 
dysfunction, possibly caused by the reduction in mtDNA copy number, plays a 
role in the development of many age-related diseases, including T2D (Mootha 
et al., 2003; Petersen et al., 2003).  It is not known whether this reduction in 
mtDNA is causative of T2DM, or merely a biomarker of the disease. 
mtDNA copy number has been artificially reduced in cell lines following 
treatment with inhibitors of mtDNA replication such as ethidium bromide 
(Chandel & Schumacker, 1999; Singh, 2006; Magda et al., 2008).  Certain anti-
retroviral NRTI drugs have been more commonly used in recent years as they 
have greater specificity for mtDNA (Lake-Bakaar et al., 2001; Hӧschele, 2006).  
Didanosine (ddI), a nucleoside analogue of adenosine, is thought to be one of 
the less toxic NRTIs (Lake-Bakaar et al., 2001), but still has high affinity for the 
mitochondrial polymerase γ, POLG (Kakunda, 2000).  Treatment of human 
pancreatic cells with ddI has shown to severely deplete mtDNA levels, but with 
less cellular cytoxicity than other NRTIs investigated (Lake-Bakaar et al., 2001). 
Many p0 hybrids have been cultured in which mtDNA has been completely 
depleted and unsurprisingly, cells have shown severe respiratory chain 
dysfunction (King & Attardi, 1989; Soejima et al., 1996).  In pancreatic β-cells 
for example, mitochondrial function as well as insulin secretion were impaired in 
p0 hybrid cells (Soejima et al., 1996).  These studies are particularly useful in 
understanding the interplay between nDNA and mtDNA but are, however, 
unrealistic in a clinical setting.  What seems to be missing from the literature is 
the effect of partial mtDNA copy number depletion beyond the mtDNA 
threshold, but not complete removal of mtDNA. 
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So we know that there is believed to be a mtDNA phenotypic threshold, beyond 
which, the deleted or mutated mtDNA presents as a phenotypic symptom 
(Rossignol et al., 2003).  We also know that p0 pancreatic β-cells completely 
devoid of mtDNA have severe impairment of mtDNA transcription, translation 
and glucose-stimulated insulin secretion (Soejima et al., 1996).  However, what 
remains unknown is the effect of partial mtDNA depletion of wild type mtDNA, 
specifically in pancreatic β-cells.  What happens when mtDNA copy number is 
depleted beyond the mtDNA threshold to cause a phenotypic effect, but cells 
still had mtDNA to carry out limited respiration?  How would this affect insulin 
secretion?  Cree et al. demonstrated that mtDNA copy number declined by 
around 50% in non diabetic islet donors aged between 17 and 75 years of age 
(Cree et al., 2008).  Therefore, could we create a model of mtDNA depletion in 
a pancreatic β-cell line such as MIN6, whereby mtDNA levels were decreased 
by 50-60% following treatment with an inhibitor of mtDNA replication such as 
didanosine?   
3.2 Aims 
The main aim of this chapter was to develop a model of mtDNA depletion in 
MIN6 cells using the nucleoside analogue didanosine.  We started by: 
• Confirming the presence of mitochondria in MIN6 cells using MitoTracker 
dye and confocal microscopy. 
• Assessing the expression of ND5 and GAPDH in MIN6 cells using real-
time PCR and establishing the optimal PCR conditions for both pairs of 
primers. 
• Investigating the dose-response effect of didanosine on the MIN6 cells 
and determining what drug concentration resulted in an overall 50% 
depletion in mtDNA. 
• Examining the effect of ddI treatment removal to determine how long the 
mtDNA depletion was stable for, which would enable us to determine 
what time period we had in order to conduct further β-cell functional 
studies.  
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3.3 Methods 
3.3.1 Real-time PCR using SYBR-Green 
Mitochondrial DNA depletion was calculated by exploiting the technique of 
relative real-time PCR and the cyanine fluorescent dye SYBR-Green.  A slight 
limitation of SYBR-Green is that it is not specific; it will bind to any dsDNA.  
Therefore, quality checks are needed to ensure the fluorescence generated is 
from the target gene amplification only, and not genomic contamination or 
primer dimer amplification, for example.  A dissociation curve, also known as a 
melting curve, was performed at the end of the PCR protocol, and involved 
slowly increasing the temperature to 95 ˚C in order to denature the DNA.  The 
point at which the DNA denatures is determined by the product sequence as 
well as product size, and is denoted as the melting temperature (Tm).  When the 
PCR product denatures to single strands, the SYBR-Green dye can no longer 
bind and so, rapidly dissociates, seen as a decrease in fluorescence.  
Therefore, the melting curve is depicted as a steep curve, peaking at the Tm and 
is unique for each amplified product.  Typical amplification curves, dissociation 
curves and melt curves can be seen in Figure 8 (GAPDH) and Figure 9 (ND5). 
3.3.2 Absolute and Relative Real-time PCR 
Real-time PCR can be quantified absolutely, giving the actual amount of 
amplified product as a concentration with the aid of a standard curve, or it can 
be given relative to the expression of a reference gene.  In the interest of the 
mitochondrial DNA copy number assay, it was thought that relative 
quantification would be better, simply because of the vast number of samples to 
be processed.  Although standard curves serially diluted 1:5 were amplified for 
both the target and reference gene to check reaction efficiencies (see Section 
3.4.2).   
 
75 
 
 
 
 
Figure 8 GAPDH amplification, dissociation and melting curves. 
A typical GAPDH standard curve amplified by real-time PCR using SYBR-Green.  A) 
The amplification curves depicting the increase in fluorescence over cycle number.  
The crossing threshold, Ct, value is denoted as the point at which the fluorescence 
exceeds a given threshold and can be seen when the amplification curve begins to 
increase exponentially.  B) Dissociation curves were routinely performed at the end of 
the real-time PCR protocol to ensure PCR specificity.  Primer dimers were amplified in 
the no template controls only, not when DNA was present in the reaction.  C) Melt 
peaks were generated from the dissociation curves and are unique for each PCR 
product.  These can be used to discriminate primer dimers (seen on the left) from the 
PCR target sequence (seen on the right). 
A 
B 
C 
Primer dimer 
Target sequence 
1 0.2 0.04 0.008 0.0016 
0.00032 
0.000064 Primer dimer 
76 
 
 
 
 
 
 
Figure 9 ND5 amplification, dissociation and melting curves. 
A typical ND5 standard curve amplified by real-time PCR using SYBR-Green.  A) 
Amplification curves from a 50 ng 1:5 serially diluted DNA standard curve B) 
Dissociation curves noting the lack of primers dimers, which are specific to GAPDH 
primers only.  C) Melt peaks showing no amplification in the no template control 
negatives. 
No template controls 
A 
B 
C 
1 0.2 0.04 0.008 0.0016 
0.00032 
0.000064 
0.0000128 
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3.3.3 Mitochondrial DNA Copy Number Assay 
Depletion in mtDNA levels was detected with the use of the mtDNA copy 
number assay, which was developed by Dr. Lynsey Cree formerly of the 
Mitochondrial Research Group, Newcastle University (unpublished data).  The 
expression of the ND5 target gene was calculated as an arbitrary ratio relative 
to the GAPDH reference gene using the Delta Delta Ct method (see Section 
2.4.5).  ND5, NADH dehydrogenase 5, is a mtDNA encoded subunit of Complex 
I (NADH Dehydrogenase) of the mitochondrial electron transport chain.  The 
ND5 gene is situated on the heavy strand of mtDNA and is approximately 1.8 kb 
in length (nt 11,742 – nt 13,565), producing a protein of 607 amino acids in 
length.  The mtDNA copy number assay targets an amplicon within the ND5 
gene of 87 bp (nt 12,789 – nt 12,875).  Figure 10 shows part of the FASTA 
sequence of the Mus musculus mtDNA genome, specifically the ND5 gene and 
the regions targeted by forward and reverse primers, which are highlighted in 
blue. 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase, is a glycolytic enzyme 
and was used as our reference gene.  In mice, the GAPDH gene is 
approximately 4.6 kb in length and is situated on chromosome 6.  The GAPDH 
gene consists of 7 exons and the total transcript length is 1420 bp, producing a 
protein of 333 amino acids in length.  Figure 11 shows the FASTA sequence of 
the GAPDH gene from the C57BL/6J mouse.  The primers used in the mtDNA 
copy number assay are highlighted in blue, and can be seen to span exons 5 – 
6.  The amplicon produced using these primers is 208 bp in size and contains 
the intervening sequence (intron) between exons 5 and 6. 
Methods are covered in detail in Section 2.4.  Briefly, after DNA was extracted, 
quantified and standardised, real-time PCR was performed using a LightCycler 
480 detector.  Fifty ng DNA was amplified using either GAPDH or ND5 primers 
using the PCR parameters detailed in Section 2.4.1.  Primer specificity was 
ensured by running a melt curve as well as separating the PCR products on a 
1% agarose gel.  Delta Ct quantification was performed using the real-time PCR 
Ct values, allowing calculation of the mtDNA / nDNA ratio. 
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ND5 FASTA Sequence (NC_005089.1) 
5’ – 
 
ATCAATATTTTCACAACCTCAATCTTATTAATCTTCATTCTTCTACTATCCCCAATCCTAATTTCAATAT
CAAACCTAATTAAACACATCAACTTCCCACTGTACACCACCACATCAATCAAATTCTCCTTCATTATTAG
CCTCTTACCCCTATTAATATTTTTCCACAATAATATAGAATATATAATTACAACCTGGCACTGAGTCACC
ATAAATTCAATAGAACTTAAAATAAGCTTCAAAACTGACTTTTTCTCTATCCTGTTTACATCTGTAGCCC
TTTTTGTCACATGATCAATTATACAATTCTCTTCATGATATATACACTCAGACCCAAACATCAATCGATT
CATTAAATATCTTACACTATTCCTGATTACCATGCTTATCCTCACCTCAGCCAACAACATATTTCAACTT
TTCATTGGCTGAGAAGGGGTGGGAATTATATCTTTCCTACTAATTGGATGATGGTACGGACGAACAGACG
CAAATACTGCAGCCCTACAAGCAATCCTCTATAACCGCATCGGAGACATCGGATTCATTTTAGCTATAGT
TTGATTTTCCCTAAACATAAACTCATGAGAACTTCAACAGATTATATTCTCCAACAACAACGACAATCTA
ATTCCACTTATAGGCCTATTAATCGCAGCTACAGGAAAATCAGCACAATTTGGCCTCCACCCATGACTAC
CATCAGCAATAGAAGGCCCTACACCAGTTTCAGCACTACTACACTCAAGTACAATAGTAGTTGCAGGAAT
TTTCCTACTGGTCCGATTCCACCCCCTCACGACTAATAATAACTTTATTTTAACAACTATACTTTGCCTC
GGAGCCCTAACCACATTATTTACAGCTATTTGTGCTCTCACCCAAAACGACATCAAAAAAATCATTGCCT
TCTCTACATCAAGCCAACTAGGCCTGATAATAGTGACGCTAGGAATAAACCAACCACACCTAGCATTCCT
ACACATCTGTACCCACGCATTCTTCAAAGCTATACTCTTTATATGCTCTGGCTCAATCATTCATAGCCTG
GCAGACGAACAAGACATCCGAAAAATAGGAAACATCACAAAAATCATACCATTCACATCATCATGCCTAG
TAATCGGAAGCCTCGCCCTCACAGGAATACCATTCCTAACAGGGTTCTACTCAAAAGACCTAATTATTGA
AGCAATTAATACCTGCAACACCAACGCCTGAGCCCTACTAATTACACTAATCGCCACTTCTATAACAGCT
ATGTACAGCATACGAATCATTTACTTCGTAACAATAACAAAACCGCGTTTTCCCCCCCTAATCTCCATTA
ACGAAAATGACCCAGACCTCATAAACCCAATCAAACGCCTAGCATTCGGAAGCATCTTTGCAGGATTTGT
CATCTCATATAATATTCCACCAACCAGCATTCCAGTCCTCACAATACCATGATTTTTAAAAACCACAGCC
CTAATTATTTCAGTATTAGGATTCCTAATCGCACTAGAACTAAACAACCTAACCATAAAACTATCAATAA
ATAAAGCAAATCCATATTCATCCTTCTCAACTTTACTGGGGTTTTTCCCATCTATTATTCACCGCATTAC
ACCCATAAAATCTCTCAACCTAAGCCTAAAAACATCCCTAACTCTCCTAGACTTGATCTGGTTAGAAAAA
ACCATCCCAAAATCCACCTCAACTCTTCACACAAACATAACCACTTTAACAACCAACCAAAAAGGCTTAA
TTAAATTGTACTTTATATCATTCCTAATTAACATCATCTTAATTATTATCTTATACTCAATTAATCTCGA
GTAA 
              -3’ 
 
 
 
 
 
 
 
Figure 10 ND5 mtDNA encoded target gene. 
FASTA sequence taken from the NCBI website of a section of the Mus musculus 
mtDNA genome, nt 11,742 – nt 14,144, on the positive strand.  The section shown 
corresponds to the ND5 gene (NCBI reference sequence NC_005089.1).  Highlighted 
in blue are the regions targeted by the ND5 forward and reverse primers used in the 
mtDNA copy number assay, with the 87 bp amplicon in bold text. 
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GAPDH FASTA Sequence (MGI: 95640; Ensembl gene ID: 14433) 
AGAGACGGCCGCATCTTCTTGTGCAGTGCCAGGTGAAAATCGCGGAGTGGGCCGCAGGAGGCCGGGGACA
GTCGGAAACTGGGAAGGGGAGTGGGCACTGTACGGGTCTAGGGATGCTGGTGCGAAGTGTGCAAGCCGGA
CCCAGGCTCCGCATTGCAGGGGGGGGATGATGGAGGACGTGATGGGGCGCACGGCGGGAATGGAGGCGGG
GTGGGGGAGGGGACTGCCTGGTGTCCTTCGGGCCACGCTAATCTCATTTTCTTCTCCTGCAGCCTCGTCC
CGTAGACAAAATGGTGAAGGTCGGTGTGAACGGGTGAGTTCCAGGGCGGGGCCCTGCTCCGTTGCCTACG
CAGGTCTTGCTGACCCGGGGGCTCTGCAGTACTGTGGGGAGGTGGATGAGGTGGCCGAAGCGCCCAAGGA
GACCTCAAGGTCAGCGCTCGGACCTGGCGATGGCTCGCACTTGCGGCCCCCAGCTGCTGCACCTCTGGTA
ACTCCGCCTTTGCGGGGATGAGCGGCCCGGAGTCTTAAGTATTAGGAACAACCCCACGCGCCCGTTCAGA
CCCATCCCGTAATCCCCAGTCCGGGGCTTCTTTCTTTACTTTCGCGCCCTGAGGAGTCACGTGCCAGGAG
GGAAGCCCCTCCCCCATCTCCCCCTTCCTCGGGGTCGGTGGCATGGCGTTGTGAGGTGCATACCTTTGCG
CATCATCTCCCAGGCTTGGGCTTCCTTTAGGGTAACTGGCCGCCGCCATGTTGCAAACGGGAAGGAAATG
AATGAACCGCCGTTATGAAATCTTGCTTAGGCCTTCCTTCTTCCTAGCTTGTGACTAACCTCATTCCTCT
CGGCTGGGTGGAGTGTCCTTTATCCTGTAGGCCAGGTGATGCAAGGCTTCCGTGCTCTCGAGAGAGTTCT
ACCTCACAATCTGTCTCACCTTATTAGCCTTAAAAGCCCTTGAGCCTTATTGTCCTCGGGCATAATGCGT
ATTCTAGATTATTCTCTGAAAATCAAAGCGGACTTACAGAGGTCCGCTTGACCTCCCAACCCCAGAGGTA
GTTATGGCGTAGTGCAGAGCCGTGGGATGGGGAGCTGAGTCATGGTGGTTCTGAAAAGAAATTTTCCACC
ACAAAATGGCTCCTGTAGTAGCAGCCCCTTCCATCCCCTGCACTTCCCATCACAGCCTCGCACTGACCCA
GGCCCTATAGGCCAGGATGTAAAGGTCATTAAGAGGATTGGGTGTCCCTGCGCCTCAGAATCCTGCCCTT
CTCCCCGTTCCATCCTCCAGAAACCAGATCTCTCCACTCCGCCCTGATCTGAGGTTAAATTTAGCCGTGT
GACCTTTCTGGATCTGGGGTCTGAGCGGGCTCTCCACCCTGCTCCCCCTACACACATCTGTTGCTCCGGC
TCTCATTTTTGCCCGAGAAGAACAGGTGTTTCGCGAACGAGCCCTGGGATTAGGGTTGGAAACCCCCCAC
ATGTTTTCTCAGTCTTTCCCCTTAGTTCGAGGGACTTGGAGGACACAGGTGGGCCCGCCCTGTGCTGCTC
ACGCTGACCTTTAGCCTTGCCCTTTGAGCTTGCTGATGAATGAGTTCACAGGTCTGCCCTGTCCAGGGGG
TGTAGCCTGAAGTCCAGCCATGCTGGAACAAACTTCCCAGGGCATGAGTGATGGGGGTGATGTGCCAAGC
TTGTACCCAGACTGGGGCAAACTGCCACTTCTTAAGAGACTTAGAATGACTTGGAGGAGGTTTGCTGGGC
AAGCAATCACCTCTTGGACAGGAAAGAAACCTCCACTTTATAACCGTGCTATAAAAGCCCTGCCAGGCCT
CGGCTGCTCAAAGAATATAAAATTAGATCTCTTTGGACTTTCTAGGGTGGGAACAGTCTATATTTGGGTT
GTACATCCAAGCATTCAACTAGCTTTATTAAAGGGAATTCTGAACAAAACATGAACTTCCTGATGCATAC
ATTTCTAATGTACTGTGTCTGCATAAAGGCTTGTACCTTTGTTGTGGTACGTGCATAGCTGATGGCTGCA
GGTTCTCCACACCTATGGTGCAACAGTATTCCACTCTGAAGAACATGAGATAGCCTGGGGCTCACTACAG
ACCCATGAGGAGTTCTGATCTCAGCTCCCCTGTTTCTTGTCTTTCAGATTTGGCCGTATTGGGCGCCTGG
TCACCAGGGCTGCCATTTGCAGTGGCAAAGTGGAGATTGTTGCCATCAACGACCCCTTCATTGACCTCAA
CTACATGGTCTACATGTTCCAGTATGACTCCACTCACGGCAAATTCAACGGCACAGTCAAGGCCGAGAAT
GGGAAGCTTGTCATCAACGGGAAGCCCATCACCATCTTCCAGGAGCGAGACCCCACTAACATCAAATGGG
GTGAGGCCGGTGCTGAGTATGTCGTGGAGTCTACTGGTGTCTTCACCACCATGGAGAAGGCCGGGGTAAG
TGGCCGGAAAGCTGAAGGTGACGGGCACCCTTGATATGGTGCAACCTGAAAACCAAGAACTGAGTCTGAA
ATCAACTTCTTTCCCTTAAACAGGCCCACTTGAAGGGTGGAGCCAAAAGGGTCATCATCTCCGCCCCTTC
TGCCGATGCCCCCATGTTTGTGATGGGTGTGAACCACGAGAAATATGACAACTCACTCAAGATTGTCAGC
AATGCATCCTGCACCACCAACTGCTTAGCCCCCCTGGCCAAGGTCATCCATGACAACTTTGGCATTGTGG
AAGGGCTCATGGTATGTAGGCAGTGGGGAGACAGCTCATGCATTTCTTATCTTACCCTGCCATGAGTGGA
CCCTTCTTTGTAGGTGTCCCTTTTGGGTAGAGGGGTGCCGTGCAGGACCTCACTCATTGCCCCCGTGTTT
TCTAGACCACAGTCCATGCCATCACTGCCACCCAGAAGACTGTGGATGGCCCCTCTGGAAAGCTGTGGCG
TGATGGCCGTGGGGCTGCCCAGAACATCATCCCTGCATCCACTGGTGCTGCCAAGGCTGTGGGCAAGGTC
ATCCCAGAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGTTCCTACCCCCAATGTGTCCGTCGTGG
ATCTGACGTGCCGCCTGGAGAAACCTGTATGTATGGGGAGAGCTGGGCTTGTCTCTGGTGTGACAGTGAC
TTGGGACAAGGATAGTCATTTTGGGGTTTGTTCTTATCAGGCCAAGTATGATGACATCAAGAAGGTGGTG
AAGCAGGCATCTGAGGGCCCACTGAAGGGCATCTTGGGCTACACTGAGGACCAGGTTGTCTCCTGCGACT
TCAACAGCAACTCCCACTCTTCCACCTTCGATGCCGGGGCTGGCATTGCTCTCAATGACAACTTTGTCAA
GCTCATTTCCTGGTATGTGGGGATGGGAAACCTGACTTTTAAGAGCAACTGGGGGTTTGGTGCCCTCTGG
TGGCTAGCTCAGAAAAGAAACCCAAACTAACAGTTGTCCCAATTTGTTCTAGGTATGACAATGAATACGG
CTACAGCAACAGGGTGGTGGACCTCATGGCCTACATGGCCTCCAAGGAGTAAGAAACCCTGGACCACCCA
CCCCAGCAAGGACACTGAGCAAGAGAGGCCCTATCCCAACTCGGCCCCCAACACTGAGCATCTCCCTCAC
AATTTCCATCCCAGACCCCCATAATAACAGGAGGGGCCTAGGGAGCCCTCCCTACTCTCTTGAATACCAT
CAATAAAGTTCGCTGCACCCAC            -3’ 
Figure 11 GAPDH nDNA encoded reference gene. 
FASTA sequence, taken from NCBI (MGI: 95640; Ensembl gene ID: 14433), of the 
GAPDH gene.  Situated on chromosome 6 of the C57BL/6J mouse, GAPDH contains 7 
exons, highlighted in green.  The primers used in the mtDNA copy number assay flank 
exons 5-6, and are highlighted in blue, with the 208 bp amplicon in bold text. 
5’- 
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3.3.4 MitroTracker staining in MIN6 cells 
MitoTracker probes passively diffuse across the cell plasma membrane and 
accumulate in active mitochondria and so were used to stain the mitochondria 
of MIN6 cells.  The rosamine-based MitoTracker Orange CMTMRos was used 
as the orange dye is retained after the cells have been fixed and permeabilised.  
The reduced dye does not fluoresce until it enters a live cell, where it is then 
oxidised and sequestered by the mitochondria.  Cells were then fixed and 
permeabilised prior to mounting using a Vectorshield mounting medium 
containing DAPI.  DAPI, 4',6-diamidino-2-phenylindole, is a nuclear staining 
blue fluorescent dye capable of binding to A-T rich regions of the minor groove 
of dsDNA (Kubista et al., 1987).  When DAPI binds dsDNA, its fluorescence is 
increased, thought to be due to the displacement of water molecules from DAPI 
as well as the minor grooves of dsDNA (Barcellona et al., 1990). 
Cells were incubated in MitoTracker staining medium (see Section 2.10.1 for 
further details) for 30 mins at 37 ºC, after which, they were mounted onto 
microscope slides and imaged using confocal microscopy.  When measuring 
fluorescence, a beam of light was used to excite the electrons in molecules of 
the dye, which then subsequently emanate light which is of a lower energy and 
therefore, a higher wavelength is used to measure the emission of light.  The 
MitoTracker dye was excited at 554 nm and emitted light was viewed at 576 nm 
(orange) using the TRITC filter.  The DAPI stain however, has an excitation 
maximum of 358 nm and an emission maximum of 461 nm (blue) and so was 
viewed using the UV filter.  Gain and offset were kept the same during analysis 
of the series. 
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3.4 Results 
3.4.1 MitoTracker staining in MIN6 cells 
It is widely understood that mitochondria are dynamic organelles that vary 
considerably in number and morphology, especially between cell types.  β-cells, 
like other high energy demanding cells such as muscle cells and neurones, 
contain many mitochondria (Lodish et al., 2004).  We wanted to begin our 
studies by first confirming that MIN6 cells do indeed contain many mitochondria, 
which is of course, where mtDNA resides. 
MIN6 mitochondria were labelled using MitoTracker CMTMRos, which 
fluoresces orange when excited under a TRITC filter.  In Figure 12, we see that 
MIN6 cells do certainly contain a plentiful supply of mitochondria, visible in the 
cell as an expansive and complex network.  When no MitoTracker dye was 
added to the cells, we see no fluorescence under the TRITC filter, only the 
nuclei are seen under the UV filter from the DAPI dye, showing that there is no 
background fluorescence (Figure 12A).  In some instances we can pick out an 
individual mitochondrion (Figure 12B), which is of expected size at 1.28 µm.   
Images were taken of early passage 25 MIN6 cells and late passage 31 MIN6 
cells.  MIN6 cells were typically used during this passage range and so we 
wanted to see if passage number had an effect on mitochondrial content.  
Visually, it seems that both early and late passage MIN6 cells have a plentiful 
supply of mitochondria, as expected (Figure 12B and Figure 12C).  As 
mitochondria accommodate mtDNA, and there are multiple copies of mtDNA 
per mitochondria, we should be able to detect mtDNA in MIN6 cells. 
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Figure 12 Confocal microscopy images of MIN6 cells following staining with 
MitoTracker (orange) and nuclear stain DAPI (blue).   
MIN6 cells were cultured on coverslips in 6 well plates.  Cells were stained with 
MitoTracker Orange CMTMRos for 30 mins before being permeabilised and fixed with 
0.1% Triton X-100 and 3% formaldehyde respectively.  Coverslips were then mounted 
on slides using Vectashield mounting medium with DAPI.  A) Negative control where 
no MitoTracker was added.  B) A single early passage (passage 25) MIN6 cell, single 
mitochondrion has been highlighted, dimension of which (1.28 µm) is of expected size.  
C) A single late passage (passage 31) MIN6 cell, the length of the cell is shown (25.15 
µm).  D) A cluster of late passage 31 MIN6 cells.  MIN6 cells preferentially grow in cell 
clusters like this. 
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3.4.2 Mitochondrial DNA Copy Number Assay: Real-time PCR Primer 
Optimisation 
Mitochondrial DNA depletion in MIN6 cells would be measured using the 
mtDNA copy number assay.  The assay was developed by Dr. Lynsey Cree 
formerly of the Mitochondrial Research Group at Newcastle University.  Dr. 
Cree kindly provided the primer sequences for the ND5 target gene and 
GAPDH reference gene.  Using these sequences, the first stage of developing 
the mtDNA copy number assay in MIN6 cells was primer optimisation.  We 
began this process by running a primer matrix consisting of combinations of 
forward and reverse primers at 300 nM, 500 nM and 900 nM.   
Ideally, it is desirable to have the same concentration of forward and reverse 
primer.  In the ND5 reaction, the 300 nM forward and reverse primers produced 
a good reaction efficiency of 86%.  When higher concentrations of the ND5 
primers were used, this efficiency did not improve much beyond 86%.  
Therefore, it was quickly decided that the optimal concentration of both of the 
ND5 primers would be 300 nM per 20 µl reaction.   
When the ND5 PCR products were separated on an agarose gel (Figure 13B), 
bands could be seen slightly below the 100 bp marker.  The ND5 primers are 
predicted to produce an amplicon of 87 bp, thus it is likely that the bands visible 
just under the 100 bp marker are the ND5 amplified product.  Only one band is 
present demonstrating that the primers are specific for the target sequence 
only.  No template control (NTC) wells were used in every PCR plate to show 
that amplification only occurs when DNA is present in the reaction, ruling out 
possible reagent contamination with genomic DNA.  The NTC wells contained 
the same master mix as sample wells, but instead of adding template DNA, 
PCR water was added instead.  Therefore, no amplification should take place in 
the NTC wells.  There is no product in the NTC wells in Figure 13B, showing 
that there was no genomic DNA contamination of PCR reagents. 
The next stage was to make sure the GAPDH reaction efficiency was as close 
to that of the ND5 reaction as possible.  By doing this, we were ensuring that 
both standard curves were parallel and so, relative quantification could be 
accurately made across the linear range of the standard curve.  Figure 14 
shows a direct comparison of three GAPDH standard curves using either 300 
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nM, 400 nM or 500 nM forward and reverse primers, to the optimal ND5 300 nM 
standard curve.  It appears that the ND5 standard curve and GAPDH 300 nM 
standard curve begin to taper at the higher DNA concentrations and so, are not 
parallel (Figure 14A).  There is a ~4% difference in both of the reaction 
efficiencies also indicating that 300 nM GAPDH may not be the best primer 
concentration for us to use.  When we increase the GAPDH primer 
concentration to 400 nM (Figure 14B), we see that the two standard curves do 
not narrow as much at the top end of the standard curve, and the reaction 
efficiency is slightly better at 84%, only 2% less than that of ND5.  In Figure 14C 
when 500 nM GAPDH primers are used, we can see the curves seem to be 
closest to being parallel at this concentration, with a reaction efficiency of 86% 
for both the GAPDH and ND5 reactions.  Therefore, the optimal GAPDH 
forward and reverse primer concentration seems to be 500 nM.  
When the GAPDH products were separated on an agarose gel (Figure 13A), we 
can see that bands are visible just above the 200 bp marker.  The GAPDH 
primers are predicted to produce a product of 208 bp in size and so, it is likely 
that the bands present are those of the amplified GAPDH amplicon.  A single 
band is present indicating that the primers are specific for the target sequence.  
GAPDH PCR products are not present in the NTC wells however, very faint and 
fuzzy bands are present at the very bottom of the gel image, highlighted by a 
red circle in Figure 13A.  These are classical indications of primer dimers and 
corroborate the results from the melt curve analysis. 
Therefore, in summary, the optimal primer concentrations were found to be 300 
nM for ND5 and 500 nM for GAPDH.  Both primers produced a reaction 
efficiency of 86% and both standard curves were parallel, allowing accurate 
relative quantification of unknowns across the linear range of the standard 
curves.  Both ND5 and GAPDH primers could be seen to be specific, only 
producing a single band of expected size, 87 bp and 208 bp respectively, when 
PCR products were separated on an agarose gel.  When no DNA template was 
added to the GAPDH reactions, primer dimers formed.  These were 
discriminated from genomic contamination by melt curve analysis and gel 
electrophoresis.  They only occur in the NTC wells and so, were deemed non 
problematic. 
 Figure 13 Agarose gel electrophoresis of real
Real-time PCR was performed using 500 nM GAPDH primers (A) and 300 nM ND5 
primers (B).  The PCR products were then separated on a 1% agarose gel to check 
primer specificity.  This gel shows the PCR products from 5 different samples.  Two no 
template controls (NTC) are also shown where DNA template was replaced with PCR 
water, and so, no amplification should occur.  GAPDH primer dimers 
bands at the bottom of the gel, and can be vaguely seen in the red circle
A 
B 
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Figure 14 Mitochondrial DNA copy number assay optimisation.  
Extracted DNA was quantified and serially diluted 1:5 in 100 ng/ml tRNA.  Real-time 
PCR was then performed comparing the standard curves using 300 nM (A), 400 nM (B) 
or 500 nM (C) forward and reverse GAPDH primers, with the ND5 standard curve.  The 
aim was to see which primer concentration produced the standard curve closest to that 
of ND5 in terms of reaction efficiency and generating parallel standard curves. 
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3.4.3 The effect of didanosine treatment on MIN6 cells 
Following optimisation of the mtDNA copy number assay, we were able to 
accurately measure mtDNA levels in MIN6 cells.  The next step was to see if we 
could then deplete mtDNA levels in MIN6 cells.  We aimed to deplete mtDNA 
using the nucleoside reverse transcriptase inhibitor (NRTI), didanosine (ddI).   
Preliminary work performed by Patrick Chinnery’s Mitochondrial Research 
Group at Newcastle University has shown how ddI has a concentration 
dependent decrease on mtDNA copy number in cultured muscle cells 
(unpublished data).  There are also many cell culture models that have been 
developed, exploring NRTI-induced mitochondrial toxicity and how this differs 
across different cell types (Hӧschele, 2006).  In Capan-1 cells (human 
pancreatic cells) for example, ddI along with 3 other NRTIs were capable of 
depleting mtDNA, but ddI and ddA, the intracellular metabolite of ddI, resulted in 
less cellular cytotoxicity (Lake-Bakaar et al., 2001). 
Patrick Chinnery’s group were able to produce a substantial 90-100% decrease 
in the levels of mtDNA by incubating muscle cells with 50 µM ddI for a period of 
7 days.  Similarly, the Capan-1 cells described above were also treated with 50 
µM didanosine.  Therefore, as a starting point, we decided to treat the MIN6 
cells with ddI concentrations ranging from 5 µM – 50 µM for a period of 7 days, 
to see what effect this had on the MIN6 cells.  Didanosine was reconstituted in 
PBS and so, PBS was added to the negative control cells as the drug vehicle 
control.  Cells were harvested after the 7 day treatment period, DNA extracted 
and mtDNA copy number assay performed to assess the mtDNA:nDNA ratio. 
In Figure 15A, we see that the MIN6 cells also respond to didanosine in a dose-
dependent manner, with the greatest decrease in mtDNA:nDNA ratio occurring 
with the highest concentration of didanosine.  Following 50 µM treatment, we 
see an approximate 75% decrease in the ratio of mtDNA:nDNA when compared 
to the PBS negative control.  After 25 µM treatment, the decrease in 
mtDNA:nDNA ratio is only 60% compared to that of the PBS negative control.  
Whereas when cells were exposed to 10 µM and 5 µM ddI, we see only a 30% 
and 20% decrease in the mtDNA:nDNA ratio respectively, when compared to 
the PBS negative control. 
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Figure 15 The effect of didanosine of MIN6 cells.   
(A) Passage 27 MIN6 cells were treated for 7 days with concentrations of ddI ranging 
from 5 – 50 µM.  Cells were then harvested, DNA extracted and quantified, and real-
time PCR performed.  The target (ND5) / reference (GAPDH) gene ratio was calculated 
using the Delta Ct method.  (B)  Experiment was repeated on early passage 24 and 
late passage 31 MIN6 cells to check the effect was uniform across passage number.  
Graph shows a direct comparison of passage 24 and passage 31 cells.  Both 
experiments performed in triplicate in all passage numbers indicated.  Error bars are 
representative of SD. 
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Throughout all experiments, MIN6 cells were used only between passage 
numbers 23 - 31.  Therefore, to ascertain that the MIN6 cells would respond in a 
similar manner to the didanosine treatment, no matter what the passage 
number within this range, we directly compared the response to ddI treatment of 
early passage 24 MIN6 cells to that of late passage 31 MIN6 cells.  The 
experiment was repeated in passage 24 and passage 31 cells.  The results are 
shown in Figure 15B, and they can be seen to mirror initial data shown in Figure 
15A in terms of the ddI dose-dependent effect on mtDNA depletion.  We can 
see that in both passage 24 and passage 31 MIN6 cells, there is an 
approximate 70-80% reduction in the mtDNA:nDNA ratio when compared to the 
PBS negative control, following 50 µM ddI treatment.  In both passage 24 and 
passage 31 cells, the degree of mtDNA depletion was reduced when lower ddI 
concentrations were used; with only a 60-70% decrease and a 50-60% 
decrease in the mtDNA:nDNA ratio compared to the PBS vehicle control cells 
following 25 µM and 10 µM ddI treatment respectively. 
Therefore, in our MIN6 mtDNA depletion model, when using cells between the 
passages of 24 and 31, we can reliably deplete mtDNA levels to approximately 
70-80% when using 7 day 50 µM ddI treatment, and 60-70% when using 7 day 
25 µM ddI treatment.  Ideally we are looking to deplete MIN6 mtDNA levels by 
approximately 50-60% and so, we will be looking to use 25 µM and 50 µM ddI 
subsequently. 
3.4.4 Time course optimisation of ddI treatment on MIN6 cells 
Now that we had observed how the MIN6 cells responded to didanosine 
treatment, we wanted to optimise the length of time of ddI exposure.  Currently, 
cells were seeded at 200,000 cells per well and were treated with 50 µM ddI for 
a period of 7 days, producing a 70-80% decrease in mtDNA levels.  There was 
a potential problem in treating for this length of time in that, after the 7 day 
treatment period, the MIN6 cells were extremely confluent in the 6 well plates.  
After treating the cells with ddI to decrease mtDNA levels, our main aim was to 
measure β-cell function, particularly glucose-stimulated insulin secretion (GSIS).  
We were concerned that if the cells were too confluent, they may become 
stressed, which may influence the future β-cell functional experiments we were 
looking to perform.  Therefore, we began investigating whether or not the ddI 
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treatment period could possibly be reduced from the current 7 day treatment 
program.   
We focused on 50 µM ddI treatment to begin with, as this concentration 
produced the greatest decrease in mtDNA depletion.  MIN6 cells were again 
seeded at a density of 200,000 cells per well in a 6 well plate.  The following 
day, after allowing the cells to settle overnight, cells were treated with either 50 
µM ddI or PBS, the drug vehicle control, with treatment medium changed every 
2-3 days.  Cells were harvested 4, 5, 6 and 7 days post ddI treatment, and DNA 
extracted.  The mtDNA copy number assay was then used to establish the 
mtDNA:nDNA ratio and hence, the degree of mtDNA depletion.   
In Figure 16, we can see that after only 4 days of 50 µM ddI treatment, there is 
a 54.6% decrease in the mtDNA:nDNA ratio, when compared to the PBS cells 
harvested at the same time.  This percentage of mtDNA depletion gradually 
decreases with prolonged 50 µM ddI exposure, until 7 days 50 µM ddI 
treatment, when there is a significant 64.9% decrease in mtDNA levels of ddI 
treated cells compared to PBS control cells harvested at the same time.  The 
PBS treated cells on the other hand, can be seen to maintain a relatively 
consistent mtDNA:nDNA ratio that ranges between 2.4 and 2.8 arbitrary units 
throughout days 4 to 7 of ddI treatment.  It is encouraging to find that after only 
4 days 50 µM ddI treatment, we can achieve the desired 50-60% mtDNA 
depletion, which signifies that it would be possible to decrease the drug 
treatment time from 7 days.  We decided that treating cells for 5 days would be 
optimal as we have found that upon ddI treatment removal, mtDNA levels begin 
to slowly increase (Figure 17) and so we did not want to remove the treatment 
too soon.  It was decided that 5 days 50 µM ddI treatment would be enough to 
deplete mtDNA levels to the desired level of 50-60%, but may also allow mtDNA 
levels to remain at this level for enough time as to enable us to perform ensuing 
β-cell and mitochondrial functional assays. 
For the mtDNA depletion model, it has become apparent that we are able to 
achieve our target of 50-60% mtDNA depletion by seeding cells at a density of 
200,000 cells per well in a 6 well plate, and treating them with 50 µM ddI for 5 
days.  Therefore, it did not seem necessary to continue using the lower 25 µM 
ddI concentration as this produced a lesser degree of mtDNA depletion.   
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Days post ddI treatment: 4 5 6 7 
PBS mtDNA:nDNA Ratio: 2.83 2.58 2.48 2.42 
50 µM ddI mtDNA:nDNA Ratio: 1.31 1.18 0.87 0.85 
mtDNA remaining: 45.45% 46.51% 35.08% 35.12% 
mtDNA depletion: 54.55% 53.49% 64.92% 64.88% 
 
 
 
Figure 16 Time course optimisation of ddI treatment on MIN6 cells.    
Passage 31 MIN6 cells were seeded at 200,000 cells per well in 6 well plates and 
incubated overnight to allow cells to settle.  The next day, cells were treated with 50 µM 
ddI or PBS (drug vehicle control).  Cells were trypsinised and harvested at days 4, 5, 6 
and 7 post treatment.  DNA was then extracted from the cell pellet and real-time PCR 
carried out to ascertain the degree of mtDNA depletion.  The mtDNA:nDNA ratio was 
then calculated using the Delta Ct method, normalising target gene ND5 expression to 
reference gene GAPDH expression.  Experiment was performed in triplicate with error 
bars representative of SD.  The Student’s t-Test was performed on the mtDNA:nDNA 
ratios, with each ratio compared to the mtDNA:nDNA ratio at 4 days for each of the 
data series.         p < 0.01 
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3.4.5 mtDNA recovery following ddI treatment removal 
As the main aim of developing the mtDNA depletion model was to allow the 
measurement of β-cell and mitochondrial function following mtDNA depletion, 
we thought it was important to ascertain how long the mtDNA remains depleted 
at 50-60% before it starts to recover.  To confirm this, cells were treated with 50 
µM ddI for the optimal 5 day treatment period, before treatment medium was 
removed from cells and replaced with normal MIN6 growth medium.  Cells were 
then harvested at various time points up to 48 hours post treatment removal, 
with 0 hours being the point at which the ddI treatment was removed.  The 
mtDNA copy number assay was then used to ascertain mtDNA depletion and is 
shown in Figure 17. 
We were interested in the time point in which the mtDNA:nDNA ratio in ddI 
treated cells differed significantly to the mtDNA:nDNA ratio of ddI cells 
harvested at time 0 hours, when ddI treatment was removed.  As with the 
results seen in Figure 16, we see that the mtDNA:nDNA ratio of PBS treated 
cells remains relatively stable, ranging between 1.46 and 2.05 arbitrary units.  
Comparing this to the ddI treated cells, we see that upon ddI removal at time 0 
hours, mtDNA levels are depleted by 63.33%.  This degree of mtDNA depletion 
is maintained at 6 hours and 12 hours post treatment removal.  At 24 hours post 
ddI removal however, we begin to see a slight increase in mtDNA levels, but not 
significantly so.  By 36 and 48 hours post treatment removal, we see a marked 
increase in the mtDNA:nDNA ratio compared to that at 0 hours, with p < 0.001 
and p < 0.0001 respectively.  We can therefore conclude that for the first 24 
hours post treatment removal, we have stable mtDNA depletion, whereby 
mtDNA remains depleted by around 60%.  This gives us a window of 24 hours 
in which we can conduct future β-cell and mitochondrial functional experiments, 
in the knowledge that mtDNA levels are still depleted to around 50-60%. 
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Hours after ddI 
treatment removal: 
0 6 12 24 36 48 
PBS mtDNA:nDNA 
Ratio: 
1.80 1.67 1.79 1.69 2.05 1.46 
ddI mtDNA:nDNA 
Ratio: 
0.66 0.71 0.66 0.77 1.12 1.15 
mtDNA remaining: 36.67% 42.51% 36.87% 45.56% 54.63% 78.77% 
mtDNA depletion: 63.33% 57.49% 63.13% 54.44% 45.37% 21.23% 
 
 
 
Figure 17 mtDNA recovery following ddI treatment removal.    
Passage 31 MIN6 cells were seeded at 200,000 cells per well in 6 well plates and 
treated for 5 days with either 50 µM ddI or the PBS vehicle control.  Didanosine 
treatment was removed after 5 days and replaced with normal MIN6 growth medium.  
Cells were harvested at 0, 6, 12, 24, 36 and 48 hours post treatment removal and 
mtDNA:nDNA ratio calculated.  Experiment was performed in triplicate with error bars 
representative of SD.  The Student’s t-Test was performed on the mtDNA:nDNA ratios, 
with each ratio compared to the mtDNA:nDNA ratio at 0 hrs for each of the data series.        
dddp = 0.01 dddp < 0.001         p < 0.0001 
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3.4.6 The effect of ddI treatment on MIN6 cell number and cell morphology 
The final stage of developing the mtDNA depletion model in MIN6 cells was to 
assess the effect of didanosine treatment on MIN6 cell proliferation, cell 
cytotoxicity and cell morphology, to explore whether the drug was having an 
adverse affect on the MIN6 cells.  Firstly, we compared MIN6 cell proliferation 
rates of ddI treated cells with PBS drug vehicle control cells.  Cells were seeded 
at a density of 200,000 cells per well in 6 well plates, before treating the 
following day with either 50 µM ddI or PBS.  Cells were then harvested 4, 5, 6 
and 7 days post ddI treatment by trypsinisation.  Cell proliferation was assessed 
using a trypan blue exclusion haemocytometer cell count (see Section 2.2.2).  
At each time point, one 6 well plate was harvested consisting of 3 ddI treated 
wells, and 3 PBS treated wells.  Four counts were made from the 
haemocytometer cell counting chamber for each well.  The average count for 
each well was used to calculate the average of the 3 ddI treated or PBS treated 
wells at each time point and can be seen in Figure 18A. 
As expected, we see a gradual increase in MIN6 cell number from days 4 to 7 
for both ddI treated cells and PBS treated cells, indicating that the cells are 
actively proliferating.  By day 6, we see a doubling in cell number from the 
number of cells harvested at day 4, for both ddI treated cells and PBS treated 
cells.  There is no statistical difference between the cell numbers of ddI treated 
cells and PBS treated cells, at any of the time points.  Therefore, it seems that 
the ddI drug treatment does not have an obvious adverse affect on MIN6 cell 
proliferation. 
To measure cell cytotoxicity, we performed an LDH, lactate dehydrogenase, 
assay.  After treating MIN6 cells for 5 days with 50 µM didanosine, the cell 
culture medium supernatant was retained and stored at -20 °C and later 
analysed using the PromoKine LDH Cytotoxicity Kit II (see Section 2.8).  Cell 
cytotoxicity was calculated as a percentage relative to the average of the LDH 
positive control wells, which exhibited 100% cytotoxicity.  In Figure 18B, we can 
see that for both ddI treated cells and PBS treated cells, there is 4% and 3% 
cell cytotoxicity respectively.  Therefore, it seems that the didanosine treatment 
does not seem to be having an adverse cytotoxic effect on the MIN6 cells. 
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Finally, we wished to examine MIN6 cellular morphology of 50 µM ddI treated 
cells with PBS negative control cells, throughout duration of the 5 day treatment 
program.  Phase contrast images of the cells were taken using the Nikon 
Eclipse TE2000-S microscope and Photometrics CoolSNAP HQ2 Turbo 1394 
camera at x10 magnification.  Cells were seeded in 6 well plates at a density of 
200,000 cells per well and allowed to settle overnight.  The following day, at 
time 0 hours, cells were incubated with either 50 µM ddI or PBS, with treatment 
medium being replaced every 2 – 3 days.  Images were taken between 0 hours, 
when treatment commenced, and 120 hours, when treatment finished, at 24 
hour intervals and can be seen in Figure 18C.   
At 0 hours, we can see that there are still some cells that are recovering after 
passaging, as they take on a small, dense, balled up morphology.  By 24 hours, 
we can see that the cells have started to spread out a bit more and have begun 
to grow again.  At this point, there does not seem to be an obvious difference in 
cell morphology or cell number when comparing ddI treated cells with PBS 
treated cells.  During hours 48 to 96, we can see the cells continuing to grow, 
and can witness the typical MIN6 cell morphology: the cells have a ‘spiky’ 
appearance, and prefer to grow in clusters with neighbouring cells.  This can be 
seen in ddI treated cells and PBS treated cells.  By 120 hours of treatment, we 
can start to see the cells becoming confluent, with the small dark dots on top of 
cell clusters indicating dying cells.  Because the cells grow in clusters, they 
never form a perfect monolayer, therefore, these dying cells on top of the cell 
clusters are what we look for when determining how confluent the cells are.  
This also corroborates why we needed to decrease the didanosine treatment 
time, as culturing the cells with ddI for 7 days was far too long without splitting 
the cells. 
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Figure 18 The effect of ddI treatment on MIN6 cell number, cell cytotoxicity and 
cell morphology. 
MIN6 cells were treated up to 7 days with 50 µM ddI or PBS (drug vehicle control).  
Cells were harvested at days 4, 5, 6, and 7 post ddI treatment and cell number of ddI 
treated cells compared to PBS control cells (A).  Cell cytotoxicity was analysed using 
an LDH assay after 5 days ddI treatment (B).  Cells were imaged using a Nikon Eclipse 
TE2000-S microscope and Photometrics CoolSNAP HQ2 Turbo 1394 camera at x10 
magnification between 0 hours, when treatment commenced, and 120 hours, when 
treatment finished, at 24 hour intervals (C). 
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3.5 Discussion 
The main aim of this chapter was to develop a model of partial mtDNA copy 
number depletion specifically in MIN6 cells.  MIN6 were chosen as they are 
responsive to external changes in glucose concentration, and secrete insulin 
accordingly (Miyazaki et al., 1990).  When this work was initially started, there 
was no human cell line equivalent.  However, this may change as last year 
Revassard et al. reported that they had established a human insulin secreting 
pancreatic β-cell line, EndoC-βH1 cells.  As with MIN6 cells, the EndoC-βH1 
cells express the SV40LT antigen under control of the insulin promoter 
(Ravassard et al., 2011).  These cells look promising but further investigations 
are needed to ascertain how robust the cells are as a model of human 
pancreatic β-cell function. 
The first step in producing a model of mtDNA depletion in MIN6 cells was to 
show that MIN6 cells contained the many mitochondria required to fuel glucose-
stimulated insulin secretion.  We labelled mitochondria using MitoTracker 
Orange CMTMRos, an orange fluorescent dye that accumulates in active 
mitochondria and is retained after cells have been fixed and permeabilised.  
Using confocal microscopy, we could see the mitochondria assembled in vast 
complex networks within the cell (Figure 12).  In some instances, individual 
mitochondria could be seen measuring approximately 1.28 µm.  Mitochondria 
can vary in size measuring less than 1 µm, or measuring up to 10 µm (Kennady 
et al., 2004).  So the mitochondria we have managed to measure are of 
expected size. 
The mtDNA genome resides inside the mitochondria and so, we moved on to 
quantifying mtDNA levels in MIN6 cells.  Using real-time PCR, the gene 
expression of mtDNA encoded ND5 was expressed relative to the nDNA 
encoded reference gene GAPDH, generating the mtDNA:nDNA ratio.  Optimal 
PCR conditions were found using 300 nM ND5 forward and reverse primers, 
500 nM GAPDH forward and reverse primers.  This produced a reaction 
efficiency of 86% for both reactions, allowing accurate relative quantification.  
The standard curves were not used during the quantification of unknown 
samples, but instilled confidence that we could accurately predict the 
mtDNA:nDNA ratio across the linear range of the standard curve. 
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Once the mtDNA copy number assay was optimised, we wanted to see if we 
could deplete mtDNA levels following treatment with the mtDNA replication 
inhibitor didanosine, ddI.  Didanosine is a nucleoside analogue of adenosine, 
but differs in that it lacks the hydroxyl (OH) group at the 3’ carbon position on 
the pentose sugar moiety (Figure 7).  As ddI lacks the 3’-OH group required for 
phosphodiester linkage, strand termination ensues following ddI incorporation.   
Didanosine is a member of a family of chemicals known as nucleoside reverse 
transcriptase inhibitors (NRTIs).  Many cell culture models have been 
developed that explore NRTI-induced mitochondrial toxicity and how this toxicity 
differs in different cell types (Hoschele, 2006).  Lake-Bakaar and colleagues 
compared the effects of ddI with 3 other NRTIs in Capan-1 cells (human 
pancreatic cells).  The group conclude that all nucleoside analogues 
investigated were capable of depleting mtDNA, but ddI and ddA 
(dideoxyadenosine, the intracellular metabolite of ddI) resulted in less cellular 
cytotoxicity (Lake-Bakaar et al., 2001). 
Our results support the literature in that ddI seems to be a potent inhibitor of 
mtDNA synthesis in MIN6 cells, causing mtDNA depletion (Figure 15).  The 
effect of ddI on MIN6 cells was dose-dependent, with the greatest mtDNA 
depletion occurring when cells were exposed to 50 µM ddI.  Similarly to Lake-
Bakaar and colleagues, we found that ddI had little toxic effects on cell 
proliferation, cell morphology or cell cytotoxicity (Figure 18).  It took some time 
to find optimal conditions in which we could culture the MIN6 cells in ddI to 
produce the desired 50-60% mtDNA depletion.  But by seeding the MIN6 cells 
at a density of 200,000 cells per well, and culturing for 5 days in 50 µM, we 
could reliably deplete mtDNA levels by 50-60%.  We wanted our MIN6 cell 
model to have 50-60% mtDNA depletion in support of the work of Cree et al., 
who found that the age-related decrease in mtDNA copy number averaged 50% 
in non-diabetic islet donors aged 17 – 75 years (Cree et al., 2008).   
Chemical intervention using inhibitors of mtDNA synthesis has proven a popular 
method to deplete mtDNA levels.  Most commonly, prolonged treatment with 
ethidium bromide (EtBr) has been an effective means of creating p0 cells 
completely devoid of mtDNA.  Soejima et al. produced two MIN6 cell 
derivatives: p0 MIN6 and mtDNA repopulated MIN6 cell cybrids.  The group 
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found that unsurprisingly, the p0 MIN6 cells were unable to respond to glucose 
during glucose-stimulated insulin secretion, and suffered severe loss of 
mitochondrial transcription, translation and respiratory activity.  However, when 
the p0 MIN6 cells were repopulated with foreign mitochondria containing wild 
type mtDNA (repopulated MIN6 cell cybrids), insulin secretion was effectively 
restored (Soejima et al., 1996).  Similarly, Hayakawa et al. showed that by 
treating βHC-9 pancreatic β-cells with EtBr for 6 days, mtDNA transcription was 
decreased to 10-20% of the control cells.  Insulin secretion was also affected in 
these cells, which was supported by a disruption in the Ca2+ dynamics of the 
cells.   
Finally, upon removal of didanosine treatment, we found that mtDNA remains 
significantly decreased by 50-60% for the first 24 hours post treatment removal.  
After 24 hours post treatment removal however, mtDNA levels begin to increase 
as mtDNA repopulates.  This gives us a time period of 24 hours in which to 
perform β-cell and mitochondrial functional studies, in the knowledge that 
mtDNA levels still remain depleted by around 50-60%.  Studies using EtBr have 
also found that the mtDNA depletion and the cellular defects caused by the EtBr 
treatment are reversed following treatment removal (Hayakawa et al., 1998; 
Maniura-Weber et al., 2004; Park & Lee, 2007).  The fact that mtDNA levels 
repopulate following treatment removal demonstrates unequivocally that it is ddI 
(or EtBr) causing the mtDNA depletion. 
Using the didanosine dependent mtDNA depletion model, we then wanted to 
see what effect partial mtDNA depletion had on β-cell function, particularly 
glucose-stimulated insulin secretion, and mitochondrial function.  
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4 Mitochondrial DNA depletion in MIN6 cells: TFAM mRNA 
knock down 
4.1 Introduction 
To complement the didanosine mtDNA depletion model developed in Chapter 3, 
we wanted to develop a second model of mtDNA depletion in MIN6 cells.  The 
didanosine mtDNA depletion model disrupts mitochondrial biogenesis through 
chemical intervention; we wanted a complementary model using genetic 
techniques.  From the literature, it seemed that TFAM, an important mtDNA 
transcription factor, may be a suitable target.  We would then use both mtDNA 
depletion models to investigate the effect of mtDNA depletion on β-cell and 
mitochondrial function. 
It has long been established following TFAM knock out studies, that TFAM 
plays an integral role in mitochondrial biogenesis (Larsson, et al., 1998; Li, et 
al., 2000; Silva, et al., 2000; Sorensen, et al., 2001; Wang, et al., 1999; 
Wredenberg, et al., 2002).  TFAM function was directly linked to mtDNA copy 
number by Erkstrand et al. when their transgenic mice harbouring the human 
TFAM gene were found to ubiquitously overexpress the TFAM protein, which 
subsequently caused an increase in mtDNA copy number (Ekstrand, et al., 
2004).  In vivo TFAM knockout mice were reported to have a 35-40% reduction 
in mtDNA levels (Larsson, et al., 1998).  Tissue specific TFAM knockout mice 
were found to exhibit similar levels of mtDNA depletion in neurones (Sorensen, 
et al., 2001) and skeletal muscle (Wredenberg, et al., 2002). 
These studies imply that mtDNA levels and TFAM expression are tightly 
correlated.  This theory is supported by studies on TFAM / mtDNA stoichiometry 
that report highly abundant TFAM association with mtDNA (Campbell, et al., 
2012; Dairaghi, et al., 1995; Ghivizzani, et al., 1994; Kaufman, et al., 2007) or 
that TFAM coats the entire mtDNA molecule (Alam, et al., 2003; Ohgaki, et al., 
2007; Takamatsu, et al., 2002).   
Whilst previous in vitro studies investigating TFAM knock down have cultured 
primary tissues extracted from TFAM knock out animal models (Silva, et al., 
2000; Sorensen, et al., 2001; Wang, et al., 1999), we would like to target TFAM 
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gene expression by exploiting siRNA technology in the MIN6 cell line.  By 
transfecting cells with TFAM siRNA probes, can we effectively silence TFAM 
gene expression in MIN6 cells and does this have a knock on effect on mtDNA 
levels, as suggested in the literature? 
4.2 Aims 
The main aim of this chapter was to develop a second model of mtDNA 
depletion to complement the didanosine mtDNA depletion model.  We aimed to 
achieve this by tackling the following objectives: 
• To repeat the TFAM transfection protocol optimised by Invitrogen to see if 
we could knock down TFAM mRNA expression by 70%. 
• To investigate whether TFAM knock down had an effect on mtDNA levels 
using the mtDNA copy number assay previously optimised. 
• To ensure that MIN6 cell viability was not compromised following 
transfection. 
4.3 Methods 
4.3.1 Design and Synthesis of TFAM siRNA probes 
The design, synthesis and validation of the TFAM small interfering RNA (siRNA) 
duplexes was performed by Invitrogen (Life Technologies, California, USA).  
Invitrogen began by first designing five Stealth RNAi duplexes specific for the 
mouse TFAM gene, accession number NM_009360.4, using the BLOCK-iT 
RNAi Designer (Figure 19).  The sense sequences of the Stealth RNAi probes 
were then used to create inserts for the pSCREEN-iT-GW/LacZ vector.  Insert 
cassettes were created by flanking the sequence targeted by the RNAi duplex 
(highlighted in red in Figure 20B) with approximately 30 nucleotides both 
upstream and downstream.  The five Stealth RNAi duplexes, and five 
pSCREEN-iT insert sequences were then synthesised, and the five pSCREEN-
iT sequences were annealed to form double stranded DNA (dsDNA).  The 
dsDNA was then cloned into the pSCREEN-iT-GW/LacZ vector, downstream of 
the LacZ coding region (Figure 20A).   
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Stealth™ Name Sense / Antisense Sequence 
NM_009360.4 - 193 Sense CCUCGUCUAUCAGUCUUGUCUGUAU 
Antisense AUACAGACAAGACUGAUAGACGAGG 
NM_009360.4 - 232 Sense CCAGCAUGGGUAGCUAUCCAAAGAA 
Antisense UUCUUUGGAUAGCUACCCAUGCUGG 
NM_009360.4 - 284 Sense CACAGAACAGCUACCCAAAUUUAAA 
Antisense UUUAAAUUUGGGUAGCUGUUCUGUG 
NM_009360.4 - 429 Sense UACAAAGAAGCUGUGAGCAAGUAUA 
Antisense UAUACUUGCUCACAGCUUCUUUGUA 
NM_009360.4 - 695 Sense GGCAUAUAUUCAGCUUGCUAAAGAU 
Antisense AUCUUUAGCAAGCUGAAUAUAUGCC 
 
 
 
Figure 19 Design of Stealth RNAi Duplexes by Invitrogen (Life Technologies, 
California, USA)   
Using the BLOCK-iT RNAi Designer, five RNAi duplexes were designed targeting the 
mouse TFAM gene, accession number NM_009360.4.   
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NM_009360.4 - 193 AGATGTGCGCGGGCTGCGGGGGTCGCATCCCCTCGTCTATCAGTCTTGTCTGTATTCCGAAGTGTTTTTCCAGCATGGGTAGCTA 
NM_009360.4 - 232 TCAGTCTTGTCTGTATTCCGAAGTGTTTTTCCAGCATGGGTAGCTATCCAAAGAAACCTATGAGTTCATACCTTCGATTTTCCAC 
NM_009360.4 - 284 GAAACCTATGAGTTCATACCTTCGATTTTCCACAGAACAGCTACCCAAATTTAAAGCTAAACACCCAGATGCAAAACTTTCAGAA 
NM_009360.4 - 429 GAAGCTGATTTTAAAGCTGAGTGGAAAGCATACAAAGAAGCTGTGAGCAAGTATAAAGAGCAGCTAACTCCAAGTCAGCTGATGG 
NM_009360.4 - 695 TTGGAAAAATCTGTCTCCTGAGGAAAAGCAGGCATATATTCAGCTTGCTAAAGATGATAGGATTCGTTACGACAATGAAATGAAG 
 
Figure 20 pSCREEN-iT/LacZ Vectors and Insert Cassettes  
Using the five sense sequences listed in Figure 19, insert cassettes were designed by adding approximately 30 nucleotides upstream and 
downstream of the region targeted by the siRNA duplexes (highlighted in red) (B).  These insert cassettes were then annealed to form double 
stranded DNA, before being cloned into the pSCREEN-iT/LacZ vector, immediately downstream of the LacZ coding region (A). 
Target Sequence 
Insert Cassette A 
B 
 Figure 21 Mus Musculus TFAM gene and mRNA
The mouse TFAM gene is approximately 12.8 kb in length.  It is situated on chromosome 10 and consists of 7 exons, shown in da
gene is transcribed to produce a 4171 bp mRNA molecule with a 341 bp 5’ untranslated region (UTR) and 3098 bp 3’
shown (B).  The arrows represent the areas targeted by the five TFAM siRNA duplexes.  The mRNA is then translated producing t
protein which is 28 kDa in size. 
Information adapted from the NCBI AceView program foun
A 
B 
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The cloned pSCREEN-iT-GW/LacZ vector was then propagated in E.coli and 
glycerol stocks made, which were shipped to Newcastle and stored at -80 °C.  
Invitrogen also supplied all five siRNA probe duplexes that had been 
reconstituted in water to a final concentration of 20 µM.  The areas of the TFAM 
mRNA molecule targeted by the five TFAM siRNA duplexes can be seen in 
Figure 21. 
4.3.2 Validation of TFAM siRNA probes 
The five siRNA duplexes were then validated in GripTite293 MSR cells, human 
kidney HEK293 derived cells expressing the human macrophage scavenger 
receptor, using the pSCREEN-iT assay system.  This work was also carried out 
by Invitrogen (Life Technologies, California, USA).  Briefly, GripTite293 MSR 
cells were transfected in triplicate in 96 well plates with the Stealth RNAi 
duplexes.  Each pSCREEN-iT/LacZ-target vector was co-transfected with the 
Scrambled Med GC negative control Stealth RNAi duplex, the Stealth RNAi 
LacZ positive control duplex, or the target-specific Stealth RNAi duplex.  Cells 
were then harvested 24 hrs post transfection and β-galactosidase activity 
measured. 
Beta-galactosidase activity was measured following addition of the CUG 
substrate to an aliquot of the cell lysate.  If active β-galactosidase was present, 
then it catalysed the cleavage of the CUG substrate to form 7-hydroxycoumarin-
3-carboxylic acid, which is highly fluorescent.  Fluorescence was then 
measured using a plate reader, with excitation centred around 390 nm and 
emission centred around 460 nm.  Cells co-transfected with the LacZ RNAi 
duplex were used as the positive control as the LacZ RNAi targets and 
downregulates LacZ gene expression.  LacZ encodes the β-galactosidase 
protein and so, little β-galactosidase protein is produced, resulting in minimal β-
galactosidase activity.  The Scrambled RNAi probe however, was used as the 
negative control as it does not target any mammalian gene and so, produces 
negligible knock down.  The effectiveness of each of the five TFAM siRNA 
duplexes was then compared against the negative and positive controls (Figure 
22). 
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It is clear that all five TFAM siRNA probes are specific for the target sequence 
on the pSCREEN-iT/LacZ cloned vector and are thus effective at knocking 
down β-galactosidase activity.  From the data in Figure 22, we subsequently 
chose to use the TFAM-193 and TFAM-429 siRNA duplexes in our experiments 
as they target different regions of the TFAM mRNA (Figure 21), and also 
produced the best knock down in the pSCREEN-iT assay. 
4.3.3 TFAM knock down in MIN6 cells 
Once Invitrogen had developed the TFAM siRNA duplexes and validated the 
probes in GripTite293 MSR cells, the next stage was to check we could knock 
down TFAM gene expression specifically in MIN6 cells.  We had previously 
attempted to transfect MIN6 cells using lipid-based transfection systems that 
had been successfully used to silence gene expression in human and mouse 
muscle cells (data not shown), but this approach proved unsuccessful in MIN6 
cells, which led us to enlist the expertise of Invitrogen through links with our 
industrial collaborators, Unilever Plc.  Similarly, Invitrogen also found that 
transfecting the MIN6 cells using lipid-based transfection systems such as 
Lipofectamine RNAiMAX and Lipofectamine 2000 yielded poor transfection 
efficiencies.  Therefore, Invitrogen attempted electroporation instead to see if 
this was more successful.  The Neon Transfection System was used to develop 
a protocol for the MIN6 cells.  The initial optimisation was performed using the 
BLOCK-iT Fluorescent Oligo for electroporation, and transfection efficiency was 
measured by GFP flow cytometry.  The transfection efficiency was only 
estimated to be around 30%, but the group found that the p53 positive control 
Stealth RNAi caused significant reduction in p53 mRNA levels.  Encouraged by 
these results, the group investigated TFAM mRNA levels and found that TFAM 
mRNA expression was decreased by 70% for both the TFAM-193 and TFAM-
429 siRNA duplexes.  The experiment was repeated twice, each time in 
triplicate.  The optimal electroporation conditions were found to be by shocking 
the MIN6 cells at a voltage of 1200 V for 20 ms, for 2 pulses. 
Figure 23 briefly explains MIN6 transfection using the Neon Electroporation 
System, more specific details are given in Section 2.3. 
 
  
 
 
 
 
 
 
 
Figure 22 siRNA probe validation using the pSCREEN
The 5 Stealth siRNA probes were validated by transfecting GripTite293
Stealth RNAi duplexes.  Each pSCREEN
the Scrambled Med GC Stealth RNAi (negative control), the LacZ Stealth RNAi 
(positive control) or the TFAM Stealth RNAi duplexes.  Beta
measured following addition of substrate CUG to the cell lysate and measuring 
fluorescence.  Results were performed in triplicate wells and were normalised to the 
Scramble Stealth RNAi negative control.  Error bars are representative of standard 
deviation. 
Validation assay performed by Invitrogen (Life Technologies, California, USA).  Data 
taken from a Custom Services Project Report, dated 04.01.10 (prepared by Megan 
Palm), project number CB5052.
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Figure 23 Neon Transfection System   
The Neon Transfection System (Life Technologies, Paisley, UK) consists of a grey 
touch screen device, attached to which is a Neon pipette station used to dock the Neon 
pipette (A).  The Neon pipette is adapted to fit a uniquely designed 10 µl or a 100 µl 
plastic tip, which contains a gold electrode piston (B).  The Neon pipette is used to 
pipette 10 µl of a pre-mixed solution containing cells and siRNA (C1).  The pipette is 
secured into the docking station and cells are transfected according to the selected 
protocol (C2).  Transfected cells are then pipetted in to 24 well plate containing 0.5 ml 
pre-warmed transfection medium per well (C3).  After transfection was complete, cells 
were incubated in a humidified incubator (37 ˚C, 5% CO2).   
All images taken from www.invitrogen.com. 
 
A B 
C 
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4.4 Results 
4.4.1 TFAM mRNA knock down in MIN6 cells 
Now that we had a fully optimised protocol from Invitrogen, the first step was to 
check we could replicate the results.  Using the Neon Transfection System also, 
we electroporated MIN6 cells in suspension with 100 nM TFAM-193 siRNA, 
TFAM-429 siRNA or Med GC Stealth Scrambled negative control siRNA.  The 
Shocked cells were resuspended in Resuspension Buffer R and shocked, but 
no siRNA was added, thus serving as a negative control also.  Cells were 
electroporated using the same conditions optimised by Invitrogen, 1200 V for 20 
ms for 2 pulses, before seeding in a 24 well plate with 500 µl transfection 
medium (without antibiotics).  The transfected cells were then incubated at 37 
°C for 48 hrs or 72hrs before harvesting.  These time periods were chosen to 
allow time for the TFAM knock down to impact on mtDNA replication.  RNA was 
extracted, quantified and reverse transcribed.  The degree of TFAM mRNA 
knock down was assessed by real-time PCR using TaqMan hydrolysis probes, 
relative to reference gene β2 Microglobulin (B2M) (see Section 2.4.2 and 2.4.3). 
We were able to knock down TFAM mRNA expression by more than 80% 
(p<0.0001) compared to the Scrambled and Shocked controls, 48 hrs post 
transfection (Figure 24A).  This corroborates Invitrogen’s result, who reported a 
70% decrease in TFAM mRNA expression 24 hrs post transfection.  Seventy 
two hrs post transfection, we see a slight increase in TFAM expression, but 
mRNA is still significantly knocked down by more than 80% (p<0.0001) (Figure 
24B).  We can also see that the Scrambled siRNA seems to be having no 
adverse effect on TFAM gene expression, with relative expression mirroring that 
of the Shocked control, in which no siRNA was added.   
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Figure 24 TFAM siRNA knock down 48 hrs and 72 hrs post transfection 
MIN6 cells were transfected in suspension using the Neon Transfection System with 
100 nM TFAM-193 siRNA, TFAM-429 siRNA, Scrambled negative control siRNA, or no 
siRNA (Shocked).  Transfected cells were transferred into a 24 well plate containing 
transfection growth medium (without antibiotics), and were incubated at 37 ˚C.  Cells 
were harvested 48 hrs (A) or 72 hrs (B) post transfection, and RNA extracted, 
quantified and reverse transcribed.  TFAM mRNA expression was quantified relative to 
control gene B2M by real-time PCR.  (A) Experiment repeated twice, each repeat 
performed in triplicate.  (B) Experiment repeated four times, each repeat performed in 
triplicate.  Error bars representative of SEM.  Results normalised to Scrambled 
negative control.  *** p<0.0001 relative to Scrambled control. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
TFAM-193 TFAM-429 Scrambled Shocked
T
F
A
M
 /
 B
2
M
 m
R
N
A
 E
x
p
re
ss
io
n
0
0.2
0.4
0.6
0.8
1
1.2
1.4
TFAM-193 TFAM-429 Scrambled Shocked
T
F
A
M
 /
 B
2
M
 m
R
N
A
 E
x
p
re
ss
io
n
A 
B 
*** 
*** 
*** *** 
113 
 
4.4.2 TFAM mRNA knock down causes mtDNA depletion 
Encouraged by the success of the TFAM knock down, we repeated the 
electroporation and extracted DNA and RNA from the harvested cells (see 
Section 2.4.3 for further detail), 48 hrs and 72 hrs post transfection.  We wanted 
to measure TFAM mRNA expression using the extracted RNA, but we also 
wanted to measure the mtDNA:nDNA ratio using the extracted DNA and the 
mtDNA copy number assay optimised in Chapter 3. 
After measuring the TFAM mRNA expression relative to the B2M reference 
gene, we found that TFAM mRNA levels were depleted by >80% in both the 
TFAM-193 and TFAM-429 transfected cells compared to the Scrambled and 
Shocked control cells (data are one of the repeats shown in Figure 24).  Again, 
TFAM levels were lowest 48 hrs post transfection in TFAM siRNA transfected 
cells, but TFAM expression was still significantly reduced by >80% 72 hrs post 
transfection in TFAM siRNA transfected cells compared to Scrambled and 
Shocked control cells. 
We found that 48 hrs post transfection, there was no difference in the 
mtDNA:nDNA ratio of TFAM siRNA transfected cells compared to Scrambled 
and Shocked control cells (Figure 25A).  After 72 hrs post transfection however, 
we see approximately 40% decrease in the mtDNA:nDNA ratio of TFAM 
transfected cells in comparison to the control cells  (Figure 25B).  It is also 
apparent that the TFAM-429 siRNA probe is slightly more effective by producing 
a slightly greater decrease in the mtDNA:nDNA ratio.   
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Figure 25 Effect of TFAM knock down on mtDNA levels in MIN6 cells, 48 hrs and 
72 hrs post transfection 
TFAM mRNA expression was silenced following transfection using the Neon 
Electroporation System.  Cells were incubated at 37 ˚C and harvested 48 hrs (A) and 
72 hrs (B) post transfection.  DNA and RNA were extracted from the cells and the 
mtDNA copy number assay performed to ascertain the degree of mtDNA depletion, by 
quantifying ND5 target gene expression relative to the GAPDH reference gene.  
Experiment repeated once in triplicate.  Error bars representative of SD.  Results 
normalised to Scrambled negative control.  * p<0.05, ** p<0.01 relative to Scrambled 
control. 
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4.4.3 Validation of mtDNA depletion following TFAM siRNA knock down 
To validate our findings so far, that 72 hrs post transfection TFAM mRNA is 
reduced by >80%, and this seems to have the desired effect of depleting 
mtDNA levels by around 40%, we first repeated the transfections to ensure this 
was not an anomaly.  MIN6 cells were again transfected and harvested 72 hrs 
post transfection.  The DNA and RNA was extracted and used to quantify 
mtDNA:nDNA and TFAM mRNA expression respectively.  In Figure 26A, we 
can see that after repeating the experiment four times, each repeat performed 
in triplicate, mtDNA:nDNA levels were significantly depleted by an average of 
40% in cells transfected with TFAM-193 or TFAM-429 (p<0.0001) compared to 
Scrambled and Shocked control cells.  The TFAM-429 siRNA probe performed 
consistently better than the TFAM-193 siRNA probe in terms of producing 
slightly greater mtDNA depletion. 
Combining the results of the four transfection repeats, we were confident that 
TFAM siRNA knock down was having an effect on mtDNA copy number.  But to 
confirm our findings further, we wanted to express mtDNA encoded ND5 
relative to a second nDNA encoded reference gene.  The gene chosen was 
CDKN2A, cyclin dependent kinase inhibitor 2A.  Also known as p16, CDKN2A is 
a tumour suppressor protein implicated in cell cycle regulation, and has recently 
been identified as a T2DM susceptibility gene (Saxena, et al., 2007).  Standard 
curves serially diluted 1:5 were amplified using the CDKN2A QuantiTect assay 
(Assay ID Mm_Cdkn2a_va.1_SG; Qiagen, Crawley, UK) and compared to 
GAPDH and ND5 standard curves.  Once it was confirmed that reaction 
efficiencies for CDKN2A were comparable to those for GAPDH and ND5 (see 
Appendix, Figure 1), real-time PCR was performed on transfection samples and 
mtDNA encoded target gene ND5 was expressed relative to nDNA encoded 
reference gene CDKN2A.  In Figure 26B, we can see that the results echo 
those obtained using the GAPDH nDNA encoded reference gene in that the 
mtDNA:nDNA ratio is significantly reduced by around 40% in both TFAM siRNA 
transfected cells.  Again, the TFAM-429 siRNA probe seems to produce slightly 
greater mtDNA depletion. 
 
 
116 
 
 
 
 
 
 
Figure 26 Validation of mtDNA depletion following TFAM knock down 
The mtDNA depletion seen following TFAM gene silencing was validated by first 
repeating the transfection experiment and measuring mtDNA levels relative to the 
GAPDH nDNA encoded reference gene 72 hrs post transfection (A).  Experiment 
repeated 4 times, each time in triplicate.  Error bars representative of SEM.  *** 
p<0.0001.  mtDNA levels were also calculated relative to a second nDNA encoded 
reference gene, CDKN2A, cyclin-dependent kinase inhibitor 2A (B).  Experiment 
repeated twice in triplicate, error bars representative of SEM.  Results normalised to 
Scrambled negative control.  * p<0.05 relative to Scrambled control. 
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4.4.4 mtDNA depletion 96 hrs and 144 hrs post transfection 
By transfecting MIN6 cells with two different siRNA probes, we could reliably 
knock down TFAM gene expression by >80%.  This then resulted in an overall 
40% decrease in mtDNA levels 72 hrs post transfection, compared to control 
cells.  As with the didanosine mtDNA depletion model, we were still looking to 
deplete mtDNA levels by approximately 50%.  Because we only witnessed 
mtDNA depletion 72 hrs post transfection, and not 48 hrs post transfection, we 
wanted to see if leaving the cells for longer than 72 hrs after initial transfection 
resulted in an even greater decrease in mtDNA.  
We transfected the MIN6 cells as we had done previously, and incubated them 
at 37 ˚C before harvesting cells 96 hrs and 144 hrs post transfection.  RNA and 
DNA were extracted and quantified before real-time PCR was performed to 
ascertain the degree of mtDNA depletion.  In Figure 27A, we can see that 96 
hrs post transfection, mtDNA levels in cells transfected with the TFAM-429 
probe have decreased by approximately 50% compared to the control cells, 
which is a 10% greater mtDNA depletion than TFAM-429 cells harvested 72 hrs 
post transfection.  TFAM-193 transfected cells on the other hand, still have 40% 
mtDNA depletion compared to control cells 96 hrs post transfection, which is the 
same degree of mtDNA depletion seen 72 hrs post transfection.  Similarly, 144 
hrs post transfection, mtDNA levels still remain depleted by 50% in TFAM-429 
transfected cells but only by 30% in TFAM-193 transfected cells, when 
compared to the Scrambled and Shocked control cells (Figure 27B).  
When we analysed the RNA samples to determine TFAM knock down, we could 
see that 96 hrs after initial transfection, the transient effects of the siRNA probes 
had started to wear off, with TFAM mRNA expression knocked down by only 
60-70% in TFAM-193 and TFAM-429 cells (Figure 28A).  TFAM mRNA 
expression further increases 144 hrs post transfection, as TFAM knock down is 
only 40-60% in TFAM-193 and TFAM-429 cells compared to Scrambled and 
Shocked control cells (Figure 28B).  If TFAM mRNA levels are beginning to 
increase 96 hrs and 144 hrs post transfection, this may explain why we are 
struggling to deplete mtDNA levels by more than 40-50% using the two TFAM 
siRNA probes. 
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Figure 27 mtDNA depletion 96 hrs and 144 hrs post transfection 
MIN6 cells were transfected and incubated at 37 ˚C before being harvested 96 hrs (A) 
and 144 hrs (B) post transfection.  DNA and RNA were extracted from the samples and 
real-time PCR carried out to assess the relative expression of target gene ND5 to 
reference gene GAPDH, expressed as the mtDNA:nDNA ratio.  Experiment was 
performed once in triplicate.  Error bar representative of SD.  Results normalised to 
Scrambled negative control.  * p<0.05 relative to Scrambled control. 
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Figure 28 TFAM mRNA knock down 96 hrs and 144 hrs post transfection 
MIN6 cells were transfected and incubated at 37 ˚C before being harvested 96 hrs (A) 
and 144 hrs (B) post transfection.  DNA and RNA were extracted from the samples and 
real-time PCR carried out to determine TFAM mRNA expression relative to reference 
gene B2M.  Experiment was perform once in triplicate.  Error bar representative of SD.  
Results normalised to Scrambled negative control.  * p<0.05, ** p<0.01 relative to 
Scrambled control. 
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4.4.5 The effect of siRNA probes on MIN6 cell cytotoxicity and cell morphology 
To finally complete the optimisation of the TFAM mtDNA depletion model in 
MIN6 cells, we wanted to investigate what effects the siRNA probes were 
having on MIN6 cell cytotoxicity and cell morphology.  As with the didanosine 
mtDNA depletion model, we measured cell cytotoxicity using an LDH assay.  
MIN6 cells were transfected and allowed to settle overnight.  Twenty four hrs 
after initial transfection, cells were washed and the transfection medium was 
changed to remove dead cells that had not survived the transfection procedure.  
An aliquot of transfection medium supernatant was then harvested 72 hrs and 
96 hrs post transfection, and LDH activity measured as a percentage of the 
positive control (see Section 2.8 for details).  Seventy two hrs post transfection, 
cell cytotoxicity is <2% in cells transfected with either of the two TFAM siRNA 
probes or the Scrambled siRNA probe (Figure 29A).  This is the same level of 
cytotoxicity seen in Shocked cells in which no siRNA was added and so, we can 
conclude that the siRNA probes used do not seem to cause cell cytotoxicity 72 
hrs post transfection.  An optical density (OD) reading was taken of an aliquot of 
MIN6 culture medium and used as a negative control to subtract from sample 
readings, which explains the negative percentage cytotoxicity in TFAM-193 cells 
in Figure 29A.  This is because LDH is sometimes present in the phenol red and 
serum used in culture mediums and so, would give a false positive result.  Cell 
cytotoxicity levels are still low 96 hrs post transfection, but we can see that there 
is a 5-fold increase in cell cytotoxicity in TFAM-193 cells and almost a doubling 
in TFAM-429 cells, when compared to the cytotoxicity levels 72 hrs post 
transfection (Figure 29B). 
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We looked at cell morphology by imaging cells 24 hrs, 48 hrs and 72 hrs post 
transfection using a Nikon Eclipse TE2000-S microscope and Photmetrics 
CoolSNAP HQ2 Turbo 1394 camera at x20 magnification.  We can see that 24 
hrs post transfection, cells appear to still be recovering from the procedure, as 
some cells are still small and compact.  This is evident for all three siRNA 
probes used as well as the Shocked control cells, proving that this is due to the 
electroporation and not the presence of siRNA.  By 48 hrs hours post 
transfection, we can see that the cells have started to grow again.  Visually, 
there does not seem to be a difference in proliferation rate across the 
transfection conditions used.  Also, all cells grow in clusters and can be seen to 
take on the typical MIN6 cell morphology, and thus, seem to be growing 
normally.  The same can be said about the images taken 72 hrs post 
transfection.  All cells seem to be growing normally, with no obvious difference 
in proliferation rate or cell morphology.   
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Figure 29 Cell viability following transfection: cell morphology and cytotoxicity 
MIN6 cells were transfected and allowed to settle overnight.  The following day, 24 hrs 
post transfection, cells were washed and transfection medium was changed to remove 
dead cells that had not survived electroporation.  Cell cyctotoxicity was then measured 
as a percentage of the positive control by an LDH assay after removing the culture 
medium 72 hrs (A) and 96 hrs (B) post transfection.  Cells were imaged using a Nikon 
Eclipse TE2000-S microscope and Photmetrics CoolSNAP HQ2 Turbo 1394 camera at 
x20 magnification 24 hrs, 48 hrs and 72 hrs after initial transfection (C). 
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4.5 Discussion 
Previous in vitro studies investigating TFAM knock down have produced 
primary cell cultures from tissues extracted from TFAM knock out animal 
models, including tissue specific disruption of the TFAM gene in mouse 
pancreatic β-cells (Silva, et al., 2000), mouse forebrain neurones (Sorensen, et 
al., 2001) and mouse cardiac and skeletal muscle (Wang, et al., 1999).  There 
have also been in vitro studies implementing siRNA gene silencing to produce 
TFAM knock down.  For one group, this involved transfecting human 143B TK- 
cells with a plasmid by the calcium-phosphate precipitation method, then 
culturing the isolated transfected cells for 3 months (Jeng, et al., 2008).  
Another group used electroporation and siRNA technology to silence TFAM 
mRNA in 3T3-L1 adipocytes (Shi, et al., 2008).  After failing to reliably 
knockdown TFAM expression using lipid-based transfection techniques, we 
enlisted the help of Invitrogen, through collaboration with our industrial partner, 
Unilever Plc, to develop a transfection protocol that would reliably knock down 
TFAM mRNA expression specifically in MIN6 cells.  Our aim was that this 
genetic manipulation of mitochondrial biogenesis would complement the 
didanosine mtDNA depletion model developed in Chapter 3, which relied on 
chemical manipulation. 
Invitrogen began this work by optimising an electroporation protocol that 
silenced TFAM mRNA by a substantial 70%, 24 hrs post transfection.  Our plan 
was to investigate whether TFAM gene silencing had a consequential effect on 
mtDNA levels.  Therefore, we needed to ensure enough time had elapsed for 
the reduced TFAM mRNA to be translated, resulting in a reduction in TFAM 
protein, and whether this would have a significant effect on mtDNA levels.  For 
this reason, we decided to harvest cells 48 hrs and 72 hrs post transfection. 
We were able to repeat the protocol set out by Invitrogen, and achieved a 
significant >80% knock down in TFAM mRNA 48 hrs and 72 hrs post 
transfection (p<0.0001).  We accomplished a slightly greater TFAM knock down 
compared to Invitrogen, which may be explained by the fact we harvested the 
cells 24 / 48 hrs later than Invitrogen, thus allowing time for a greater knock 
down.  The next step was to look at what effect this was having on mtDNA 
levels.  Our initial findings suggested that mtDNA was depleted by 40% 72 hrs 
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post transfection in TFAM knock down cells, but mtDNA depletion was not seen 
48 hrs post transfection.  To corroborate these results, we first repeated the 
transfection experiment multiple times, and found that 72 hrs post transfection, 
mtDNA was indeed significantly depleted by 40% using both the TFAM-193 and 
TFAM-429 siRNA probes (p<0.0001).  Although, it seemed that the TFAM-429 
probe produced slightly greater mtDNA depletion compared to the TFAM-193 
probe, but not significantly so.  We then validated our findings further by 
measuring our mtDNA encoded ND5 target gene relative to a second nDNA 
encoded reference gene, CDKN2A.  Again, we found that mtDNA levels were 
depleted by 40% in TFAM siRNA transfected cells, 72 hrs post transfection. 
The 40% depletion in mtDNA following TFAM knock down we have reported is 
echoed in many other studies.  The pioneering research performed by Larsson 
et al. showed that in heterozygous TFAM knockout mice, mtDNA levels were 
decreased by 35-40% compared to wild type mice.  The group also concluded 
that homozygous TFAM knockout mice possessed a lethal phenotype causing 
them to died during gestation (Larsson, et al., 1998).  By silencing TFAM gene 
expression specifically in neurones, Sorensen et al. produced mitochondrial 
late-onset neurodegeneration (MILON) mice, and found that the mice had a 
40% reduction in mtDNA from 2 months of age, when compared to wild type 
mice.  An in vitro study by Shi et al. implemented siRNA technology to silence 
TFAM gene expression whilst investigating adipocyte differentiation.  The group 
managed to decrease TFAM mRNA expression by 80% also, and found that 
this resulted in a 30% mtDNA depletion compared to the Scrambled controls 72 
hrs post transfection, which mirrors our findings precisely (Shi, et al., 2008).  
However, Wrendenberg et al. reported a slightly greater mtDNA depletion of 
70% following tissue specific TFAM gene silencing in mouse skeletal muscle. 
As with the didanosine mtDNA depletion model, our target was to achieve 50% 
mtDNA depletion.  We saw no effect on mtDNA levels 48 hrs post transfection 
which may be explained by a slow turnover rate of the TFAM protein, which has 
been estimated as having a half-life of >12 hrs (Maniura-Weber, et al., 2004).  
Because we saw no effect on mtDNA levels at 48 hrs, but a 40% decrease 72 
hrs post transfection, we wanted to extend the incubation period after initial 
transfection to see if this would allow greater mtDNA depletion.  After 96 hrs 
post transfection, mtDNA was depleted by 50% using the TFAM-429 probe, and 
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this level of mtDNA depletion was sustained at 144 hrs post transfection.  
However, this was at the cost of an increase in cytotoxicity in the MIN6 cells.  
Again, the TFAM-429 seems to produce better mtDNA depletion as the TFAM-
193 probe can only produce a maximum of 40% mtDNA depletion 72 hrs and 
96 hrs post transfection, but only a 30% mtDNA depletion 144 hrs post 
transfection.  The slight increase in mtDNA 144 hrs post transfection could be 
the mtDNA repopulating after the transient effects of the TFAM-193 siRNA start 
to wear off.  This is supported by the fact that TFAM mRNA levels begin to 
increase from >80% TFAM gene silencing 72 hrs post transfection, to 60-70% 
TFAM gene silencing 96 hrs post transfection and only 40-60% TFAM gene 
silencing 144 hrs post transfection. 
So in summary, it seems that by extending the incubation period after initial 
transfection, we get a slightly better 50% mtDNA depletion with the TFAM-429 
probe only 96 hrs post transfection, but at the expense of increased cytotoxicity.  
By 96 hrs post transfection, we see the transient effects of the siRNA begin to 
fade as TFAM mRNA expression increases.  This suggests that the only way to 
deplete mtDNA levels further would be to re-transfect the cells.  But the level of 
mtDNA depletion we have reported is corroborated by other groups (Larsson, et 
al., 1998; Shi, et al., 2008; Sorensen, et al., 2001).  Therefore we can confirm 
that by silencing TFAM mRNA expression by >80% in MIN6 cells using 
electroporation transfection, we can reliably deplete mtDNA levels by 40% 72 
hrs post transfection.  Now we have managed to optimise two models of mtDNA 
depletion in MIN6 cells, using both chemical and genetic intervention of 
mitochondrial biogenesis, we can now utilise both depletion models to 
investigate the effects of mtDNA depletion on β-cell and mitochondrial function. 
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Chapter 5 
The effect of mtDNA depletion on 
mitochondrial function 
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5 The effect of mtDNA depletion on mitochondrial function 
5.1 Introduction 
Now that we had successfully optimised two independent models to deplete 
mtDNA levels by approximately 40-50%, we were keen to see what effect this 
had on mitochondrial function.  Studies to date have created severe mtDNA 
depletion in pancreatic β-cells by chemical inhibition of mtDNA replication 
(Hayakawa, et al., 1998; Kennedy, et al., 1998; Soejima, et al., 1996; Tsuruzoe, 
et al., 1998), or tissue specific knock down of the mitochondrial transcription 
factor TFAM (Silva, et al., 2000).  These groups have successfully shown that 
severe mtDNA depletion drastically affects mitochondrial function by causing: 
respiratory chain dysfunction (Kennedy, et al., 1998; Silva, et al., 2000; 
Soejima, et al., 1996; Tsuruzoe, et al., 1998), reduced mtDNA transcription 
(Hayakawa, et al., 1998; Soejima, et al., 1996; Tsuruzoe, et al., 1998)  and 
translation (Soejima, et al., 1996), impaired Ca2+ signalling (Hayakawa, et al., 
1998; Silva, et al., 2000; Soejima, et al., 1996; Tsuruzoe, et al., 1998), reduced 
mitochondrial membrane hyperpolarisation (Kennedy, et al., 1998; Silva, et al., 
2000), reduced oxygen consumption (Soejima, et al., 1996) and reduced ATP 
content (Kennedy, et al., 1998; Tsuruzoe, et al., 1998). 
These studies have managed to show the effects of severe mtDNA depletion on 
mitochondrial function, but little is known regarding the effects of partial mtDNA 
depletion on mitochondrial function.  Using the two models of mtDNA depletion 
optimised in Chapters 3 and 4, we wanted to investigate the effect of partial 
mtDNA depletion, to levels seen in ageing human islets (Cree, et al., 2008), on 
mitochondrial function. 
5.2 Aims 
The aim of this chapter was to explore the effect of partial mtDNA depletion on 
mitochondrial function in MIN6 cells.  We compared both mtDNA depletion 
models on aspects of mitochondrial function including: 
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• COX1 mRNA expression using real-time PCR 
• COX1 protein levels using western blotting 
• ATP content using a luciferase ATP assay 
• Mitochondrial membrane potential using JC-1 staining 
5.3 Methods 
5.3.1 JC-1 staining 
The JC-1 dye is commonly used to measure mitochondrial membrane potential 
as it has a unique property: when in the cell cytosol, it exists in a monomeric 
form and emits a green fluorescence; when the dye enters the mitochondrial 
matrix however, it forms J-aggregates and emits a red fluorescence.  The 
cationic dye selectively enters the mitochondrial matrix by utilising the 
mitochondrial membrane potential, which is much lower than that of the plasma 
membrane.  Once inside the mitochondrial matrix, the low mitochondrial 
membrane potential causes the monomeric JC-1 to aggregate, thus forming J-
aggregates.  This causes a spectral shift, resulting in the dye emitting red 
fluorescence (see Figure 30).  The proportion of red and green fluorescence 
was measured using a live cell fluorescence microscope, and mitochondrial 
membrane potential was calculated as a ratio of red / green fluorescence.  JC-1 
cytosolic monomers were imaged using a 470 nm ± 40 nm excitation filter, 520 
nm ± 40 nm emission filter whereas JC-1 mitochondrial J-aggregates were 
imaged using a 575 nm ± 25 nm excitation filter, 632 nm ± 40 nm emission filter.   
Briefly, MIN6 cells were incubated with JC-1 staining medium for 10 mins at 
37ºC to allow the dye to permeate the cells.  Cells were then washed in pre-
warmed PBS before normal MIN6 growth medium was added prior to imaging 
the cells immediately.  All images were then quantified using ImageJ and the 
mitochondrial membrane potential calculated as the ratio of red / green 
fluorescence (see Section 2.10.2 for further details). 
  
  
 
 
 
 
Figure 30 Measurement of mitochondrial membrane potential using JC
JC-1 enters the cytosol down the plasma membrane potential (
exists in monomeric form in the cytosol, e
nm when excited at a wavelength of 470 nm 
enters the mitochondrial matrix, which is of a lower electrical potential to the cytosol, 
where it aggregates to form J
J-aggregate JC-1 emitting a red fluorescence at 632 nm 
wavelength of 575 nm 
prevents JC-1 monomers aggregating in the mitochondria
red fluorescence.  Mitochondrial membrane potential is measured as a ratio of red / 
green fluorescence. 
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5.4 Results 
5.4.1 mtDNA depletion causes reduced mitochondrial gene transcription 
One of the first measures of mitochondrial function we decided to investigate 
was mitochondrial gene transcription.  We considered the didanosine model of 
mtDNA depletion first.  MIN6 cells were treated with 50 µM ddI or PBS for a 
period of 5 days, before harvesting cells and extracting RNA.  RNA was 
quantified and reverse transcribe before assessing mitochondrial gene 
expression using TaqMan hydrolysis probes and real-time PCR.  We chose to 
investigate the COX1 mtDNA subunit of cytochrome c oxidase, Complex IV, as 
our target gene.  The three mtDNA encoded subunits of Complex IV (COX1, 
COX2 and COX3) initially form a holoenzyme which is pivotal for the assembly 
of the rest of the complex (Larsson, 2010) and so, COX1 is an important mtDNA 
encoded subunit.  Our reference gene was nDNA encoded β2-microglobulin 
(B2M), a component of the Class 1 major histocompatibility complex (MHC) on 
the cell surface of most nucleated cells (Gussow, et al., 1987). 
In Figure 31, we see that didanosine-induced mtDNA depletion significantly 
reduces mitochondrial gene expression by 45.3% compared to vehicle control 
PBS cells (p<0.0001).   
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Figure 31 COX1 mRNA expression following didanosine-induced mtDNA 
depletion 
MIN6 cells were treated with 50 µM ddI for a period of 5 days before cells were 
harvested and RNA extracted.  RNA was quantified and reverse transcribed, and real-
time PCR performed using TaqMan hydrolysis probes.  mtDNA encoded COX1 mRNA 
expression was calculated relative to the nDNA encoded B2M reference gene.  Data 
are normalised to PBS vehicle control cells.  Experiment repeated 3 times in triplicate.  
Error bars representative of SEM.  *** p<0.0001 
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Similarly, we repeated the same experiment but using the TFAM mtDNA 
depletion model.  MIN6 cells were transfected using the TFAM-193 and TFAM-
429 siRNA probes to silence TFAM mRNA expression.  Cells were then 
incubated at 37 ºC for 72 hrs before harvesting.  RNA was extracted, quantified 
and reverse transcribed prior to real-time PCR.  COX1 mRNA expression was 
examined relative to the reference gene B2M.  In support of the didanosine 
mtDNA depletion model, we also see reduced COX1 mRNA expression using 
the TFAM silencing model of mtDNA depletion (Figure 32).  There is a 23.9% 
and 33.4% decrease in COX1 mRNA expression using the TFAM-193 and 
TFAM-429 siRNA probes respectively, compared to the Scrambled control cells 
(p<0.001 and p<0.0001, respectively).  The TFAM-429 probe produced a 
greater decrease in COX1 gene expression.  This is consistent with the mtDNA 
depletion data for the TFAM mtDNA depletion model, whereby the TFAM-429 
probe produced greater mtDNA depletion also, compared to the TFAM-193 
probe.  It is also known for this set of experiments, TFAM mRNA expression 
was silenced by 80.7% ± 0.092 and 79.1% ± 0.04 (mean ± SEM) in TFAM-193 
and TFAM-429 cells respectively, compared to the Scrambled control cells in 
these 3 experimental repeats (data not shown). 
In summary, both methods of mtDNA depletion result in decreased mtDNA 
gene expression.  But it is worth noting that COX1 gene expression is more fully 
suppressed following didanosine-induced mtDNA depletion, compared to TFAM 
silencing-induced mtDNA depletion. 
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Figure 32 COX1 mRNA expression following TFAM silencing-induced mtDNA 
depletion 
MIN6 cells were transfected with TFAM-193, TFAM-429 or Scrambled siRNA probes, 
or with no siRNA (Shocked).  Cells were incubated at 37 ºC for 72 hrs before 
harvesting.  RNA was extracted, quantified and reverse transcribed, and real-time PCR 
performed using TaqMan hydrolysis probes.  COX1 mRNA expression was measured 
relative to the B2M reference gene.  Data are normalised to Scrambled control cells.  
Experiment repeated 3 times in triplicate.  Error bars representative of SEM.  ** 
p<0.001,  *** p<0.0001 
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5.4.2 mtDNA depletion causes a decrease in mitochondrial encoded protein 
levels 
To confirm whether the reduction in COX1 gene expression had a knock on 
effect on COX1 protein levels, we performed a series of western blots to 
determine COX1 protein levels following mtDNA depletion.  We decided to 
analyse COX1 protein levels in mtDNA depleted MIN6 cells using the 
didanosine-induced mtDNA depletion first.  This was for the reason that the 
didanosine model produced the greatest mtDNA depletion, as well as the 
greatest decrease in COX1 gene expression, when compared to the TFAM 
mtDNA depletion model.  After MIN6 mtDNA had been depleted following 5 day 
50 µM ddI treatment, cells were harvested in protein extraction buffer and 
protein quantified using the Bradford assay.  Twenty five µg protein was 
separated by SDS-PAGE, and the separated proteins transferred onto a 
nitrocellulose membrane, which was then used to probe for COX1, SDH70 and 
β-Actin proteins.  SDH70 is the 70 kDa subunit of succinate dehydrogenase, 
Complex II, the only mitochondrial complex whose subunits are entirely nDNA 
encoded and so, should not be affected by mtDNA depletion.  Protein loading 
was assessed using β-Actin. 
We performed two separate experiments in quadruplicate, and then analysed 
the samples from each experiment using two independent western blots.  This 
was because each blot was cut in half to allow separate probing of COX1 and 
β-Actin, as the proteins were very similar in size (40 kDa and 42 kDa 
respectively), and there were only a limited number of wells per gel.  One of the 
blots was then washed and re-probed with the SDH70 antibody.  The SDH70 
protein was expected to be 70 kDa in size and so, would show up on a different 
area of the blot, thus allowing easy distinction from COX1 / β-Actin proteins (all 
antibodies used were monoclonal, but were raised in mouse and so, the same 
secondary antibody was used). 
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The results of both experimental repeats are shown in Figure 33.  In both 
western blots of both repeats, we can visually discern a difference in COX1 
band density with the ddI bands tending to be slightly less intense than the PBS 
bands (Figure 33Ai and 33Bi).  Comparing the COX1 bands to those of SDH70 
and β-Actin, visually, there does not seem to be an obvious difference in band 
density between ddI treated and PBS control cells when probed with SDH70 or 
β-Actin.  These visual observations are supported by the optical density (OD) 
readings obtained from densitometric analysis. 
When the OD readings are used to calculate the ratio of COX1 protein to the β-
Actin loading control, we see that COX1 protein is reduced in ddI treated cells 
by approximately 30% in repeat 1 (Figure 33Aii) and 40% in repeat 2 (Figure 
33Bii) when normalised to PBS control cells.  The β-Actin loading control bands 
are uniform in all blots, indicating that this difference in COX1 protein in ddI 
treated cells is not a result of unequal protein loading.  When we calculate the 
ratio of SDH70 / β-Actin however, we see that there is no real difference in the 
protein ratios in ddI treated and PBS control cells (Figure 33Aiii and 33Biii), 
showing that there is a loss in mtDNA encoded protein subunits only in mtDNA 
depleted cells.   
When the data from both experimental repeats are combined, we see that 
overall, there is a 34.3% decrease in COX1 protein in ddI treated cells 
compared to PBS control cells (p=0.015) (Figure 34A).  However, we see no 
change in SDH70 protein levels with ddI treatment compared with PBS control 
cells, which was to be expected as SDH70 is nDNA encoded and so, would not 
be affected my mtDNA depletion (Figure 34B). 
 
 
 Figure 33 Effect of didanosine
proteins 
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extracted and analysed by western blott
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SDH70 proteins relative to 
each repeat assayed in two independent western blots.  The blots for repeat 1 (A) and 
repeat 2 (B) are shown, error bars represent SD.  Data normalised to PBS control cells.
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Figure 34 Effect of didanosine-induced mtDNA depletion on mtDNA encoded 
proteins (both repeats combined) 
The data from both experimental repeats presented Figure 33 were combined.  COX1 
(A) and SDH70 (B) proteins were both normalised to β-Actin loading control.  Data 
shown from 2 experiments performed in quadruplicate, error bars representative of 
SEM.  ** p=0.015.  Data normalised to PBS control cells. 
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After encouraging results of a decline in COX1 protein levels in mtDNA depleted 
cells using the didanosine mtDNA depletion model, we decided to investigate 
whether the same would be seen using the TFAM silencing method of mtDNA 
depletion.  The transfections were performed in 24 well tissue culture plates and 
as we required 25 µg protein to load per lane during SDS-PAGE, we needed to 
pool the protein lysates together from 3 separate wells to make one sample.  It 
was decided at this point that as the TFAM-429 siRNA probe had consistently 
performed better than the TFAM-193 siRNA probe, we would continue using the 
TFAM-429 probe only.  In addition, we were confident that the Scrambled 
siRNA probe was not having adverse affects on the cells in comparison to the 
Shocked cells.  Therefore, in future experiments, it was decided that we would 
silence TFAM mRNA using the TFAM-429 siRNA probe only, and that cells 
transfected with the Scrambled siRNA would act as our control cells. 
MIN6 cells were transfected with TFAM-429 or Scrambled siRNA probes and 
incubated at 37 ºC.  Seventy two hrs post transfection, cells were harvested in 
protein extraction buffer and quantified using the Bradford assay.  As with 
samples obtained following didanosine-induced mtDNA depletion, 25 µg protein 
was separated by SDS-PAGE.  Separated proteins were transferred onto a 
nitrocellulose membrane and mouse monoclonal antibodies were used to probe 
for COX1, SDH70 and β-Actin proteins.  Bound antibodies were detected using 
enhanced chemiluminescence (ECL) and photographic film.  Protein bands 
were quantified using densitometry.   
The experiment was repeated three times in duplicate.  Each of the three 
repeats is shown in Figure 35.  In repeats 1 and 2, we can see that some 
TFAM-429 bands probed with the COX1 antibody are slightly less intense 
compared to those of the Scrambled cells (Figure 35Ai and 35Bi), but in repeat 
3, visually there does not seem to be much difference between TFAM-429 cells 
or Scrambled control cells probed with the COX1 antibody (Figure 35Ci).  The 
β-Actin loading looks to be comparable in all three repeats, and SDH70 bands 
appear uniform in all samples in all repeats (Figure 35Ai, 35Bi and 35Ci). 
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These observations are supported by the densitometry OD readings.  The ratio 
of COX1 / β-Actin protein is reduced in repeats 1 and 2 by around 30-40% in 
TFAM-429 cells compared to Scrambled control cells (Figure 35Aii and 35Bii).  
However, the reduction in the COX1 / β-Actin protein ratio is less pronounced in 
repeat 3 (Figure 35Cii).  As seen with the didanosine mtDNA depletion model, 
there is no difference in SDH70 / β-Actin protein levels in TFAM-429 and 
Scrambled transfected cells (Figure 35Aiii, 35Biii and 35Ciii). 
When the results from all three repeats are combined, we see that overall, there 
is a 21.7% decrease in COX1 protein levels in TFAM-429 transfected cells 
compared to Scrambled transfection control cells (Figure 35Di).  Although this 
decrease in COX1 protein is not significant, there is a definite trend.  
Corroborating the results seen with the didanosine model, there is no change in 
SDH70 protein levels following TFAM silencing-induced mtDNA depletion 
(Figure 35Dii).   
In conclusion, there is a trend of decreased COX1 protein levels following 
TFAM gene silencing which would need further repeats to deem its significance.  
This is in support of the decreased COX1 mRNA expression found following 
TFAM gene silencing-induced mtDNA depletion.  However, this decrease in 
COX1 protein is not as prominent as that obtained using the didanosine model 
of mtDNA depletion. 
 
  
 Figure 35 Effect of TFAM silencing
proteins 
MIN6 cells were transfected with TFAM
harvested 72 hrs post transfection.  Protein was extr
blotting, probing for COX1, SDH70, and 
quantified by densitometry, and OD readings used to calculate the ratio of COX1 and 
SDH70 proteins relative to 
The blots for repeat 1 (A), repeat 2 (B) and repeat 3 (C) are shown, error bars 
represent SD.  All repeats were then combined (D), error bars represent SEM.  Data 
normalised to Scrambled control cells.
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5.4.3 mtDNA depletion has no effect on ATP content 
The next measure of mitochondrial function we decided to investigate was ATP 
content.  So far we have seen that partial mtDNA depletion causes a reduction 
in COX1 mRNA and protein levels.  We were keen to examine whether this 
decrease in COX1 mRNA and protein resulted in respiratory chain dysfunction 
and as a consequence, did this affect ATP production.  Similarly to 
investigations on COX1 protein, we decided to test the didanosine mtDNA 
depletion model first as this model produced the greatest mtDNA depletion. 
Cells were treated with 50 µM ddI for 5 days to deplete mtDNA.  Cells were then 
stimulated with 3 mM (basal) or 25 mM (high) glucose for 1 hr, before being 
harvested in perchloric acid to prevent degradation of ATP.  ATP lysates were 
centrifuged to pellet cell debris.  The supernatant was retained and used to 
quantify ATP content.  The cell debris pellet was resuspended in NaOH and 
used to quantify protein using the Lowry assay (protein levels were adjusted to 
account for loss of protein following perchloric acid harvesting, see Appendix 
Figure 2).  ATP content was then determined using an ATP luciferase assay, 
with resultant luminescence measured using a luminometer.  ATP content of 
unknown samples was then calculated against a standard curve of known ATP 
concentrations and was normalised to protein. 
In Figure 36, we can see that there is no real difference in ATP content of ddI 
treated cells compared to PBS control cells.  This is apparent whether the cells 
are stimulated with 3 mM basal glucose or 25 mM high glucose.  What is 
interesting though is that there is no increase in ATP content in either control or 
ddI treated cells following 25 mM glucose stimulation.  We would have expected 
an increase in ATP content in control cells following 25 mM glucose stimulation 
as ATP is needed to drive glucose-stimulated insulin secretion. 
 
  
144 
 
 
 
 
 
 
 
 
Figure 36 ATP content following didanosine-induced mtDNA depletion and 
glucose stimulation 
mtDNA levels were depleted in MIN6 cells following 5 day incubation with 50 µM ddI.  
Cells were then stimulated with either 3 mM (basal) or 25 mM (high) glucose for 1 hr 
after which, cells were harvested in perchloric acid.  ATP content was determined by 
an ATP luciferase assay against a standard curve of known ATP concentrations, which 
were then normalised to protein content.  Data shown are from 4 separate experiments 
performed in triplicate, error bars representative of SEM.  Data normalised to 3 mM 
basal glucose stimulated PBS cells. 
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We continued our investigations on the effect of mtDNA depletion on ATP 
content using the TFAM silencing mtDNA depletion model (Figure 37).  Cells 
were transfected with the TFAM-429 or Scrambled control siRNA.  Seventy two 
hrs post transfection, cells were stimulated with either 3 mM or 25 mM glucose 
prior to harvesting in perchloric acid.  As with harvesting protein from 
transfected cells in Section 5.4.2, cell lysates from three wells of a 24 well tissue 
culture plate were pooled together to make one sample.  The cell lysate was 
centrifuged to separate the supernatant, which was used to determine ATP 
content, from the cell debris, which was used to determine protein 
concentration.   
We can see that as with didanosine-induced mtDNA depletion, there does not 
seem to be a difference in the ATP content of TFAM-429 and Scrambled 
transfected cells when faced with 25 mM glucose stimulation.  When cells were 
stimulated with 3 mM basal glucose however, TFAM-429 cells appear to contain 
slightly more ATP compared to Scrambled control cells.  We see that in both 
TFAM-429 and Scrambled control cells, ATP content increases following 25 mM 
glucose stimulation compared to basal 3 mM glucose stimulation.  This is in 
contrast to the didanosine mtDNA depletion model, where we do not see a 
change in ATP content with increasing glucose concentration. 
Summarising the effect of partial mtDNA depletion on whole cell ATP content, it 
seems that with both mtDNA depletion models, there is no difference in the ATP 
content of mtDNA depleted cells compared to control cells.  In the TFAM 
mtDNA depletion model, we see an increase in ATP content following 25 mM 
glucose stimulation compared to basal 3 mM glucose stimulation, which is 
apparent in both TFAM-429 and Scrambled control cells.  However, this 
increase in ATP content with glucose stimulation is not seen using the 
didanosine-induced mtDNA depletion model, in either PBS control or ddI treated 
cells. 
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Figure 37 ATP content following TFAM silencing-induced mtDNA depletion and 
glucose stimulation 
MIN6 cells were transfected with TFAM-429 or Scrambled siRNA probes.  Seventy two 
hrs post transfection, cells were stimulated with either 3 mM or 25 mM glucose for 1 hr 
after which, cells were harvested in perchloric acid.  ATP content was determined by 
an ATP luciferase assay against a standard curve of known ATP concentrations, which 
were then normalised to protein content.  Data shown are from 4 separate experiments 
performed in duplicate, error bars representative of SEM.  Data normalised to 3 mM 
basal glucose stimulated Scrambled cells.  * p<0.05 
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5.4.4 mtDNA depletion does not affect mitochondrial membrane potential 
To round up our investigations on the effects of partial mtDNA depletion on 
mitochondrial function, we wanted to explore whether mtDNA depletion directly 
affected mitochondrial membrane potential.  We measured mitochondrial 
membrane potential by staining cells with the cationic JC-1 fluorescent dye, 
which fluoresces green in the cell cytosol and red in the cell mitochondria.  To 
ensure we could measure changes in mitochondrial membrane potential, we 
first treated cells with hydrogen peroxide (H2O2), which abolishes mitochondrial 
membrane potential (Figure 38).  H2O2 was added to normal live MIN6 cells, 
immediately after which, cells were imaged using a live cell microscope at time 
0 mins.  The same field of cells was then periodically imaged at 5 min intervals, 
until 20 mins after initial H2O2 addition.  The red fluorescence emitted by the JC- 
J-aggregates in the cell mitochondria is clearly visible at time 0 mins after initial 
H2O2 addition.  Also, the location of red fluorescence can be distinguished from 
that of the cytosolic green fluorescence emitted from the JC-1 monomers 
(Figure 38).  After 5 mins post H2O2 treatment, we see a drastic reduction in the 
amount of red fluorescence emitted, indicating a loss of mitochondrial 
membrane potential.  Red fluorescence progressively decreases throughout 
prolonged H2O2 exposure, until it is virtually non-existent after only 15 mins 
H2O2 treatment.  Comparing this to the green fluorescence of the JC-1 
monomers in the cytosol, there is no obvious change in green fluorescence 
throughout H2O2 exposure.  Photo bleaching is evident in the green 
fluorescence images, especially during the later time points, which is to be 
expected with prolonged UV exposure on the same field of cells. 
Fluorescent images were quantified using the ImageJ computer software 
programme.  Red and green fluorescence was quantified at each time point and 
can be seen in Figure 39A.  The image quantification supports the visual 
observations made: that green fluorescence does not change, but red 
fluorescence progressively decreases with increased H2O2 exposure.  The 
mean sum of fluorescence obtained from ImageJ quantification was then used 
to find the ratio of red / green fluorescence and can be seen in Figure 39B.  We 
can see that red / green fluorescence, which is representative of mitochondrial 
membrane potential, progressively decreases with prolonged H2O2 treatment 
and was completely abolished after only 20 mins H2O2 exposure.   
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Figure 38 JC-1 staining in MIN6 cells following H2O2 treatment 
JC-1 staining was used to measure mitochondrial membrane potential in MIN6 cells.  The JC-1 dye exists in its monomeric form in the cell cytosol 
and emits a green fluorescence.  JC-1 selectively enters the mitochondria where it aggregates and emits a red fluorescence.  To show that we could 
measure loss of mitochondrial membrane potential, we treated live cells with hydrogen peroxide (H2O2) which abolishes the mitochondrial membrane 
potential.  Live cells were imaged immediately after H2O2 was added (0 mins) using a live cell microscope.  Images were then taken periodically at 5 
min intervals until 20 mins post H2O2 treatment. 
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Figure 39 ImageJ quantification of mitochondrial membrane potential following 
H2O2 exposure 
The images taken in Figure 38 were quantified using the ImageJ computer software 
programme.  The programme was used to calculate the mean sum of fluorescence for 
both green and red fluorescent images at each time point after H2O2 addition (A).  The 
mean sum of fluorescence values were then used to calculate the ratio of red / green 
fluorescence, which is representative of the mitochondrial membrane potential (B). 
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Now that we could detect loss of mitochondrial membrane potential using JC-1 
staining, we proceeded to treat MIN6 cells with 50 µM ddI for 5 days to 
investigate what effect partial mtDNA depletion had on mitochondrial membrane 
potential.  As with previous measures of mitochondrial function, we decided to 
try out the didanosine-induced mtDNA depletion method initially as this 
produced the greatest degree of mtDNA depletion.  After the 5 day ddI 
treatment period, cells were stained with JC-1 staining medium containing JC-1 
and the nuclear stain Hoechst 33342.  Figure 40A shows representative images 
of one field from one well of ddI treated cells, and one field from one well of 
PBS treated cells.  The experiment was repeated twice in duplicate wells, with 6 
random fields taken of each well.  Visually, there is no clear drastic difference in 
the green cytosolic JC-1 fluorescence or the red mitochondrial JC-1 
fluorescence in ddI treated and PBS control cells (Figure 40A).  This 
observation was confirmed following ImageJ quantification, with no difference 
seen in the ratio of red / green fluorescence in ddI treated and PBS control cells 
(Figure 40B).  The partial mtDNA depletion following didanosine treatment does 
not appear to have an effect on mitochondrial membrane potential. 
Because the degree of mtDNA depletion was greater using the didanosine 
model of mtDNA depletion, and because we failed to see an effect on 
mitochondrial membrane potential using this model, it was decided that 
measuring mitochondrial membrane potential in TFAM transcriptionally silenced 
cells was not necessary. 
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Figure 40 The effect of partial didanosine-induced mtDNA depletion on mitochondrial 
membrane potential 
MIN6 cells were treated with 50 µM ddI for 5 days to deplete mtDNA levels.  Cells were then 
stained with JC-1 and the nuclear stain Hoechst 33342.  Experiment was repeated twice in 
duplicate, with 6 random fields taken for each well.  Images in (A) are representative of one field 
of one ddI treated well, and one field of one PBS control well.  Images were then quantified using 
ImageJ, error bars representative of SEM (B). 
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5.5 Discussion 
Different aspects of mitochondrial function have been examined following 
mtDNA depletion in previous studies, but we decided to explore what effect 
mtDNA depletion had specifically on mitochondrial gene expression and protein 
translation, as well as ATP content and mitochondrial membrane potential. 
Upon investigating mtDNA gene transcription, we decided to focus on the COX1 
gene; one of the mtDNA encoded subunits of cytochrome c oxidase, Complex 
IV, of the respiratory chain.  Cytochrome c oxidase consists of 13 protein 
subunits in total, 10 of which are nDNA encoded and 3 are mtDNA encoded 
(Dell'agnello, et al., 2007; Fontanesi, et al., 2006).  The 3 mtDNA encoded 
subunits, COX1, COX2 and COX3, are essentially required to form the catalytic 
holoenzyme of the cytochrome c oxidase and so, their loss would be 
detrimental not only for catalytic function of the complex, but for the complex 
assembly also (Fontanesi, et al., 2006; Larsson, 2010).  We are able to 
conclude that partial mtDNA depletion, whether by didanosine treatment or 
TFAM gene silencing, results in decreased COX1 mRNA expression.  The level 
of COX1 suppression was greater following didanosine-induced mtDNA 
depletion compared to TFAM silencing-induced mtDNA depletion, but we 
believe this was due to the didanosine model of mtDNA depletion causing 
slightly greater mtDNA depletion compared to the TFAM model.  That being 
said, we did achieve significant reduction in COX1 gene expression using the 
TFAM mtDNA depletion model also. 
Out results are in agreement with many other reports detailing the loss of 
mtDNA gene expression following mtDNA depletion (Gauthier, et al., 2009; 
Hayakawa, et al., 1998; Soejima, et al., 1996; Tsuruzoe, et al., 1998).  Some 
reports have looked at the mtDNA encoded components of cytochrome c 
oxidase in MIN6 cells just as we have however, these studies completely 
eradicated mtDNA levels following prolonged EtBr treatment and so, 
understandably, mtDNA gene expression was severely suppressed, if not 
nonexistent (Soejima, et al., 1996; Tsuruzoe, et al., 1998).  One group has 
managed to create partial mtDNA depletion following transcriptional silencing of 
the β-cell master transcription factor PDX1 (Gauthier, et al., 2009).  By infecting 
rat islets with a PDX-1 specific adenovirus, the group managed to silence PDX-
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1 transcription by 90% relative to control islets, which resulted in a 50% 
reduction in TFAM mRNA levels.  Concomitantly, this caused a 40% decrease 
in mtDNA levels and a 40% reduction in ND1 mRNA expression, a mtDNA 
encoded subunit of NADH dehydrogenase (Complex I) (Gauthier, et al., 2009).  
In accordance with Gauthier et al.’s findings, we also managed to achieve 40-
50% depletion in mtDNA levels using both of our depletion models, which 
resulted in an overall 45% decrease and 24-33% decrease in COX1 gene 
expression following didanosine-induced and TFAM silencing-induced mtDNA 
depletion respectively. 
Following the loss of mtDNA gene expression, we were keen to see if this 
culminated in the loss of mtDNA encoded protein.  Again, we focused on the 
COX1 protein but we also looked at the nDNA encoded SDH70 subunit of 
succinate dehydrogenase (Complex II).  Succinate dehydrogenase is the only 
complex of the respiratory chain that is entirely nDNA encoded with no mtDNA 
components and so, should be immune to the effects of mtDNA depletion.  After 
performing a series of western blots, we found that reduced COX1 gene 
expression as a result of mtDNA depletion affects COX1 protein levels also.  
We saw a 34% loss in COX1 protein levels in didanosine-induced mtDNA 
depleted cells relative to control PBS cells.  When using the TFAM model of 
mtDNA depletion however, we saw a slightly less 22% decrease in COX1 
protein levels.   
This difference in the level of COX1 protein decrease between the two models 
may be explained by the different degree of mtDNA depletion obtained from 
each model: the didanosine model produced a 50% reduction in mtDNA 
whereas the TFAM model only produced 40% mtDNA depletion.  Another 
explanation for the slightly less decrease in COX1 protein levels following TFAM 
gene silencing could be the turnover rate of the COX1 protein.  Many 
mitochondrial encoded proteins are predicted to have half-lives of up to several 
days (Aschenbrenner, et al., 1970; Ip, et al., 1974).  In addition, the cytochrome 
c oxidase complex is predicted to have a turnover rate of 5.7 days in rat liver 
(Ip, et al., 1974).  Therefore, it is possible that the 72 hrs post transfection was 
not long enough to see full COX1 protein turnover in the TFAM mtDNA 
depletion model, in comparison to the 5 day treatment period with didanosine.  
An interesting observation to be made from the TFAM depletion model western 
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blots is that two of the experimental repeats showed clear loss of COX1 protein 
in mtDNA depleted cells, whereas in one repeat, the loss in COX1 protein was 
open to debate.  It is widely recognised that there is a mtDNA threshold level, 
below which is when we begin to see phenotypic or biochemical defects in the 
cell (Bai, et al., 2000; Moraes, et al., 1992; Sciacco, et al., 1994).  It may be that 
in the TFAM mtDNA depletion model where we induce a 40% reduction in the 
level of mtDNA, that we are just on the cusp of the mtDNA threshold?  Could 
this explain how some repeats show a reduction in COX1 protein and some 
repeats do not? 
The final conclusion to be made from the protein studies is that mtDNA 
depletion did not seem to have an effect on nDNA encoded subunits of the 
mitochondrial respiratory chain.  The protein levels of nDNA encoded SDH70 in 
mtDNA depleted cells were comparable to SDH70 protein levels in control cells, 
which was seen using both mtDNA depletion models.  This shows 
unequivocally that in both mtDNA depletion models, the artificial mtDNA 
depletion we manage to induce only affects mtDNA encoded components of the 
respiratory chain.  Gathier et al. were able to show that partial mtDNA depletion 
following PDX1 silencing resulted in decreased ND1 gene expression (mtDNA 
encoded), but failed to have an effect on SDH gene expression (nDNA 
encoded) (Gauthier, et al., 2009).  Although the group only looked at mRNA 
expression and not protein levels, their findings support ours in that mtDNA 
depletion only effects mtDNA encoded genes and polypeptides.  Another group 
showed a reduction in mitochondrial protein translation in p0 MIN6 cells with no 
mtDNA, but as expected, the level of protein was barely detectable and so not 
comparable with our own results (Soejima, et al., 1996).  Other groups have 
shown a progressive decrease in mtDNA encoded proteins in ageing muscle 
(Lanza, et al., 2008; Short, et al., 2005; Taanman, et al., 1997). 
Encouraged by our findings that partial mtDNA depletion has an effect on 
mtDNA gene transcription and protein levels, we continued our investigations 
on mitochondrial function by analysing ATP content following glucose 
stimulation.  Closure of ATP-gated K+ channels in the plasma membrane of 
pancreatic β-cells is a pivotal step in glucose-stimulated insulin secretion 
(Ashcroft, et al., 1994).  The rise in the cytosolic ATP/ADP ratio following 
glucose metabolism is key in investigating K+ channel closure, which relies on 
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ATP generated from the electron transport chain (see Figure 3 and Section 
1.1.6).  Therefore, by first depleting mtDNA levels and then stimulating the 
mtDNA depleted cells with basal (3 mM) or high (25 mM) glucose, we wanted to 
see what effects this had on ATP content. 
Didanosine-induced or TFAM silencing-induced mtDNA depletion does not 
seem to have an effect on ATP content in mtDNA depleted cells compared to 
control cells.  This was apparent whether the cells were stimulated with basal or 
high glucose concentrations.  Even though the partial mtDNA depletion we have 
induced in these models affects mtDNA transcription and translation, it does not 
have an effect on ATP content.  Other studies investigating the effects of 
mtDNA depletion on ATP content have conducted their experiments in a similar 
manner to us, in that rodent pancreatic β-cells have been stimulated with 
varying glucose concentrations before harvesting in acidic solutions which 
require neutralising prior to performing a luminescence assay (Kennedy, et al., 
1991; Tsuruzoe, et al., 1998).  However, these studies were performed on p0 
pancreatic β-cells containing no mtDNA and so understandably, the ATP 
production in these p0 cells was severely hindered (Tsuruzoe, et al., 1998), or 
not present at all (Kennedy, et al., 1991).  In addition, the age-related decline in 
mtDNA copy number in human muscle was found to correlate with an age-
related decline in ATP content (Lanza, et al., 2008).  The fact that other groups 
have reported a decrease in ATP content following mtDNA depletion may be 
attributable to the degree of mtDNA depletion reported in these papers.  It 
seems that the level we have depleted mtDNA in both of our depletion models 
is not enough to hinder ATP production.   
It is also worth noting that even though the electron transport chain is the major 
source of ATP production, other pathways can be utilised for ATP production 
such as glycolysis.  For instance, it is know that cancer cells experience 
mitochondrial respiratory chain dysfunction and increased glycolysis 
(Kaipparettu, et al., 2010).  As MIN6 cells are derived from a mouse insulinoma, 
is it possible that MIN6 cells rely on glycolysis for their main source of ATP 
which is why we are not seeing an effect of partial mtDNA depletion on ATP 
content?  But when mtDNA is completely removed, as seen in the Kennedy et 
al. and Tsuruzoe et al. studies on p0 cells (Kennedy, et al., 1991; Tsuruzoe, et 
157 
 
al., 1998), the ATP produced via glycolysis is not enough to sustain glucose-
stimulated insulin secretion. 
Interestingly, when using the TFAM silencing-induced mtDNA depletion model, 
cells responded with an increased ATP content to glucose stimulation.  When 
cells were stimulated with 25 mM glucose, ATP content increased in both 
TFAM-429 and Scrambled control cells.  This was to be expected as an 
increase in ATP is needed to drive glucose-stimulated insulin secretion, and has 
been reported in control pancreatic β-cells with intact mtDNA levels in similar 
studies (Kennedy, et al., 1991; Tsuruzoe, et al., 1998).  We are unsure as to 
why the cells used in the didanosine model did not respond in the same way to 
glucose stimulation.  The reason cannot be off target effects of the drug as no 
change in ATP content with increasing glucose stimulation was seen in control 
PBS cells also.  One would question whether the cells actually responded to the 
glucose stimulation in the first place.  To be sure of this, analysis of the insulin 
secretion samples from the same cells would be required, to be sure that an 
increase in insulin secretion was seen following 25 mM glucose stimulation.  
Our final measure of mitochondrial function was that of mitochondrial 
membrane potential using the JC-1 cationic fluorescent dye.  We successfully 
abolished mitochondrial membrane potential after only 20 mins H2O2 treatment, 
which we managed to quantify using ImageJ, and so we were confident that we 
were able to quantify changes in mitochondrial membrane potential.  However, 
we found that there was no difference in the mitochondrial membrane potential 
of didanosine-induced mtDNA depleted cells compared to control PBS cells.  
Other groups have used fluorescent probes such as rhodamine 123 to measure 
mitochondrial membrane potential, but as we have seen with many other 
measures of mitochondrial function, these groups reported reduced 
hyperpolarisation in pancreatic β-cells with severe mtDNA depletion (Kennedy, 
et al., 1998; Silva, et al., 2000), and not partial mtDNA depletion. 
5.6 Conclusions 
We can therefore conclude that partial mtDNA depletion by 50% or 40%, using 
drug inhibition of mtDNA replication or gene silencing of key mitochondrial 
transcription factors respectively, does have an effect on some aspects of 
158 
 
mitochondrial function.  Key findings include a significant 33-45% reduction in 
the mtDNA encoded COX1 gene, which culminated in a 22-34% decrease in 
COX1 protein.  COX1 is one of the three mtDNA encoded subunits that 
assemble to form the holoenzyme of cytochrome c oxidase, Complex IV, and so 
loss of this protein would impair the mitochondrial respiratory chain.  However, 
we did not see a decrease in the nDNA encoded subunit SDH70, a component 
of succinate dehydrogenase, Complex II.  This implies that the decrease in 
COX1 gene expression and the resultant loss of COX1 protein is the 
consequence of mtDNA depletion.   
We measured other indices of mitochondrial function including ATP content and 
mitochondrial membrane potential however, we did not find the partial mtDNA 
depletion inflicted on MIN6 cells following didanosine treatment or 
transcriptional silencing of the TFAM transcription factor, was enough to cause 
an effect.  More severe mtDNA depletion which is greater than 40-50% may be 
needed in order to see an effect on cellular ATP content or mitochondrial 
membrane potential. 
The key question now is whether the decrease in mitochondrial function seen 
with partial mtDNA depletion has an effect of glucose-stimulated insulin 
secretion. 
5.7 Limitations 
Potential criticisms may be made of the methods employed when harvesting 
protein and ATP samples using the TFAM mtDNA depletion model.  
Transfections were performed in 24 well plates and samples were combined 
from three separate wells in order to make one sample, thus ensuring enough 
lysate for subsequent analyses.  However, this may have introduced a large 
and unhelpful degree of variation unnecessarily.  Performing transfections in 6 
well plates, as we did when treating cells with didanosine would have been 
more ideal but due to time constraints, we were unable to re-optimise the 
protocol given to us by Invitrogen to cater for transfecting cells in larger 6 well 
plates. 
Another limitation may lie in the method of quantifying ATP content.  We chose 
to extract the ATP from cells using an acidic solution, similar to other studies 
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(Kennedy, et al., 1991; Tsuruzoe, et al., 1998), but decided to retain the cell 
debris after centrifugation in order to quantify whole cell protein concentration, 
which would be used to normalise ATP content to protein.  It could be argued 
that this may be introducing unnecessary variation also.  Even though cells 
were seeded at the same density, whether prior to didanosine treatment or 
during transfection, cells were then incubated for 72 hrs or for 5 days, 
depending on the method of mtDNA depletion.  We could have then assumed 
that all cells grew at the same rate in all wells, but we wanted to be sure that 
any potential differences in ATP content were undoubtedly due to mtDNA 
depletion and not differences in cell number.  By harvesting cells using 
perchloric acid, we prevented degradation of ATP, but experienced a reduction 
in whole cell protein in the process.  We know this because during each 
experiment, we had wells of cells in which we only extracted protein and so, we 
used these wells to adjust for the loss of protein following perchloric acid 
extraction (see Figure 2 in Appendix).  Therefore, it could be argued that we are 
introducing more variation.  But even though previous studies have normalised 
ATP content to protein, they have used representative wells in which they have 
extracted protein and have assumed that all wells are equal (Kennedy, et al., 
1991).  Included in Figure 3 of the Appendix are the data from the ATP 
experiments, without protein normalisation.   
Finally, it could be debated whether the reduction in mtDNA gene expression 
and subsequent loss of mtDNA encoded protein we have reported is enough to 
define mitochondrial dysfunction.  What about oxygen consumption or 
cytochrome c oxidase (COX) complex activity?  Measurement of oxygen 
consumption requires a vast number of cells and with the TFAM model of 
mtDNA depletion especially, we would have struggled to meet the demand.  We 
did attempt COX/SDH staining, which we thought would be a great measure of 
COX complex activity, however, we found the MIN6 cells showed severe toxic 
effects to the staining procedure resulting in cell death.   
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6 The effect of mtDNA depletion on insulin secretion 
6.1 Introduction 
Our results so far have detailed the optimisation of two independent models of 
partial mtDNA depletion in MIN6 cells.  We then found that both methods of 
mtDNA depletion were comparable, and mitochondrial dysfunction ensued with 
a significant decrease in mtDNA transcription resulting in loss of mtDNA 
encoded proteins.  However, we found that ATP content and mitochondrial 
membrane potential were not affected by partial mtDNA depletion.  As glucose 
metabolism and insulin secretion are closely associated in pancreatic β-cells 
(Wollheim, 2000), our next question was does the partial loss of mtDNA copy 
number affect glucose-stimulated insulin secretion? 
Many reports have documented impairment in insulin secretion following 
mtDNA depletion in rodent pancreatic β-cells (Hayakawa, et al., 1998; Kennedy, 
et al., 1998; Soejima, et al., 1996; Tsuruzoe, et al., 1998) and rodent animal 
models (Gauthier, et al., 2009; Silva, et al., 2000).  Some groups have managed 
to restore the loss in insulin secretion following mtDNA depletion by treating 
cells with membrane depolarising agents (Hayakawa, et al., 1998; Kennedy, et 
al., 1998; Tsuruzoe, et al., 1998) or by repopulation of cybrid clones with foreign 
mtDNA (Soejima, et al., 1996).  The restoration of insulin secretion in these 
studies pinpoints the impairment of insulin secretion being mitochondrial in 
origin. 
6.2 Aims 
The aim of this chapter was to explore what effect mtDNA depletion in MIN6 
cells had on glucose-stimulated insulin secretion.  Using the two mtDNA 
depletion models optimised in Chapters 3 and 4, we: 
• Investigated glucose-stimulated insulin secretion in mtDNA depleted cells, 
using 3 mM and 25 mM glucose, compared to control cells. 
• Examined the insulin content of mtDNA depleted cells post glucose-
stimulated insulin secretion, compared to control cells. 
• Measured insulin gene expression following mtDNA depletion. 
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• Explored the effect of the insulin secretagogue glibenclamide on insulin 
secretion in mtDNA depleted cells. 
6.3 Results 
6.3.1 MIN6 cells respond to increasing glucose stimulation by secreting 
increased insulin 
We initially picked MIN6 cells when embarking on this project because they 
were reported to respond to changes in glucose concentration (Ishihara, et al., 
1994; Miyazaki, et al., 1990).  To test this, we first stimulated MIN6 cells with 
increasing concentrations of glucose ranging from 0 – 25 mM for a period of 1 
hr.  The cell supernatant was removed and used to determine insulin secretion 
using a rat insulin ELISA.  A rat insulin ELISA was used as there is high 
sequence homology between rat and mouse insulin and at the time, there was 
no mouse insulin ELISA available.  Insulin secretion was determined using a 
standard curve of known insulin concentrations. 
There is an obvious positive correlation between glucose concentration and 
insulin secretion, which is dose-dependent (Figure 41).  The glucose 
concentrations used are obviously not in the physiological range seen in 
humans.  However, in mice, the normoglycaemic range is considered to be 7 – 
10 mM glucose, with hyperglycaemia diagnosed when glucose exceeds 20 mM 
(Keren, et al., 2000; Kunjathoor, et al., 1996; Park, et al., 1998).  As MIN6 cells 
are a mouse pancreatic β-cell line, it was decided that we would stimulate cells 
with 3 mM glucose to represent low, basal glucose stimulation, and with 25 mM 
glucose to represent high glucose stimulation. 
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Figure 41 Glucose-stimulated insulin secretion in MIN6 cells 
MIN6 cells were stimulated with increasing concentrations of glucose for 1 hr.  Cell 
supernatant was removed and insulin secretion was determined using a rat insulin 
ELISA against a standard curve of known insulin concentrations.  Experiment repeated 
once in triplicate, error bars representative of SD. 
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6.3.2 Didanosine-induced mtDNA depletion causes an increase in insulin 
secretion following 25 mM glucose stimulation 
Now that we were confident that the MIN6 cells could respond to varying 
concentrations of glucose, we wanted to deplete mtDNA levels first using the 
didanosine model of mtDNA depletion, to see what effect this had on insulin 
secretion.  Cells were treated for 5 days with 50 µM ddI to deplete mtDNA, after 
which, cells were stimulated for 1 hr with either 3 mM or 25 mM glucose.  The 
cell supernatant was removed and insulin secretion determined using a rat 
insulin ELISA against a standard curve of known insulin concentrations.  Protein 
was extracted from the MIN6 cells, quantified via a Bradford assay, and used to 
normalise insulin secretion to whole cell protein content. 
In Figure 42A, we see that both didanosine treated and PBS control cells 
respond to increased glucose stimulation by secreting more insulin, which 
supports the data presented in Figure 41.  There is a significant 6.5-fold and 
4.5-fold increase in insulin secretion at 25 mM glucose stimulation compared to 
3 mM glucose stimulation, in both didanosine treated and PBS control cells 
respectively (p<0.001).  Furthermore, there does not seem to be a difference in 
insulin secretion of didanosine treated and PBS control cells when faced with 3 
mM glucose challenge.  However, we do see a difference in insulin response in 
didanosine treated and PBS control cells following a high glucose challenge.  
Surprisingly, we see that didanosine treated cells secrete significantly more 
insulin compared to PBS control cells, when stimulated with 25 mM glucose 
(p=0.0026).   
This result was unexpected as we predicted the loss of mtDNA would result in 
decreased insulin secretion.  We repeated the experiment a total of 6 times to 
ensure we were recording a true result.  Our only explanation as to why 
didanosine-induced mtDNA depletion caused an increase in insulin secretion 
following 25 mM glucose stimulation was that didanosine was possibly having 
off target effects on the MIN6 cells.   
Because protein was extracted from cells to normalise insulin secretion, 
additional wells were seeded in each experiment so we could extract DNA and 
measure mtDNA depletion.  We can confirm that mtDNA levels were reduced 
by 50% in ddI treated cells compared to PBS control cells (Figure 42B). 
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Figure 42 The effect of didanosine-induced mtDNA depletion on glucose-
stimulated insulin secretion 
(A) MIN6 cells were treated for 5 days with 50 µM ddI to deplete mtDNA.  Cells were 
then stimulated with basal (3 mM) or high (25 mM) glucose concentrations for a period 
of 1 hr.  Cell supernatant was removed and insulin secretion determined by insulin 
ELISA against a standard curve of known insulin concentrations.  Protein was 
extracted from the MIN6 cells and used to normalise insulin secretion.  Data 
normalised to 3 mM glucose stimulated PBS control cells. (B) mtDNA levels were 
checked by seeding additional wells whereby DNA was extracted and used in the 
mtDNA copy number assay.  Data shown are from 6 separate experiments (A) or 3 
separate experiments (B), each performed in triplicate.  Error bars are representative of 
SEM.    ** p = 0.0026,  *** p<0.001 
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6.3.3 TFAM silencing-induced mtDNA depletion causes a decrease in insulin 
secretion following 25 mM glucose stimulation 
To corroborate our theory that didanosine may cause off target effects on 
insulin secretion, we investigated the effect of TFAM silencing-induced mtDNA 
depletion on insulin secretion to see if we obtained similar results.  MIN6 cells 
were transfected with TFAM-429 or Scrambled siRNA probes and incubated for 
72 hrs to deplete mtDNA levels.  Cells were then stimulated with either 3 mM or 
25 mM glucose for a period of 1 hr.  Insulin secretion was determined using an 
insulin ELISA and insulin secretion was normalised to whole cell protein 
content.   
As with the didanosine mtDNA depletion model, both TFAM-429 and Scrambled 
transfected cells responded to 25 mM glucose stimulation by secreting 
significantly more insulin, compared to 3 mM glucose stimulation (p<0.001) 
(Figure 43A).  However, we are starting to see divergence in the two methods of 
mtDNA depletion in their effects on insulin secretion.  Insulin secretion was 
seen to be significantly less in TFAM-429 cells compared to Scrambled control 
cells, when cells were faced with 3 mM (p=0.004) and 25 mM (p=0.03) glucose 
stimulation.  This is in total contrast to the results seen with the didanosine 
mtDNA depletion model, which further supports our hypothesis that didanosine 
is perhaps exhibiting off target effects on insulin secretion in the MIN6 cells. 
As with the didanosine mtDNA depletion model, additional wells were 
transfected so we could extract DNA and measure mtDNA depletion using the 
mtDNA copy number assay.  We can confirm that mtDNA levels were depleted 
by 40% in TFAM-429 transfected cells compared to Scrambled control cells 
(Figure 43B). 
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Figure 43 The effect of TFAM silencing-induced mtDNA depletion on glucose-
stimulated insulin secretion 
(A) MIN6 cells were transfected with TFAM-429 or Scrambled siRNA to deplete 
mtDNA.  Seventy two hrs post transfection, cells were stimulated with basal (3 mM) or 
high (25 mM) glucose concentrations for a period of 1 hr.  Cell supernatant was 
removed and insulin secretion determined by insulin ELISA against a standard curve of 
known insulin concentrations.  Protein was extracted from the MIN6 cells and used to 
normalise insulin secretion.  Data normalised to 3 mM glucose stimulated Scrambled 
control cells.  (B) mtDNA levels were checked by seeding additional wells whereby 
DNA was extracted and used in the mtDNA copy number assay.  Data shown are from 
5 separate experiments (A) or 3 separate experiments (B), each performed in triplicate.  
Error bars are representative of SEM.    * p=0.03,  ** p = 0.004,   *** p<0.001 
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6.3.4 The effect of mtDNA depletion on insulin content 
To understand the reason behind the differences in insulin secretion in our two 
models of mtDNA depletion after 25 mM glucose stimulation, we decided to 
investigate the insulin content of cells post glucose-stimulated insulin secretion.  
Starting with the didanosine mtDNA depletion model first, we depleted mtDNA 
levels following 50 µM didanosine treatment for 5 days.  Just as we had done 
previously, cells were then stimulated with 3 mM or 25 mM glucose for 1 hr.  
Cell supernatant was removed and cells were then harvested in ice cold PBS.  
Insulin was liberated from cells after repeated freezing of cells in liquid nitrogen, 
and rapidly thawing them in a water bath.  As with insulin secretion, insulin 
content was determined following insulin ELISA.  Protein content was 
determined using the same PBS lysate, and insulin content was normalised to 
whole cell protein content. 
In Figure 44, we start to understand why ddI treated cells secrete more insulin, 
because it seems they contain more insulin compared to PBS control cells.  
When control PBS cells are stimulated with high 25 mM glucose, we see insulin 
content increase by 50% compared to 3 mM glucose stimulation.  This is to be 
expected as the increased insulin content with increased glucose stimulation 
would be required to increase insulin secretion.  In ddI treated cells however, 
we still see an increase in insulin content with increased glucose stimulation, 
but it is much greater than that seen in PBS control cells.  Didanosine treated 
cells contain approximately 30% more insulin compared to PBS control cells 
following 3 mM glucose stimulation, and approximately 45% more insulin 
compared to PBS control cells following 25 mM glucose stimulation (data 
showed no statistical significance). 
We conducted the same experiment using the TFAM mtDNA depletion model 
(Figure 45).  We found that in Scrambled control cells, there was a 53% 
increase in insulin content in cells stimulated with 25 mM glucose compared to 
cells stimulated with 3 mM glucose.  This mimics what we found in PBS control 
cells when using the didanosine mtDNA depletion model.  However, there was 
no change in the insulin content of TFAM-429 cells with increased glucose 
stimulation compared to basal glucose.  Not only that, but it seems that TFAM-
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429 cells contained less insulin compared to Scrambled control cells, which was 
more pronounced following 25 mM glucose stimulation.   
In summary, our results suggest that there is an approximate 50% increase in 
insulin content in the respective control cells (PBS and Scrambled) following 25 
mM glucose stimulation, compared to 3 mM glucose stimulation.  After 25 mM 
glucose stimulation, didanosine-induced mtDNA depleted cells tended to have a 
greater insulin content compared to PBS control cells, whereas TFAM silenced 
mtDNA depleted cells have less insulin content compared to Scrambled control 
cells.  These differences in insulin content following 25 mM glucose stimulation 
are in line with the differences seen in insulin secretion when comparing the two 
mtDNA depletion models. 
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Figure 44 The effect of didanosine-induced mtDNA depletion on insulin content 
following glucose-stimulated insulin secretion 
mtDNA levels were reduced following incubation with 50 µM ddI for 5 days.  Cells were 
stimulated with either 3 mM or 25 mM glucose before removing cell supernatant and 
harvesting cells in PBS.  Insulin was liberated from cells by repeated freeze/thaw using 
liquid nitrogen.  Insulin content was determined by insulin ELISA and was normalised 
to whole cell protein content.  Experiment was repeated 3 times in triplicate, error bars 
represent SEM.  Data normalised to 3 mM glucose stimulated PBS control cells. 
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Figure 45 The effect of TFAM silencing-induced mtDNA depletion on insulin 
content following glucose-stimulated insulin secretion 
MIN6 cells were transfected with either TFAM-429 or Scrambled siRNA probes to 
deplete mtDNA levels.  Cells were stimulated with either 3 mM or 25 mM glucose 
before removing cell supernatant and harvesting cells in PBS.  Insulin was liberated 
from cells by repeated freeze/thaw using liquid nitrogen.  Insulin content was 
determined by insulin ELISA and was normalised to whole cell protein content.  
Experiment was repeated 3 times in triplicate, error bars represent SEM.  Data 
normalised to 3 mM glucose stimulated Scrambled cells.  ** p=0.01 
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6.3.5 The effect of mtDNA depletion on insulin gene expression 
In an attempted to uncover why after 25 mM glucose stimulation didanosine-
induced mtDNA depleted cells secreted more insulin and contained more 
insulin, whereas TFAM silenced mtDNA depleted cells secreted less insulin and 
contained less insulin when compared to control cells, we wanted to investigate 
Ins1 insulin gene expression. 
MIN6 cells were depleted of their mtDNA following 5 day 50 µM ddI treatment or 
TFAM transcriptional silencing.  RNA was then extracted from cells, quantified 
and reverse transcribed.  Real-time PCR was used to assess Ins1 gene 
expression relative to reference gene B2M using TaqMan hydrolysis probes. 
In didanosine-induced mtDNA depleted cells, Ins1 gene expression is reduced 
by 20% compared to PBS control cells (p<0.001) (Figure 46A).  Could this 
decrease in Ins1 gene expression be an attempt to reduce the amount of insulin 
protein in didanosine treated MIN6 cells?  Conversely, in TFAM silencing-
induced mtDNA depleted cells, there is no change in Ins1 gene expression 
(Figure 46B), suggesting that the decrease in insulin secretion and insulin 
content in these cells is not due to reduced gene expression. 
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Figure 46 The effect of mtDNA depletion on Ins1 insulin gene expression 
MIN6 cells were depleted of mtDNA following didanosine treatment (A) or TFAM 
transcriptional silencing (B).  RNA was then extracted from cells, quantified and reverse 
transcribed.  Real-time PCR was used to determine target gene Ins1 expression 
relative reference gene B2M.  Data shown are from three individual experiments 
performed in sextuplet (A) or triplicate (B).  Error bars represent SEM.  **   p<0.001 
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6.3.6 The effect of glibenclamide on MIN6 cells 
We are still unable to explain why didanosine treatment causes an increase in 
insulin secretion and insulin content in didanosine treated cells.  However, using 
the TFAM model where we had successfully impaired insulin secretion following 
mtDNA depletion, we were interested to see what effect the insulin 
secretagogue glibenclamide had on MIN6 cells.  Glibenclamide is a second 
generation sulphonylurea drug used in the treatment of T2DM.  It targets the 
sulphonylurea receptor 1 (SUR1) protein on the β-cell K+ channel, promoting 
channel closure and subsequent plasma membrane depolarisation.  Therefore, 
the sulphonylurea drug can be seen to bypass certain processes of the glucose-
stimulated insulin secretion pathway. 
The data presented in sections 6.3.6 and 6.3.7 was completed under my 
supervision and guidance by Meutia Kumaheri, for her Masters by Research 
which was submitted July 2012. 
To examine the response of normal MIN6 cells to glibenclamide, cells were 
exposed to glibenclamide between the range of 0.01 µM and 10 µM for 1 hr, 
along with either basal 3 mM glucose stimulation or high 25 mM glucose 
stimulation.  Glibenclamide was reconstituted in DMSO and so, DMSO was 
used as the drug vehicle control.  To ensure that DMSO was not having off 
target effects on the cells, we also used a media control in which no 
glibenclamide or DMSO was added, only 3 mM or 25 mM glucose. 
Glibenclamide can be seen to augment insulin secretion following 3 mM 
glucose stimulation compared to both the media and drug vehicle controls, 
especially with 0.1 µM and 1 µM glibenclamide (p<0.05) (Figure 47).  After 25 
mM glucose stimulation, we see significant increases in insulin secretion in all 
glibenclamide treated and control cells relative to the media control cells 
stimulated with 3 mM glucose.  It is interesting that we do not see an additive 
response of high 25 mM glucose with glibenclamide, but that 25 mM glucose 
stimulation in media and drug vehicle control cells stimulates the maximal 
insulin secretory response.  It can also be noted that the DMSO drug solvent 
used does not seem to be exhibiting off target effects, with the response of 
these cells mimicking that of media control cells. 
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Figure 47 The effect of varying concentrations of glibenclamide on insulin 
secretion after basal 3 mM and high 25 mM glucose stimulation 
Normal MIN6 cells were stimulated with basal 3 mM glucose or high 25 mM glucose for 
1 hr with 0.01 µM, 0.1 µM, 1 µM or 10 µM glibenclamide.  DMSO was the drug vehicle 
control, and media cells did not contain any glibenclamide or DMSO.  Cell supernatant 
was retained and insulin secretion determined by insulin ELISA, which was normalised 
to whole cell protein content.  Data presented are from 3 separate experiments each 
performed in duplicate, and are normalised to basal 3 mM glucose media control cells.  
Error bars representative of SEM.  * p<0.05,  ** p<0.01 vs DMSO vehicle control cells 
at 3 mM glucose. 
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The data presented Figure 47 was reconfigured to represent the effect of basal 
3 mM and high 25 mM glucose stimulation on glibenclamide treatment (Figure 
48).  High 25 mM glucose stimulation provokes a significant increase in insulin 
secretion in media and vehicle control cells, as well as the lowest 0.01 µM 
glibenclamide concentration used, relative to 3 mM glucose stimulation in these 
cells (p<0.05).  However, there is not great difference in the insulin secretion of 
0.1 µM, 1 µM and 10 µM glibenclamide treated cells following 3 mM or 25 mM 
glucose stimulation.  In fact, it seems insulin secretion slightly decreases with 
the highest glibenclamide concentrations used, perhaps indicating toxic effects 
at these concentrations.   
Therefore in summary, it seems that after 25 mM glucose stimulation, there is 
no additive effect of increasing glibenclamide concentration on insulin secretion.  
For future studies, we would be looking to use 0.1 µM glibenclamide as this 
concentration invokes a significant and optimal increase in insulin secretion at 3 
mM glucose stimulation. 
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Figure 48 The effect of basal 3 mM and high 25 mM glucose stimulation on 
glibenclamide treatment 
The data presented in Figure 47 was reconfigured to represent the fold-change in 
insulin secretion after 3 mM and 25 mM glucose stimulation on glibenclamide 
treatment.  DMSO was the drug vehicle control, and media cells did not contain any 
glibenclamide or DMSO.  Data presented are from 3 separate experiments each 
performed in duplicate, and are normalised to basal 3 mM glucose media control cells.  
Error bars representative of SEM.  * p<0.05 vs insulin secretion at 3 mM glucose for 
each condition. 
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6.3.7 Glibenclamide rescues the impaired insulin secretion seen with TFAM 
silencing-induced mtDNA depletion 
Having defined how normal MIN6 cells respond to glibenclamide treatment, we 
wanted to see how this response differed with mtDNA depletion.  Cells were 
transfected with either TFAM-429 or Scrambled control probes and incubated 
for 72 hrs post transfection.  They were then stimulated with basal 3 mM 
glucose or high 25 mM glucose for 1 hr, with or without 0.1 µM glibenclamide.  
Insulin secretion was determined by rat insulin ELISA and normalised to whole 
cell protein content.  The results are presented in Figure 49. 
The data corroborate what we have seen previously, that insulin secretion is 
impaired in TFAM-429 cells after 25 mM glucose stimulation compared to 
Scrambled control cells (p<0.05).  After basal 3 mM glucose stimulation, insulin 
secretion is comparable in TFAM-429 cells and Scrambled control cells, but can 
be seen to significantly increase by 2.81-fold and 2.73-fold respectively with 0.1 
µM glibenclamide treatment (p<0.01).  After high 25 mM glucose stimulation 
however, we see the glibenclamide restores insulin secretion to normal in the 
TFAM-429 cells compared to control cells. 
Therefore, we have managed to restore the insulin secretion deficit in mtDNA 
depleted MIN6 cells seen after 25 mM glucose stimulation by treating cells with 
0.1 µM glibenclamide.  This leads us to suggest the impairment in insulin 
secretion we have seen occurs prior to K+ channel closure. 
 
  
  
Figure 49 The effect of glibenclamide on insulin secretion in TFAM silencing
induced mtDNA depleted cells
Mitochondrial DNA levels were partially depleted following TFAM transcriptional 
silencing and incubation for 72 hrs post transfection.  Cells were then stimulated with 
basal 3 mM or high 25 mM glucose for a period of 1 hr, supplemented with or without 
0.1 µM glibenclamide.  Insulin secretion was determined by insulin ELISA and 
normalised to whole cell protein content.  Data shown are from 4 separated 
experiments performed in triplicate, and are normalised to Scrambled negative control 
cells stimulated with 
SEM.  * p<0.05,  ** p<0.01
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6.4 Discussion 
Glucose-stimulated insulin secretion is one of the main functions of the 
pancreatic β-cell.  First phase and second phase insulin secretion were found to 
be significantly reduced in patients diagnosed with prediabetes and T2DM 
(Hosker, et al., 1989; Porte, 2001; Wollheim, 2000).  Impaired insulin secretion 
is also a key characteristic of patients suffering from mitochondrial diabetes 
(Lynn, et al., 2003; Maassen, et al., 2004).  Decreased insulin secretion has 
been linked to increasing age (Basu, et al., 2003; Chang and Halter, 2003; Gao, 
et al., 2011; Suzuki, et al., 1997) and mtDNA depletion (Gauthier, et al., 2009; 
Hayakawa, et al., 1998; Kennedy, et al., 1998; Silva, et al., 2000; Soejima, et 
al., 1996; Tsuruzoe, et al., 1998).  Insulin secretion is closely associated with 
glucose metabolism (Wollheim, 2000), which involves the mitochondrial 
respiratory chain.   
Following didanosine-induced mtDNA depletion, we were quite surprised to find 
that there was an increase in insulin secretion at 25 mM glucose stimulation.  
During stimulus-secretion coupling in the pancreatic β-cell, the rise in cytosolic 
ATP/ADP ratio following glucose metabolism is a pivotal step in order to 
promote closure of plasma membrane-bound K+ channels, resulting in 
subsequent membrane depolarisation and Ca2+ influx.  Therefore, the loss of 
mtDNA would be predicted to affect the mtDNA encoded components of the 
respiratory chain, as we reported in the previous chapter, culminating in 
decreased ATP production and subsequent insulin secretion.  And indeed, 
when we deplete mtDNA levels using TFAM transcriptional silencing, we found 
that insulin secretion was reduced in these cells by 39% compared to control 
cells (p=0.03) following high 25 mM glucose stimulation.  We therefore began to 
suspect that didanosine drug treatment was perhaps exerting off target effects 
on MIN6 cells in regards to insulin secretion. 
Didanosine (ddI) is one of the 7 certified nucleoside analogue reverse 
transcriptase inhibitor (NRTI) drugs currently used in the treatment of HIV 
(Hӧschele, 2006).  As a nucleoside analogue of the nucleotide adenosine, ddI 
competes with endogenous adenosine for incorporation into the replicating 
mtDNA strand (Lewis, et al., 2003; Mitsuya, et al., 1990).  However, ddI lacks 
the 3’-OH group required to form phosphodiester linkages and so, strand 
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termination ensues following ddI incorporation (Mitsuya, et al., 1990).  Long 
term NRTI-drug use has been reported to have severe side effects on 
mitochondrial toxicity thought to be via oxidative damage to mtDNA (de la 
Asuncion, et al., 1999; Szabados, et al., 1999; Yamaguchi, et al., 2002).  It is 
also known that a number of HIV patients receiving NRTI drug therapy later 
develop T2DM (Brown and Glesby, 2012; Brown, et al., 2005; Hadigan, et al., 
2001; Lo, et al., 2005; Tien, et al., 2008) with prolonged NRTI treatment being 
linked to insulin resistance (Blanco, et al., 2011; Tien, et al., 2008), 
hyperinsulinaemia (Hadigan, et al., 2001; Mallon, et al., 2005) and 
hyperlactataemia (Lo, et al., 2005).  Hadigan et al. reported that HIV patients 
receiving NRTI therapy presented hyperinsulinaemia at both fasting and post-
glucose challenge, which was supported by these patients displaying increased 
insulin resistance and increased β-cell dysfunction also (Hadigan, et al., 2001).  
These results are in support of our own findings in that didanosine treated cells 
were found to secrete more insulin after high 25 mM glucose stimulation.  
Mallon et al. also reported hyperinsulinaemia in HIV patients receiving NRTI 
therapy however the patients studied also presented lipodystrophy, a common 
phenotype of HIV patients (Brown and Glesby, 2012) and so, the reported 
hyperinsulinaemia cannot be solely attributed to NRTI use alone (Mallon, et al., 
2005).  Because it is known that some patients do also develop T2DM, it may 
be that the acute effect of ddI is to increase insulin secretion, but that longer 
term there may be associated β-cell failure. 
Nonetheless, these studies substantiate our theory that didanosine is perhaps 
exhibiting off target effects on insulin secretion.  We attempted to investigate 
why didanosine treated cells secrete increased insulin in response to high 
glucose and we found that these cells actually contained 32% more insulin 
compared to control cells.  This can partly explain how these cells secrete more 
insulin.  However, there is a 20% reduction in insulin Ins1 gene expression, 
which does not explain the increase in insulin content.  Our only explanation is 
that the MIN6 cells attempt to oppose the off target effects of didanosine by 
possibly downregulating insulin gene expression in a negative feedback 
mechanism. 
Unlike humans who possess only one copy of the insulin gene, rodents have 2 
non-allelic copies of the insulin gene: insulin 1 (Ins1) and insulin 2 (Ins2) 
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(Steiner, et al., 1985).  Ins2 has most sequence homology to the human insulin 
gene, whereas Ins1 is thought to have arisen through a retrotransposition event 
(Steiner, et al., 1985).  Both Ins1 and Ins2 genes are expressed in MIN6 cells 
(Roderigo-Milne, et al., 2002).  It is known that intracellular changes in glucose 
concentrations act to regulate insulin gene expression via the regulatory β-cell 
specific transcription factors PDX1 (pancreatic and duodenal homeobox-1), 
NeuroD1 (neurogenic differentiation 1) and MafA (V-maf musculoaponeurotic 
fibrosarcoma oncogene homologue A) (Andrali, et al., 2008).  But there is also 
evidence to suggest autocrine regulation of insulin gene expression in human 
pancreatic β-cells, as they are reported to express components of the insulin 
signalling pathway such as insulin receptor substrate-1 and -2 (IRS-1 and -2), 
phosphoinositide 3-kinase (PI3K) and phosphoinositide-dependent protein 
kinase-1 (PDK1) (Muller, et al., 2006).  We found that Ins1 gene expression was 
reduced in didanosine treated cells and so it is possible to hypothesise that 
MIN6 cells downregulate their Ins1 gene expression via autocrine signalling, in 
an attempt to reduced insulin protein content.   
In total contrast, when mtDNA levels were depleted following TFAM 
transcriptional silencing, we found that insulin secretion was decreased in 
mtDNA depleted cells compared to control cells, which was more pronounced 
after 25 mM glucose stimulation.  Similar results have been reported in MIN6 
cells (Soejima, et al., 1996; Tsuruzoe, et al., 1998), and clonal rat INS-1 
pancreatic β-cells (Kennedy, et al., 1998), following chemical inhibition of 
mtDNA replication; however, these studies generated p0 cells in which mtDNA 
was drastically reduced by >90%.  It comes as no surprise that the p0 cells 
failed to respond to increased glucose stimulation, with insulin secretion at 25 
mM glucose comparable to that at low basal glucose (Kennedy, et al., 1998; 
Soejima, et al., 1996; Tsuruzoe, et al., 1998).  The finding that mtDNA depletion 
hinders glucose-stimulated insulin secretion has also been replicated in 
transgenic mouse (Silva, et al., 2000) and rat (Gauthier, et al., 2009) animal 
models. 
However, the severe mtDNA depletion reproduced in animal models (Silva, et 
al., 2000) and rodent cell lines (Hayakawa, et al., 1998; Kennedy, et al., 1998; 
Soejima, et al., 1996; Tsuruzoe, et al., 1998) does not accurately reflect mtDNA 
depletion in a clinical setting.  In human pancreatic islets, it was noted that there 
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was a 50% decrease in the mean mtDNA copy number in non-diabetic islet 
donors aged between 17 and 75 years (Cree, et al., 2008).  Concurrently, Ihm 
et al. correlated the decline in glucose-stimulated insulin secretion and 
decreased ATP content to islet donor age (Ihm, et al., 2006).  Gauthier et al. 
observed partial mtDNA depletion to similar levels produced by ourselves 
following transcriptional silencing of the β-cell regulatory transcription factor 
PDX1 (Gauthier, et al., 2009).  By silencing Pdx1 gene expression by >90%, the 
group found this depleted mtDNA levels by 40% via TFAM suppression, which 
resulted in impaired insulin secretion at high glucose stimulation only (Gauthier, 
et al., 2009).  Pancreatic β-cell insulin content was not reported.  The group 
were then able to show that the mtDNA depletion and impaired insulin secretion 
following Pdx-1 silencing hinged on TFAM suppression by adenoviral 
transduction of rat islets to increase TFAM expression.  Both mtDNA copy 
number and insulin secretion were restored to levels comparable to control cells 
(Gauthier, et al., 2009).  However, PDX1 is a critical regulator of β-cell function 
and mass, and it is clear that altered PDX1 expression affects multiple gene 
pathways in addition to TFAM expression (Babu, et al., 2007).  In this sense, 
the model is not a specific model of mtDNA depletion unlike the targeted TFAM 
knockdown developed in this project. 
We were able to restore impaired insulin secretion in TFAM silenced mtDNA 
depleted cells to levels comparable with control cells following treatment with 
the insulin secretagogue glibenclamide.  Glibenclamide is an oral 
hypoglycaemic agent used as an effective treatment in T2DM by targeting the 
sulphonylurea receptor 1 (SUR1) subunit of the ATP-gated K+ channel situated 
in the β-cell plasma membrane.  Upon targeting the SUR1 protein, 
glibenclamide promotes K+ channel closure and plasma membrane 
depolarisation (Proks, et al., 2002).  Glucose-stimulated insulin secretion was 
also partially restored in mtDNA depleted mouse clonal β-cells following 
treatment with glibenclamide (Hayakawa, et al., 1998; Tsuruzoe, et al., 1998) or 
in rat clonal INS-1 cells using the depolarising agent KCl (Kennedy, et al., 
1998).  Whereas Soejima et al. restored the defective insulin secretion seen 
with mtDNA depletion by repopulating cybrid MIN6 clones with foreign mtDNA 
(Soejima, et al., 1996).  These studies, along with our own results, signify that 
the impairment in insulin secretion following mtDNA depletion is prior to K+ 
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channel closure, with the work by Soejima et al. pinpointing the defect to be 
mtDNA in origin (Soejima, et al., 1996).   
This is strengthened by our finding that there was no difference in Ins1 insulin 
gene expression in TFAM silenced mtDNA depleted cells compared to control 
cells, allowing us to conclude that the deficit in insulin secretion is not due to 
reduced insulin gene transcription.  A similar finding was reported by Soejima et 
al. and Hayakawa et al. who found that Ins1 gene expression did not change in 
severely mtDNA depleted mouse clonal β-cells compared to control cells 
(Hayakawa, et al., 1998; Soejima, et al., 1996), even after low and high glucose 
stimulation (Soejima, et al., 1996).  We did find however that there was 
decreased insulin content in TFAM silenced mtDNA depleted cells compared to 
control cells.  Conversely, other groups have reported no significant change 
(Silva, et al., 2000) or an increase (Hayakawa, et al., 1998; Silva, et al., 2000; 
Tsuruzoe, et al., 1998) in insulin content in rodent pancreatic β-cells or islets.  
This disparity may be explained by the slightly imprecise methods of detecting 
insulin content, where one cannot be entirely sure whether we are detecting 
mature insulin or immature proinsulin (see Limitations section 6.6). 
6.5 Conclusions   
In conclusion, we start to see a divergence in the two mtDNA depletion models 
we have optimised in terms of insulin secretion.  We were surprised to find that 
didanosine-induced mtDNA depletion resulted in an increase in insulin secretion 
when cells were posed with high 25 mM glucose stimulation.  Didanosine is 
currently used in NRTI drug therapy in HIV patients.  It has been reported that 
HIV patients exhibit hyperinsulinaemia and increased insulin resistance, which 
may explain why a large number of HIV patients later develop T2DM.  The off 
target effects didanosine displays on insulin secretion we have demonstrated in 
this chapter have not been reported in the literature.  However, more research 
is certainly deemed necessary in order to determine why didanosine treatment 
causes pancreatic β-cells to secrete and produce more insulin. 
In contrast, mtDNA depletion following TFAM transcriptional silencing caused 
significant impairment in insulin secretion following 25 mM glucose stimulation.  
Like many other studies, we managed to restore impaired insulin secretion in 
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TFAM silenced mtDNA depleted cells following treatment with the insulin 
secretagogue glibenclamide.  We therefore conclude that the defect in insulin 
secretion in TFAM silenced mtDNA depleted cells must occur prior to K+ 
channel closure.  We also found that there was no change in Ins1 gene 
expression following mtDNA depletion, suggesting that the defect in insulin 
secretion is not due to changes in insulin gene expression.  This leads us to 
believe that the culprit of impaired insulin secretion is possibly respiratory chain 
dysfunction, as a result of the decreased COX1 mRNA and protein levels we 
reported in the previous chapter. 
6.6 Limitations 
Possible limitations in this chapter can be seen in the detection of insulin 
content of the MIN6 cells.  We used a commercial ELISA kit designed for rat; 
yet there is high sequence homology (75%) to the mouse insulin protein, which 
is why it was chosen.  However, there is also cross-reactivity to mouse 
proinsulin 1 and proinsulin 2 (33% and 51% respectively).  The translation 
product from Ins gene mRNA is preproinsulin; which contains an N-terminal 
signal peptide that subsequently becomes cleaved during insulin granule 
maturation to form proinsulin (Steiner, et al., 1985).  Because there is cross-
reactivity between the mouse proinsulin proteins and insulin, we are unable to 
confirm what form of insulin we have detected.  Therefore, it is difficult to 
conclude why we see decreased insulin content in TFAM transcriptionally 
silenced cells compared to control cells: is it due to translation of the insulin 
gene or insulin protein processing?  There are also ELISA commercial kits 
available for detecting proinsulin with <1% cross-reactivity to insulin, so perhaps 
these could be utilised for future studies? 
There is no doubt however that we have detected mature insulin after glucose-
stimulated insulin secretion, because the supernatant was harvested and used 
to determine insulin secretion.  But criticism could be made on the static 
incubation used.  Other groups have used static incubation also (Hayakawa, et 
al., 1998; Kennedy, et al., 1998; Soejima, et al., 1996; Tsuruzoe, et al., 1998) 
whereas others have used perifusion (Silva, et al., 2000) whereby cells are 
bathed in a continuous supply of fresh medium.  Perhaps this would have been 
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a more correct method as it would also more accurately reflect what occurs in 
vivo? 
An overall limitation in this study is that measurements of mtDNA depletion, β-
cell function and mitochondrial function were performed in separate cells.  This 
was a limitation that we struggled to avoid as it was difficult to extract DNA, 
RNA and protein simultaneously.  We attempted it with a commercial extraction 
kit, as well as with Trizol reagent, but we found that the quality of DNA was very 
poor, and the solutes require to resuspend the protein interfered with the 
Bradford dye during protein quantification. 
Finally, we only detected Ins1 gene expression, like many other studies 
(Hayakawa, et al., 1998; Soejima, et al., 1996).  However, there have been 
reports of differential expression of the Ins1 and Ins2 genes in different tissues 
(Deltour, et al., 2004), including pancreatic β-cells (Roderigo-Milne, et al., 2002) 
so perhaps we should have measured Ins2 gene expression also? 
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7 General Discussion 
7.1 General Discussion 
The prevalence of T2DM has been found to increase with advancing age 
(Cowie, et al., 2006; Cowie, et al., 2009; Harris, et al., 1987).  This is thought to 
be due to the age-related progressive decline in pancreatic β-cell function 
(Rudenski, et al., 1988), which results in an age-related decrease in insulin 
secretion (Chang and Halter, 2003) and an associated deterioration in glucose 
tolerance (Basu, et al., 2003).  Insulin secretion relies heavily on the ATP 
generated by mitochondrial oxidative phosphorylation (Wollheim, 2000).  This is 
supported in cellular models in which mtDNA has been severely depleted, 
resulting in impaired insulin secretion (Kennedy, et al., 1998; Silva, et al., 2000; 
Soejima, et al., 1996; Tsuruzoe, et al., 1998).  It is also known that certain 
mtDNA abnormalities are diabetogenic, particularly the A3243G mutation, which 
has been associated with impaired insulin secretion (Lynn, et al., 2003; 
Maassen, et al., 2004).  An age-related decline in mtDNA copy number has 
been reported in numerous human tissues (Cree, et al., 2008; Kaaman, et al., 
2007; Laderman, et al., 1996; Short, et al., 2005).  In pancreatic islets, Cree et 
al. showed that mtDNA copy number was significantly reduced in non-diabetic 
islet donors aged ≥50 years compared to donors aged ≤50 years; and that the 
mean mtDNA copy number decreased by 50% in individuals aged between 17 
and 75 years (Cree, et al., 2008).  Therefore, we were keen to investigate 
whether partial mtDNA depletion to levels of around 50% in pancreatic β-cells is 
merely a biomarker of ageing, or whether it directly affects β-cell function and 
insulin secretion. 
We began by optimising two independent models of mtDNA depletion in the 
murine pancreatic β-cell line, MIN6.  The first mtDNA depletion model relied on 
chemical inhibition of mtDNA replication using the adenosine nucleoside 
analogue didanosine.  Didanosine is currently an effective means of treating 
HIV patients as it targets the HIV reverse transcriptase enzyme thus preventing 
HIV viral DNA replication.  But it has also been found to have high affinity for the 
mitochondrial polymerase γ, POLG (Kakunda, 2000; Lewis, et al., 2003).  
Didanosine competes with endogenous adenosine for incorporation into the 
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growing mtDNA strand and as didanosine lacks the 3’-OH group required for 
the phosphodiester linkage, subsequent stalling of POLG and strand 
termination ensues (Lewis, et al., 2003; Mitsuya, et al., 1990).  Lake-Bakaar et 
al. were able to show that 8 day treatment of human pancreatic  endocrine cells, 
Capan-1 cells, with 20 µM ddI results in 70% reduction of mtDNA levels.  
Indeed, we similarly found that by treating MIN6 cells with 50 µM ddI for 5 days 
resulted in 50% mtDNA depletion (Lake-Bakaar, et al., 2001). 
Our second model of mtDNA depletion silenced TFAM gene transcription using 
siRNA technology.  TFAM is an important nuclear encoded mitochondrial DNA 
transcription factor found to play a key role in mtDNA transcription (Campbell, et 
al., 2012; Ohgaki, et al., 2007), as well as mtDNA copy number (Ekstrand, et 
al., 2004)  and maintenance (Larsson, 2010).  Indeed, tissue specific (Silva, et 
al., 2000; Sorensen, et al., 2001; Wang, et al., 1999) and global knockdown 
(Larsson, et al., 1998) of the TFAM gene in mouse animal models has proven 
an effective means of depleting mtDNA levels.  It has also been shown that 
severe (>90%) loss of the β-cell specific regulatory transcription factor PDX1 
was also found to significantly deplete mtDNA levels by around 30%, which was 
unexpectedly shown to occur through TFAM suppression (Gauthier, et al., 
2009).  Similarly, after transcriptionally silencing the TFAM gene >80%, we 
achieved a 40% reduction in mtDNA levels.  Therefore, in summary, both 
mtDNA depletion models produced a comparable degree of mtDNA depletion to 
levels seen in aged human islets (Cree, et al., 2008).   
Using the two models of mtDNA depletion, we moved on to investigate what 
effect partial mtDNA depletion was having on mitochondrial function.  COX1, 
cytochrome c oxidase subunit 1, is one of the three mtDNA encoded subunits of 
cytochrome c oxidase (Complex IV), and is essential during the assembly of the 
cytochrome c oxidase complex (Fontanesi, et al., 2006; Larsson, 2010).  By 
inducing partial mtDNA depletion in MIN6 cells, we managed to produce a 45% 
and 33% reduction in COX1 mRNA expression using the didanosine and TFAM 
mtDNA depletion models respectively.  Upon analysis of COX1 protein, we 
were able to show that that decreased COX1 gene expression translated to 
decreased COX1 protein.  We observed that COX1 protein was reduced by 
34% and 22% in the didanosine and TFAM mtDNA depletion models 
respectively.  Our finding that mtDNA depletion results in decreased mtDNA 
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transcription and protein translation has also been shown in previous studies in 
rodent clonal β-cells (Hayakawa, et al., 1998; Soejima, et al., 1996; Tsuruzoe, 
et al., 1998) and rodent pancreatic islets (Gauthier, et al., 2009).   
We also measured ATP content as a measure of mitochondrial function.  
However, we found that neither didanosine-induced nor TFAM silencing-
induced mtDNA depletion had an effect on the ATP content in mtDNA depleted 
cells compared to control cells.  We found this was the case whether the cells 
were stimulated with low 3 mM or high 25 mM glucose.  Therefore, it seems the 
partial mtDNA depletion we have created in both models is enough to effect 
mtDNA gene transcription and translation, but it does not affect ATP content.  
Our results are in contrast to other groups who have reported a substantial 
decrease in ATP production following high 25 mM glucose stimulation in mtDNA 
depleted cells (Kennedy, et al., 1998; Tsuruzoe, et al., 1998).  But unlike 
ourselves, these groups have produced severe mtDNA depletion of >90%.  
Therefore, the fact that other groups have reported a loss in ATP production 
following mtDNA depletion may be attributable to the degree of mtDNA 
depletion produced in these studies.   
It is also worth mentioning that although the electron transport chain is the main 
generator of ATP, other cellular pathways such as glycolysis can be utilised for 
ATP production too.  In fact, it is known that cancer cells experience 
mitochondrial respiratory chain dysfunction and increased glycolysis 
(Kaipparettu, et al., 2010).  MIN6 cells are derived from a mouse insulinoma 
and so, could it be possible that MIN6 cells rely on glycolysis instead of the 
respiratory chain for their source of ATP?  Could this be the reason why the 
partial mtDNA depletion we produced did not affect ATP production, because 
glycolysis is not affected by mtDNA depletion?  But in the Kennedy et al. and 
Tsuruzoe et al. studies where they depleted mtDNA >90%, the energy 
generated by glycolysis was not enough to sustain glucose-stimulated insulin 
secretion alone, which is why they saw a decrease in ATP production?  Our 
result could also be limited by the nature of the technique we used, was it 
specific enough to detect small changes in ATP content?   
We also investigated the effect of mtDNA depletion on mitochondrial membrane 
potential using the JC-1 cationic fluorescent dye.  However, like the ATP 
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content data, we did not see an effect of didanosine-induced mtDNA depletion 
on mitochondrial membrane potential.  As with the ATP content data, we found 
disparity between our results and the literature.  Using another mitochondrial 
fluorescent probe, rhodamine 123, it has been shown that there is reduced 
hyperpolarisation in pancreatic β-cells with mtDNA depletion (Kennedy, et al., 
1998; Silva, et al., 2000).  However, these reports examined cells with severe 
mtDNA depletion (>90%) and not partial mtDNA depletion as we have done, 
which may explain this discrepancy. 
So in summary, it appears that the partial mtDNA we created using both mtDNA 
depletion models caused a decrease in COX1 mRNA and subsequent reduction 
in COX1 protein levels.  However, we failed to see an effect of partial mtDNA 
depletion on ATP content or mitochondrial membrane potential.  Our next 
question was: does the partial mtDNA depletion generated in both models 
impair glucose-stimulated insulin secretion?  It is at this point that we begin to 
notice a divergence in the two mtDNA depletion models.  We were surprised to 
find that didanosine treated cells secreted more insulin in response to high 25 
mM glucose stimulation compared to control cells.  We hypothesise that this is 
possibly due to didanosine treatment exhibiting off target effects on insulin 
secretion.   
Didanosine drug therapy in HIV patients has been closely related to the onset of 
acute pancreatitis (Butler, et al., 1993; Martin, et al., 1994).  It is also interesting 
to note that a proportion of HIV patients receiving NRTI therapy later go on to 
develop T2DM (Brown and Glesby, 2012; Brown, et al., 2005; Hadigan, et al., 
2001; Lo, et al., 2005; Tien, et al., 2008).  This may be explained by prolonged 
NRTI use being associated with insulin resistance (Blanco, et al., 2011; Tien, et 
al., 2008) and hyperinsulinaemia (Hadigan, et al., 2001; Mallon, et al., 2005).  
What is currently lacking in the literature are possible mechanisms as to why 
these patients are insulin resistant and hyperinsulinaemic.  The fact that we 
have reported increased insulin secretion and increased insulin content in 
didanosine-induced mtDNA depleted cells may go some way to possibly 
explaining this, but more research is certainly needed to uncover reasons why.   
When mtDNA was depleted following TFAM transcriptional silencing however, 
we found that insulin secretion was significantly impaired in mtDNA depleted 
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cells compared to control cells following high 25 mM glucose stimulation.  It has 
also been shown that glucose-stimulated insulin secretion is impaired following 
mtDNA depletion in rodent clonal β-cells (Kennedy, et al., 1998; Soejima, et al., 
1996; Tsuruzoe, et al., 1998) and rodent animal models (Gauthier, et al., 2009; 
Silva, et al., 2000).  Similar to our results obtained using the TFAM mtDNA 
depletion model, it was found that insulin secretion was significantly deceased 
following high glucose stimulation in mtDNA depleted cells (Gauthier, et al., 
2009; Kennedy, et al., 1998; Silva, et al., 2000; Soejima, et al., 1996; Tsuruzoe, 
et al., 1998).   
However, we also found that insulin secretion was also significantly impaired 
following basal 3 mM glucose stimulation.  Therefore, when you compare the 
fold increase in insulin secretion after high glucose stimulation, it is similar in 
both TFAM-429 cells and Scrambled control cells.  But there seems to be slight 
discrepancy in that we did not detect this same decrease in insulin secretion at 
basal glucose in the TFAM-429 silenced cells following glibenclamide treatment.  
This may be because of the fewer number of repeats in these experiments, or 
indeed because the experimental conditions were slightly different in that data 
were normalised to DMSO vehicle control cells.  In light of this, our key finding 
is that absolute insulin secretion is decreased following TFAM-induced mtDNA 
depletion in both the glibenclamide and non-glibenclamide studies, and this is 
the main and consistent finding of the work. 
So what might be causing the reduced insulin secretion seen in TFAM silenced 
mtDNA depleted cells?  We observed a decrease in COX1 mRNA and protein 
in these cells and so, an obvious candidate would be reduced ATP from the 
respiratory chain in mtDNA depleted cells.  However, we also reported no 
change in ATP content in TFAM mtDNA depleted cells, so something else must 
be causing the impaired insulin secretion.  We found no change in the Ins1 
insulin gene expression in TFAM silenced mtDNA depleted cells, so the defect 
is not due to a reduction in insulin gene transcription.  There was however, 
decreased insulin content in TFAM silenced mtDNA depleted cells, but we are 
unable to confirm whether this decrease in insulin content is a result of reduced 
protein translation from the Ins1 gene, or a default in the insulin processing 
pathway during granule maturation.  Silva et al. produced tissue specific TFAM 
knockdown in mice and found that along with severe mtDNA depletion in 
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pancreatic β-cells, the phenotype of the TFAM knockout mice changed with 
time.  Interestingly, the group found that there was an age-dependent decrease 
in β-cell mass (Silva, et al., 2000).  Therefore, could the decrease in glucose-
stimulated insulin secretion we have observed in TFAM silenced mtDNA 
depleted cells be due to other mechanisms such as apoptosis?  We did not 
measure cell number in the TFAM mtDNA depletion model, but found no 
difference in DNA, RNA or protein levels in TFAM-429 transfected cells 
compared to Scrambled control cells.  One thing we can conclude however, is 
that the deficit in insulin secretion must be prior to the closure of K+ channels 
because we managed to rescue insulin secretion in TFAM mtDNA depleted 
cells following treatment with the insulin secretagogue glibenclamide. 
Glibenclamide is an effective oral hypoglycaemic agent used in the treatment of 
T2DM (Groop, 1992).  By targeting the sulphonylurea receptor SUR1 protein of 
the K+ channel situated on the β-cell plasma membrane, glibenclamide causes 
K+ channel closure and subsequent membrane depolarisation (Proks, et al., 
2002).  Glibenclamide has been predicted to circulate in blood plasma at 
concentrations below 0.4 µM and so, the concentrations we used are within the 
pharmacological range (Anello, et al., 1999; Jaber, et al., 1994).  Our finding 
that the impaired glucose-stimulated insulin secretion seen with partial mtDNA 
depletion is restored following glibenclamide treatment is supported by other 
studies that have also used glibenclamide (Hayakawa, et al., 1998; Tsuruzoe, et 
al., 1998) or other membrane depolarising agents such as KCl (Kennedy, et al., 
1998).  Taken together, these studies, along with our own results using the 
TFAM mtDNA depletion model, signify that the reduced insulin secretion seen 
following mtDNA depletion occurs prior to K+ channel closure and is perhaps 
mtDNA in origin. 
7.2 Conclusions 
Our original aim was to investigate the effects of partial mtDNA depletion on 
pancreatic β-cell function and mitochondrial function.  We found that mtDNA 
depletion in MIN6 cells to levels seen in human islets with ageing has a direct 
effect on insulin secretion when depleting mtDNA via TFAM gene silencing.  
This effect on insulin secretion may be due to a defective electron transport 
chain following a decrease in the mtDNA encoded components.  There was no 
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change in ATP levels or mitochondrial membrane potential.  We found impaired 
insulin secretion was rescued following treatment with the insulin secretagogue 
glibenclamide, suggesting that the deficit in insulin secretion occurs prior to K+ 
channel closure.  However, we also reported that didanosine-induced mtDNA 
depletion resulted in an increase in insulin secretion, which we postulate to be 
due to possible off target effects of the drug.  Strategies to slow or even prevent 
islet mtDNA depletion in man could help to preserve insulin secretion and delay 
the development of Type 2 diabetes. 
7.3 Future Work 
We have managed to produce two independent models of mtDNA depletion that 
partially deplete mtDNA by 40-50%.  However, both of these models produce 
acute and transient mtDNA depletion therefore, future studies into the effect of 
chronic partial mtDNA depletion might more accurately reflect mtDNA depletion 
in a clinical setting.  It has been shown that chronic mtDNA depletion in mouse 
models resulted in reduced pancreatic β-cell mass (Silva, et al., 2000).   
Also, investigations into TFAM protein levels following TFAM gene silencing 
would indicate whether or not we have managed to affect the TFAM protein.  
This is something that was attempted during this project however; the 
commercial antibodies used were non-specific, producing multiple protein 
bands.  We evaluated certain aspects of mitochondrial function following 
mtDNA depletion during this project, but other key measures that could be 
investigated include calcium signalling and β-cell apoptosis. 
Finally, exploration of therapeutics to increase mtDNA copy number would be 
beneficial.  Certain studies have shown an increase in mtDNA copy number 
following increased TFAM gene expression (Ekstrand, et al., 2004; Gauthier, et 
al., 2009).  Investigation into therapeutics that could stimulate mitochondrial 
biogenesis via TFAM would help alleviate the decrease in mtDNA copy number 
seen with advancing age. 
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Figure 1 Standard curves for ND5 (300nM), GAPDH (500 nM) and CDKN2A va.1 
(QuantiTect Assay Mm_Cdkn2a_va.1_SG) 
Complementary DNA was serially diluted 1:5 and amplified by real-time PCR using 
SYBR-Green and primers specific for GAPDH (500 nM), ND5 (300 nM) or CDKN2A 
(QuantiTect Assay Mm_Cdkn2a_va.1_SG).  The CDKN2A QuantiTect assay (Qiagen, 
Crawley, UK; Cat No QT01164891) was already optimised and 2 µl was added per 20 
µl reaction.  Reaction efficiencies were 92.61% (GAPDH), 98.87% (ND5) and 95.07% 
(CDKN2A). 
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Figure 2 Correction for protein loss following perchloric acid ATP extraction 
During analysis of ATP content (Section 5.4.3), cells were harvested in perchloric acid 
to prevent degradation of ATP.  Cell lysates were then centrifuged, the supernatant 
removed for ATP analysis and the cell debris pellet resuspended in 0.15 M NaOH.  
Protein quantification was obtained using a Lowry assay.  It was evident that harvesting 
cells in perchloric acid resulted in loss of whole cell protein content and so, this loss of 
protein was corrected for using control wells in which cells were harvested in NaOH 
only.  We found an approximate 50% loss of protein when processing didanosine 
model samples (A), but this loss of protein was slightly greater in TFAM model samples 
(B), possibly because of fewer cells in these wells. 
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Figure 3 ATP content of MIN6 cells following partial mtDNA depletion: raw data 
This is the data from Section 5.4.3 prior to protein normalisation.  MIN6 cells were 
partially depleted of mtDNA following didanosine treatment (A) or TFAM transcriptional 
silencing (B) and ATP content measured as previously describe in Section 5.4.3. 
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